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T CELL MEDIATED CYTOTOXICITY IN THE MPTP MOUSE
MODEL OF PARKINSON’S DISEASE

Rebecca A. Wilshusen, Ph.D.
University of Nebraska, 2018

Supervisor: R. Lee Mosley, Ph.D.

Increasing evidence suggests that neurotoxic inflammatory activities affect the
pathogenesis and progression of PD.

Neuroinflammatory processes also produce

oxidized and modified self-central nervous system (CNS) proteins which lead to
dysfunction, mis-folding, aggregation, and retention of those oxidized products. In PD,
nitrated α-synuclein (N-α-syn) is found aggregated within the cytoplasm and Lewy
bodies of dopaminergic neurons within the substantia nigra and is released to the
extraneuronal environment by dying and damaged neurons.

Previous studies have

shown that after 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) intoxication,
adoptive

transfer

of

effector

T

cells

(Teff)

exacerbates

microglial-mediated

neuroinflammation and amplifies dopaminergic neurodegeneration with accelerated and
prolonged neuropathology. Additionally, Teffs that secrete IL-17 (Th17 type) exacerbate
neurodegeneration to greater levels than those Teff types that secrete IFN-ɣ (Th1 type).
Thus, we hypothesize that N-α-syn specific Th17 effector T cells exacerbate
neurodegeneration indirectly via activation of microglial-mediated neurotoxicity or
alternatively by direct cytotoxicity to neurons.
To test this hypothesis we first established the long-term culture of CD4+ effector T cell
lines of the Th17, Th1, and Th17.1 phenotype. These cell lines stably produced their
respective classical cytokines while retaining phenotype, without de-differentiation to
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other phenotypic subsets, and were functional both in vitro and in vivo.

The

development of a cloned Th17, Th1, and Th17.1 cell lines allowed their utilization to test
in vitro and in vivo effects on microglia and cytotoxicity to dopaminergic neurons through
direct and indirect mechanisms.
With the generation of cloned Th17 effector T cell line we sought to test its toxicity to
neuronal cells in vitro through the use of the BV-2 microglial cell line and MES23.5
neuronal cell line.

In vitro culture of MES23.5 neuronal cells with Th17 cells or

supernatants increased neuronal cell toxicity while decreasing viability. Moreover, the
supernatant from activated Th17 cells proved more neurotoxic to MES23.5 cells than
cells. While Th17 cells demonstrated direct toxicity to neuronal cells, they also exhibited
the ability to induce microglial-mediated neurotoxicity through apoptotic mechanisms,
which were ablated with the use of a Z-VAD-FMK pan caspase inhibitor.
Growing evidence supports the notion that not all Teff cells are created equally, and
some are more pathogenic than others, with IFN-γ/IL-17 dual expressing TH17.1 cells
sufficient for heightened pathogenicity. In vitro analysis of Th17, Th1, and Th17.1 cell
line pathogenicity indicated that compared to other cell lines, Th17.1 cells or
supernatants exhibit the most pathogenic nature upon co-culture with neuronal cells
(direct toxicity) as well as through microglial-mediated cell death (indirect toxicity). In
fact, the Th17.1 cell line caused the largest increase in apoptosis, and induced the most
extensive neuronal cell death directly via T cell/T cell supernatant interactions, and
indirectly via microglial-mediated cellular death.

Moreover, the Th17.1 cell line also

demonstrated similar effects in vivo, as adoptive transfer of Th17.1 cells produced the
greatest loss of TH+ dopaminergic neurons, and the most exacerbation of microgliosis
compared to the Th17 and Th1 cell lines.
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Taken together, this research has shown the ability of effector T cell types to exacerbate
neurodegeneration in vitro and in vivo, possibly through apoptotic mechanism(s).
Additionally, this work has detailed the generation and long-term culture of effector T cell
lines in vitro through the use of specific cytokine and antibody milieus, which affects
effector T cell type pathogenicity. Further investigations into the mechanistic details
behind exacerbation of neurodegeneration induced by CD4+ effector T cells in PD
models, for instance by TNFα or Fas/FasL interactions, have the potential to advance
therapeutic strategies that target neurotoxic mechanisms to attenuate neuroinflammation
and ameliorate neuronal loss in PD.
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INTRODUCTION
Parkinson’s disease (PD) is a relatively common neurodegenerative disorder,
second in prevalence only to Alzheimer’s

disease,

but the most common

neurodegenerative movement disorder. Rare before 50 years of age, PD affects
approximately 1% to 2% of the population older than 60 years, with the incidence
increasing to 3%-5% for those over 85 years of age (Fahn, 2003). Most studies in the
USA and Europe estimate the annual incidence rate at 16-19 per 100,000 (Twelves et
al., 2003). An estimated 5 million people worldwide are afflicted with PD, with 1-1.5
million people each in the USA and Europe. The average age of onset for PD is
approximately 60 to 65 years with the peak incidence between 70 and 80 years of age.
Thus, age represents a primary risk factor for PD with an increased prevalence among
the population of increased age. This is particularly noteworthy given the increasing
levels of neuroinflammation and oxidative stress associated with progressive age
(Godbout and Johnson, 2009).
Clinical signs and severity of disease associated with PD result from the
progressive loss and neuropathology of neurons that synthesize the neurotransmitter
dopamine and are responsible for initiation of movement. The dopaminergic neurons
that are primarily lost in PD are those that originate in the substantia nigra pars
compacta (SN) and enervate the dorsal striatum. This nigrostriatal pathway represents
one of the four major dopamine signaling pathways in the brain and is prominently
involved in controlling movement (Appel et al., 2010).

Thus, degeneration of these

neurons and loss of dopamine along this axis results in the presentation of the
pathophysiological clinical signs of PD; tremors, gait disturbance, muscle rigidity, and
cognitive dysfunction. Dynamic neuronal dysfunction and loss that progresses without
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intervention eventually lead to total loss of physical movement and ultimately death
(Peterson and Flood, 2012).
Other pathological hallmarks in PD include neuronal cytoplasmic inclusions
known as Lewy bodies. Lewy bodies are eosinophilic inclusions composed primarily of
aggregated proteins including α-synuclein (α-Syn) and ubiquitin as two major
components (Shimura et al., 2001, Corti et al., 2011, Hutter-Saunders et al., 2011,
Mosley et al., 2012, Wan and Chung, 2012). Although, typically only observed among
post-mortem brain samples from PD patients, Lewy bodies are considered diagnostic for
PD. In the brain α-Syn exists as a natively unfolded and soluble protein localized in the
pre synaptic terminals of neurons and is postulated to be involved in chaperoning
vesicles to synaptic membranes. Post-translational modifications of α-Syn through
nitration, oxidation, or phosphorylation enhance misfolding, oligomerization, fibril
formation, and aggregation (Giasson et al., 2000, Fujiwara et al., 2002, Parihar et al.,
2009, Koprich et al., 2010).

These processes are responsible for converting non-toxic

molecules of α-Syn into toxic fibrillar species that produce annular pore formation in
neuronal membranes and eventually lead to neurodegeneration (Uversky et al., 2005,
Cavallarin et al., 2010).

Misfolding of α-Syn is also caused by genetic mutation or

overexpression. While most cases of PD have no family history of disease, point
mutations in the gene encoding α-Syn (SNCA; OMIM 163890) are linked to autosomal
dominant Parkinsonism (PARK1, OMIM 168601) (Polymeropoulos et al., 1996,
Polymeropoulos et al., 1997, Kruger et al., 1998, Zarranz et al., 2004) as are
duplications and triplications of the SNCA gene (PARK4, OMIM 605543) (Singleton et
al., 2003, Chartier-Harlin et al., 2004); all of which increase the aberrant misfolding of αSyn (Narhi et al., 1999, Li et al., 2001, Uversky, 2007).

Taken together, these

observations led to the α-Syn burden hypothesis of PD which posits that misfolding of
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excess wild type or mutated α-Syn and the inability of the cell to clear the misfolded toxic
species leads to the etiology or progression of familial and sporadic disease (McGeer
and McGeer, 2008).
The reason(s) for increased susceptibility of dopaminergic neurons along the
nigrostriatal axis in PD remains enigmatic. Neuronal death can be induced along several
different, but cross-signaling pathways. One parameter thought to be responsible for
increased susceptibility was the oxidative synthesis and metabolism of dopamine, which
would increase oxidative stress within neurons (Riederer and Wuketich, 1976,
Greenamyre and Hastings, 2004).

Additionally, dopaminergic neurons in the SN

possess low intracellular glutathione which results in reduced antioxidant capacity and
are rendered more susceptible to oxidative stress than other types of cells located in the
same area (Banerjee et al., 2008). However, dopaminergic neurons in close proximity to
the SN, which exist under similar conditions, appear undisturbed. Reactive oxygen
species produced by activated microglia also have the potential to cause dopaminergic
cell death by directly crossing the membrane to enter the dopaminergic neuron and
overwhelming the endogenous antioxidant systems to cause oxidative stress that
eventually leads to increased apoptosis and degeneration of the neuron. In that same
vein, since dopaminergic neurons in the SN widely express the death signaling tumor
necrosis factor (TNF) receptor, chronic inflammation and delivery of proinflammatory
cytokines such as TNF-α can induce and augment apoptotic cell death processes (Cao
et al., 2011).

Neuroinflammation and Neurodegeneration in Parkinson’s
Disease
While the etiology of PD remains enigmatic, strong evidence now supports a
non-cell autonomous theory, which promotes the notion that neuroinflammation is
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strongly implicated in etiology and/or disease progression (Dawson, 2008).

Indeed,

other hallmarks of PD include the abundant signs of neuroinflammation as evidenced by
activated glia in ante- and post-mortem analyses of patient brains (McGeer et al., 1988b,
Vila et al., 2001, Ouchi et al., 2009). Interestingly, the predominant inflammatory glial
cell population in PD is the microglia, whereas reactive astrocytes are largely absent
(Banati et al., 1998, Mirza et al., 2000, Vila et al., 2001).
Microglia, a population of cells derived from the myeloid lineage of the innate
immune system, constitute approximately 20% of the glia in the brain and represent the
brain’s resident phagocytic cells, thereby making them the first line of defense against
pathogens and foreign material (Czlonkowska et al., 2002, Stone et al., 2009).
Microglial progenitor cells enter the brain during early embryogenesis and develop
throughout the brain within the parenchyma, choroid plexus, leptomeninges, and among
the microvasculature (Czlonkowska et al., 2002, Laurie et al., 2007). Resident microglial
cells in a healthy brain are typically in a resting or dormant state with a ramified
morphology, and not until activation are structural changes observed that include motile
branches or the migration of somata (Nimmerjahn et al., 2005). Resting microglia have
small rod shaped somata that remain fixed with few signs of migration capacity.
Numerous and highly ramified processes extend from the somata and continuously
undergo cycles of de novo formation and withdrawal, participating in immune
surveillance by sampling the extracellular space in a seemingly random fashion with a
high turnover rate (Nimmerjahn et al., 2005, Cao et al., 2011). These processes enable
the microglia to efficiently sample and control the microenvironment of the brain and
clear the surrounding tissue of increased metabolic products and deteriorated tissue
components. The extensive processes and protrusions of the microglia enable direct
contact with other cells of the brain, particularly astrocytes, neuronal cell bodies, and
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blood vessels, suggesting that microglia dynamically interact with other cellular elements
to generate a finely tuned communications network that quickly allow microglia to
become activated in response insult and injury rapidly (Nimmerjahn et al., 2005, Stone et
al., 2009, Cao et al., 2011).

In contrast, some interactions seem necessary for

homeostasis and regulation, such as the interaction of CD200 (cluster of differentiation)
on neurons and endothelial cells with CD200R on microglia, whereby deletion of CD200
or blockade with CD200R antagonists results in increased levels of microglia
demonstrating an activated phenotype (Peterson and Flood, 2012).
Microglia have a multitude of receptors on the cell surface, including toll-like
receptors, cytokine and chemokine receptors, and ion channels that allow the microglia
to remain sensitive to small changes in the extracellular environment. These changes
result from a plethora of stimuli and danger signals including pathogens, viral DNA,
lipopolysaccharide (LPS), interferon gamma (IFN-γ), CD40 ligand (CD40L), chemokines,
and proteases such as thrombin and tissue plasminogen activator (tPA) as well as
neurotransmitters, gangliosides such as GM1, matrix metalloproteinase-3 (MMP-3) and
even simple alterations in ion homeostasis (abd-el-Basset and Fedoroff, 1995, Tsirka,
1997, Suzumura et al., 1998, Aloisi et al., 1999, Moller et al., 2000, Tan et al., 2000, Kim
et al., 2005, Stone et al., 2009). More important to neurodegenerative disorders such as
Alzheimer’s disease and PD are microglial responses to misfolded proteins such as
amyloid beta (β-amyloid) and α-Syn, respectively. Under homeostatic conditions
damaged and misfolded proteins in the brain are cleared by the ubiquitin-proteasome
pathway (Kosloski et al., 2010). The immune surveillance function of myeloid cells in the
brain, such as microglia enables the cells to contact and control the neuronal
microenvironment, thereby maintaining the homeostatic conditions of the brain.
However, encounters with misfolded proteins, such as aggregated or modified α-
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synuclein, that cannot be cleared adequately from the microenvironment can lead to
increased microglial activation (Reynolds et al., 2008a).
Detection of disturbances within the neuronal microenvironment induce microglia
to become activated with graded responses relative to the extent of perturbation
(Kreutzberg, 1996). Upon activation, resting microglia undergo several physical and
metabolic changes including increases in proliferative capability, morphogenesis, cell
volume, and extension of their processes into an amoeboid appearance, which is
morphologically distinct from resting microglia that present small cell bodies with ramified
processes (Whitton, 2007, Stone et al., 2009, Peterson and Flood, 2012).
Morphological changes of microglia become more macrophage-like in appearance,
express surface proteins such as CD11b or major histocompatibility complex (MHC)
antigens, and change the expression pattern of cytokines that resemble a more
proinflammatory profile (Czlonkowska et al., 2002, Mosley et al., 2006, Su et al., 2008).
During activation, maximal densities of reactive microglia are found close to the lesion or
epicenter of injured cells (Mosley et al., 2006).
Among their many innate immune functions, activated microglia are also involved
in the induction of inflammation as well as cytokine-mediated cytotoxicity and antibodydependent cell cytotoxicity (ADCC). Moreover, microglia with antigen presentation and
co-stimulatory capabilities are able to induce and regulate T cell responses (Aloisi,
2001).

In the activated state, microglia show increased expression of Fc receptors

leading to increased IgG reactivity necessary for ADCC, upregulation of complement
receptors, and increased expression of cell adhesion molecules such as lymphocyte
function-associated antigen-1 (LFA-1), intercellular adhesion molecule-1 (ICAM-1)
(CD54), vascular cell adhesion molecule-1 (VCAM-1) (CD106) and CD1 (Kreutzberg,
1996), thus amplifying the abilities of microglia to traffic and migrate. Of interest, deletion
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of the FcγR by genetic ablation inhibits microglial activation and dopaminergic cell death
in animal models of PD (He et al., 2002). Activated microglia are known to produce a
variety of toxic substances that, in addition to killing infectious agents, also can
accelerate neuronal injury and death. These toxic substances include reactive oxygen
species (ROS), reactive nitrogen species (RNS), and proinflammatory mediators such as
cytokines, chemokines, and prostaglandins (Nimmerjahn et al., 2005, Mosley et al.,
2006, Stone et al., 2009, Phani et al., 2012).

As expected, generation of reactive

species is potentiated by upregulation of enzymes such as inducible nitric oxide
synthase (iNOS), cyclooxygenase 1 (COX1), COX 2 and nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase resulting in increased levels of oxidative
stress. These inflammatory conditions alter most cellular functions including proliferation,
differentiation, and cell death. High levels of ROS and RNS can cause proteins to
become inactivated and damaged, which then result in cellular death and degeneration
(Peterson and Flood, 2012). iNOS produces high levels of nitric oxide and superoxide
radicals which increase the nitration and modification of neuronal proteins such as αSyn, which in turn preferentially amplify microglial activation and cell surface expression
of MHC class II (MHC II) molecules (Hutter-Saunders et al., 2011, Mosley et al., 2012,
Phani et al., 2012). Large numbers of activated microglia that express increased human
lymphocyte antigen-DR (HLA-DR) (i.e., a human MHC II) have been shown in the SN of
post-mortem samples from brains of patients with PD or parkinsonism with dementia
(McGeer et al., 1988b, Vila et al., 2001) and in ante-mortem analyses by PET analysis
with PK11195, a ligand for the peripheral benzodiazepine receptor that is preferentially
expressed by activated microglia and correlates with disease severity in PD (Ouchi et
al., 2009).

Additionally, activated microglia are present in the SN and striatum of

animals used in models of PD such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)- and 6-hydroxydopamine (6-OHDA)-induced parkinsonism (Brecknell et al.,
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1995, Revuelta et al., 1999, Sugama et al., 2003a, Sugama et al., 2003b, Reynolds et
al., 2007, Reynolds et al., 2008a, Reynolds et al., 2008b, Reynolds et al., 2009a, b,
Reynolds et al., 2010).
Unregulated microglial activation has proven toxic to neurons due, in part, to
release of proinflammatory factors including, but not limited to IL-1β, TNF-α, IL-6, IFN-γ,
nitric oxide (NO), prostaglandin E2 (PGE2), and superoxide radical (Hunot and Hirsch,
2003, Mosley et al., 2006, Reynolds et al., 2008b, Hutter-Saunders et al., 2011, Mosley
et al., 2012). IL-1β activates microglial iNOS and NADPH oxidase that generate NO and
superoxide radicals, respectively (Czlonkowska et al., 2002, Laurie et al., 2007); both of
which directly and indirectly produce oxidative damage to neurons that is sufficiently
severe to result in imminent death. In addition, IL-1β secretion from microglia activates
the cells in an autocrine-fashion and induces the upregulated expression of cell surface
receptor CD23 (FcεRII), an early biomarker of microglial activation. Subsequent
activation after CD23 expression induces microglia to express greater amounts of iNOS
which subsequently leads to the production and buildup of nitric oxide (Phani et al.,
2012). This cascade of inflammation set up by acutely-activated microglial cells can
eventually progress to chronicity and lead to the activation and recruitment of the
adaptive immune system in PD (Mosley et al., 2006)
Interestingly, the SN contains the highest concentration of microglia in the brain,
especially in the ventral tier of the pars compacta (Lawson et al., 1990, Kim et al., 2000),
thus making this region especially susceptible to perpetuated microglial activation.
Abnormally high levels of IL-1β (interleukin) and TNF-α found in the plasma and cerebral
spinal fluid in patients with PD support this contention (Blum-Degen et al., 1995,
Gonzalez-Scarano and Baltuch, 1999). Reactive microglia are highly localized, found
closely to cell bodies of dead or injured nigral dopaminergic neurons, but not around
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striatal degenerating termini (Mirza et al., 2000), which suggests a retrograde
mechanism for neuronal death. Cell death can also result from loss of trophic support
stemming from microglia induced neuritic beading or synaptic stripping along dendrites
(Schiefer et al., 1999, Takeuchi et al., 2005).

These findings suggest a direct link

between dopaminergic neuronal death in PD and microglial activation. Indeed, postmortem examinations demonstrate that neuronal degeneration in PD is associated with
a substantive gliosis linked to activated microglia that also has been shown in MPTPinduced parkinsonism in primates, rodents, and humans (Langston et al., 1983, McGeer
et al., 1988b, Czlonkowska et al., 2002, McGeer et al., 2003, Teismann et al., 2003a).
Moreover, activated microglia have been shown phagocytizing dying dopaminergic cells
and are well-correlated with α-Syn deposition in neuronal inclusions (Giasson et al.,
2000). Importantly, in vivo and in vitro studies demonstrated that microglia become
activated in response to overexpression of α-Syn or nitrated and aggregated forms of αSyn, a major component of Lewy bodies found in the brains of PD patients (Reynolds et
al., 2008a, Su et al., 2008). Release of modified and misfolded proteins such as α-Syn
from injured or degenerating neurons increases proximate microglial activation and
subsequent degeneration of dopaminergic neurons in the SN. Moreover, oxidative stress
is upregulated by a multitude of mediators including increased levels of reactive oxygen,
nitrogen, and carbonyl species, which in turn raise high oxygen demand in the absence
of low antioxidant defense mechanisms (Stone et al., 2009). The increased oxidative
stress induces more modified α-Syn to become misfolded and aggregated with formation
of more fibrillar species and Lewy bodies associated with degenerating nigral neurons
that feed this cyclic cascade of progressive neuroinflammation and neurotoxicity in PD
(Mosley et al., 2006, Reynolds et al., 2008a, Reynolds et al., 2008b, Kosloski et al.,
2010, Sekiyama et al., 2012)
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Adaptive Immune-Mediated Exacerbation of Neuroinflammation
and Neurodegeneration
In addition to the involvement of the immune system’s innate arm, adaptive
immunity plays a profound role in neurodegeneration of the nigrostriatal pathway and
disease progression. A controlled immune response to infection and injury supports
homeostasis of the central nervous system (CNS) microenvironment by protecting the
host via killing pathogens and clearance of pathogenic debris to promote healing. A
chronically activated immune response without regulation amplifies inflammatory and
immune responses that lead to further tissue and cellular damage (Faraco et al., 2009).
Adaptive immunity utilizes immunological memory to recognize specific pathogens and
mount a stronger, amplified response than that afforded by innate immunity. Adaptive
immunity is typically initiated after innate immune cells, such as dendritic cells,
macrophages, or microglia via their pattern recognition receptors (PRRs), recognize
broad-specificities of pathogen-associated molecular patterns (PAMPs) and damageassociated molecular patterns (DAMPs), which are associated with microbial pathogens,
cellular stress, or cell components of damaged tissues (Mills, 2011).

By activating

antigen processing programs innate immune cells digest and process these substances,
insert the processed peptides into the groove of MHC molecules, and present the
peptide epitopes in context of MHC I or II molecules. Upon recognition of antigen by T
cells and their T cell receptor (TCR) for antigen, antigen presenting cells (APCs) become
activated to express co-stimulatory molecules and second signals such as IL-12 and IL-4
that aid in the maturation of type 1 T helper (Th1) or Th2 effector T cells that influence
cell- or antibody-mediated immunity, respectively.
While auto-antibodies against dopamine neuron antigens are present in the sera
and cerebrospinal fluid (CSF) of PD patients (McRae-Degueurce et al., 1988, Dahlstrom
et al., 1990, Kunas et al., 1995), the role of antibody-mediated or humoral immunity in
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PD has only recently begun to be investigated in depth. In addition to a variety of
antibodies directed against globally-expressed tissue antigens such as heat shock
protein (HSP)-65 and HSP-70 (Fiszer et al., 1996), PD patients also exhibit
autoantibodies to brain-associated molecules including GM1, S100B, glial fibrillar acidic
protein (GFAP), nerve growth factor (NGF), neurofilament, myelin basic protein, tau, Aβ,
neuronal calcium channels, as well as α-Syn and its modified and fibrillar forms (Elizan
et al., 1983, Karcher et al., 1986, Appel et al., 1994, Terryberry et al., 1998, Poletaev et
al., 2000, Zappia et al., 2002, Papachroni et al., 2007, Gruden et al., 2011, Yanamandra
et al., 2011). Immunohistochemical staining of post-mortem tissues from idiopathic and
familial PD patients show dopaminergic neurons within the SN that have bound IgG,
while tissues from age-matched controls and non-nigral control tissues show no
detectable bound immunoglobulin (Hong et al., 2005). The IgG was reactive with
approximately 30% of the dopaminergic neurons within the nigra and directly correlated
with numbers of MHC II+ and CD64+ (FcγRI) reactive microglia, but not with disease
duration. In PD patients, about 4% of the pigmented neurons contain Lewy bodies and
all pigmented, Lewy body-containing neurons presented detectable amounts of bound
IgG as well as α-Syn within inclusions. These patterns of antibody reactivity were
consistent with numbers of activated microglia around dopaminergic neurons that are atrisk of dying in PD. Together these data suggest that endogenous antibodies of
unknown specificity have the capacity to cross the blood brain barrier (BBB) and bind
cognate antigens expressed by dopaminergic neurons. Moreover, levels of antibodies to
α-Syn and catecholamine-derived melanin (i.e., neuromelanin) are increased in PD
patients, while anti-neuromelanin immunoglobulin binding to neurons is more prevalent
in early disease (Vellas et al., 2009). Opsonization or autoantibody binding of neurons,
targets those cells for phagocytosis and degradation by mononuclear phagocytes such
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as macrophages and microglia, and also can activate the complement system, a major
mediator of cell lysis and inflammatory reactions. Interestingly, activation of the
complement system may also be involved in microglia-mediated neuronal death since
microglia are the only cells within the SN that express the initial recognition component
of complement, C1q (Depboylu et al., 2011).

Moreover compared to controls, PD

patients exhibit increased areas of C1q-opsonized extracellular depositions of
neuromelanin within the parenchyma, and C1q-expressing phagocytic microglia
surround those areas as well as cells around the luminal surfaces of the vasculature
which express neuromelanin and C1q, suggesting a role for anti-self-antibodies and
C1q-mediated clearing pathways in PD.
In addition to activated microglia and astrocytes, T cells also comprise an integral
component of the PD lesion, although their function or even the mechanism(s) by which
they infiltrate remains enigmatic. Early autopsy evidence within the substantia nigra of
PD patients showed increased numbers of CD8+ T cells in close proximity to activated
microglia and degenerating neurons (McGeer et al., 1988b). More recently, both CD4+
and CD8+ T cells have been discovered within the SN of PD patients as well as MPTPtreated mice (Kurkowska-Jastrzebska et al., 1999b, a, Benner et al., 2004, Benner et al.,
2008, Brochard et al., 2009, Reynolds et al., 2009b). As PD patients exhibit some
leakiness across the BBB, the lymphocytic infiltration was thought to reflect a
dysfunctional BBB (Kortekaas et al., 2005); however, CD4:CD8 lymphocyte ratios of 1:5
in the SN of PD patients (Brochard et al., 2009) and 1:4 in the SN of MPTP-treated mice
(Kurkowska-Jastrzebska et al., 1999a) contrast the typical 2:1 ratio expected for
peripheral T cells performing surveillance functions and strongly suggest the
involvement of active processes other than dysfunctional BBB. Thus, the mechanism(s)
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by which these T cells gain access to the SN, their activation state, and their actual
function are questions that remain to be answered.
Peripheral immune aberrations, particularly in T lymphocyte subsets are
abundant in PD patients.

Total numbers of lymphocytes have been shown to be

diminished by 17%, while CD19+ B cells are diminished as much as 35% and CD3+ T
cells diminished by 22% (Bas et al., 2001). Among CD3+ T cells, numbers of CD4+ T
cells have been shown to be diminished by 31%, whereas numbers of CD8+ T cells are
not significantly changed. Naïve helper CD4+ T cells (CD45RA+) are diminished and
levels of effector/memory helper T cell subset (CD29+ or CD45R0+) are either
unchanged or increased. Selective loss of CD4+CD45RA+ naïve cells are also detected
in other neuropathological-associated disorders such as multiple sclerosis and Down’s
syndrome, suggesting a common immunological abnormality in neurological disorders
(Fiszer et al., 1994a, Crucian et al., 1995). Studies of PD patients’ peripheral blood
showed increased frequencies of activated CD4+ T cells expressing Fas (Hisanaga et
al., 2001),

increased IFN-γ-producing Th1 cells, diminished frequencies of IL-4-

producing Th2 cells, and CD4+CD25+ T cells (Baba et al., 2005). Circulating levels of IL15, RANTES (regulated on activation, normal T cell expressed and secreted), IL-10 and
IL-12 are significantly elevated in PD patients compared to controls suggesting that
immune effector cells are activated in PD (Rentzos et al., 2007, 2009). Evidence for the
increased mutual co-expression of CD4 and CD8 by CD45RO+ T cells with increased
expression of CD25 (α-chain of the high affinity IL-2 receptor), TNF-α receptors, and
diminished expression of IFN-γ receptors also suggested the presence of activated T cell
subsets in PD patients. In addition to T cells that express α- and β-chains of the T cell
receptor (TCRαβ+ T cells), elevated frequencies of T cell populations expressing γ- and
δ-chains of the TCR (TCRγδ+T cells) also have been found in the CSF of PD patients
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(Fiszer et al., 1994b) and are thought to play a regulatory role in CNS inflammation
(Ponomarev and Dittel, 2005, Bennett and Stuve, 2009, Blink and Miller, 2009).
Moreover, a larger proportion of the TCRγδ+ T cells also express CD25 compared to
controls, suggesting these CSF-obtained T cells are preferentially activated in PD
patients (Fiszer et al., 1994a). More recently, T cell frequencies were compared to
disease severity as measured by the Unified Parkinson's Disease Rating Scale, part III
scores. Those studies showed that in peripheral blood from PD patients compared to
age- and environment-matched caregivers, frequencies of CD45RO+ and FAS+
effector/memory CD4+ T cells were increased and were directly correlated with disease,
while those of CD31+ and α4β7+ CD4+ T cells were diminished and were indirectly
correlated with disease progression (Saunders et al., 2012a). No correlations could be
established between frequencies of CD4+ cells within any T cell subsets and age or
disease duration. Additionally, the ability of CD4+ regulatory T cells (Tregs) from PD
patients to suppress anti-CD3 stimulated effector T cell function from healthy donors was
impaired. Overall, these data support the notion that chronic immune stimulation, notably
effector/memory T cell activation and Treg dysfunction, is linked to PD pathobiology and
disease severity, but not disease duration. The association of T cell phenotypes with
motor symptoms provides fresh avenues for novel biomarkers and therapeutic designs.
One mechanism by which T cells are mobilized to infiltrate the CNS during PD is
though the drainage of aberrant forms of α-Syn into the lymphatic system, which
activates APCs to induce T cells that recognize aggregated or nitrated α-Syn (N-α-Syn)
species (Figure 1).

Indeed, in MPTP-intoxicated mice, α-Syn and most likely other

inflammatory mediators, drains to cervical lymph nodes where APCs are activated to
induce effector T cells (Benner et al., 2008). An influx of α-Syn-specific T helper 1 (Th1)
or Th17 effector T cells into the brain during PD could increase the inflammatory
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phenotype and neurotoxic response of microglia near dopaminergic neurons by
increasing the concentration of proinflammatory molecules in the substantia nigra
(Reynolds et al., 2010). Taken together, increased frequencies of memory and activated
peripheral T cell subsets, as well as those cells within the nigra of PD patients suggest
putative roles of T cells in disease progression and possibly PD etiology. Although,
those roles have yet to be delineated, activated effector T cells (Teffs) or Tregs both
exhibit effector/memory T cell phenotypes and may migrate to foci of inflammation in PD
patients and lead to Teff-mediated exacerbation or Treg-mediated attenuation of PDassociated neuroinflammation and neurodegeneration. Thus, Tregs have the capacity to
keep the disorder in check during the early or asymptomatic phase, while Teffs can
accelerate disease progression (Figure 1). Whether T cell aberrations in PD patients
reflect specifically-activated effector or regulatory T cell subsets and to which specific
antigen(s) those T cells are activated, require answers to develop more precise immunebased therapeutic strategies.
Modified α-Syn exposed to the immune system in sufficient quantity and under
the appropriate conditions, such as a proinflammatory milieu, can function as a foreign
antigen to engage adaptive immunity. Previous studies have demonstrated that nitrated
α-synuclein acts as a neoantigen that breaks immunological tolerance and exacerbates
MPTP-induced

neuroinflammation

and

enhances

subsequent

dopaminergic

neurodegeneration along the nigrostriatal axis (Benner et al., 2008, Kosloski et al., 2010,
Ha et al., 2012, Mosley et al., 2012). In MPTP-treated mice, the inflammatory milieu,
which includes N-α-Syn, drains to the cervical lymph nodes within 24 hours and
activates APCs. Conceivably, N-α-Syn that is chronically released from degenerating
neurons would reach the circulation and afferent lymphatics of PD patients, be
sequestered in the secondary lymphoid tissues, and be processed and presented by
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MHC II of activated APCs to induce effector T cells (Kosloski et al., 2010). Indeed, after
several weeks, MPTP-treated mice produce antibodies to N-α-syn, but not to unmodified
α-syn (Benner et al., 2008). Moreover, immunization with N-α-Syn induces Teffs that
recognize nitrated epitopes, but not non-nitrated α-Syn moieties. In contrast,
immunization with unmodified α-syn yields no detectable effector T cells that recognize
either unmodified or N-α-Syn. The induced N-α-Syn-specific Teffs are thought to be
recruited to areas of inflammation surrounding the dopaminergic neurons in the
substantia nigra. Since the Teffs are specific for the disease-associated protein
modifications in α-Syn, presentation of N-α-Syn epitopes by MHC II of already activated
APCs (microglia, macrophages, or dendritic cells) within the inflamed substantia nigra
would evoke a helper Teff-mediated immune response and promote expansion and/or
cytokine secretion appropriate for the type of induced helper Teff subtype that includes
Th1, Th2, or Th17 Teffs. Th1 cells express various proinflammatory cytokines such as
IL-2, IFN-ɣ, and TNF-α that act to induce activated microglial release of ROS, nitric
oxide, and proinflammatory factors, all of which are neurotoxic (Kosloski et al., 2010,
Cao et al., 2011) (Figure 1). Th17 cells also release proinflammatory cytokines such as
TNF-α, IL-17A, IL-17F, IL-21, and IL-22 which a) induce non-hematopoietic tissue
reactions due to the distribution of IL-17 and IL-22 receptors among both epithelial and
endothelial cells; b) stimulate the production of inflammatory cytokines such as TNF-α,
IL-1β, and IL-6; and c) induce IL-21/IL-21 receptor mediated signaling by T cell, B cell,
myeloid-derived cells, and natural killer cells (Aggarwal et al., 2001, Kebir et al., 2007,
Hecker et al., 2009, Korn et al., 2009, Monteleone et al., 2009, Kosloski et al., 2010).
Secretion of proinflammatory cytokines such as TNF-α, IL-1β, and IL-12 disrupts the
BBB integrity by increasing the expression of cellular adhesion molecules, such as Eselectin, while inducing chemokine gradients to allow the extravasation of Teff subtypes
through the endothelial cells of the microvasculature and into the brain at the site of
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inflammation (Czlonkowska et al., 2002, Stone et al., 2009, Reynolds et al., 2010,
Hutter-Saunders et al., 2011, Mosley et al., 2012). Once within inflammatory sites of the
substantia nigra, Th1 and Th17 effectors can secrete proinflammatory and neurotoxic
cytokines (Figure 1). Alternatively, Teffs could drive microglia to a hyper-activated or
neurotoxic phenotype that produces greater levels of neurotoxic mediators within the
microenvironment, killing surrounding dopaminergic neurons, and leading to accelerated
disease progression. In the MPTP model, N-α-Syn-specific Teffs exacerbate the extent
of the neuroinflammatory response with increased numbers of activated microglia,
prolong the intensity of the inflammatory response, accelerate the rate of dopaminergic
cell death, and worsen the extent of the nigrostriatal lesion by 50% (Benner et al., 2008,
Reynolds et al., 2010). Moreover, N-α-Syn Teffs polarized to yield Th17 effectors afford
significantly greater capacity to kill dopaminergic neurodegeneration compared to those
Teffs polarized as Th1 effectors (Reynolds et al., 2010, Mosley et al., 2012). Thus, the
omnipresent inflammatory cytokine gradients produced not only from Teffs, but also from
hyper-activated microglia, combined with injured and dying neurons that release
modified and misfolded proteins, come together to form the perfect storm sufficient for a
chronically inflamed CNS environment and persistent oxidative reactive state along the
nigrostriatal axis that ultimately is responsible for disease progression in PD (Kebir et al.,
2007, Appel, 2009, Kosloski et al., 2010, Mosley et al., 2012).

Control of Immune-Mediated Neuroinflammation and
Neurodegeneration in PD
While proinflammatory effector T cells upregulate neuroinflammatory responses
of microglia, Th2 effector cells secrete anti-inflammatory cytokines such as IL-4, IL-5,
and IL-13 which work to enhance the neuroprotective activity of the microglial cells.
Induction of Th2 effectors have been successfully utilized in strategies of
immunomodulation therapy in multiple sclerosis using glatiramer acetate (Schrempf and
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Ziemssen, 2007, Yong, 2009). In that same vein, CD4+ Th2 effectors from glatiramer
acetate immunized mice attenuate MPTP-induced neuroinflammation and dopaminergic
neurodegeneration presumably by diminishing levels of activated microglia resulting
from anti-inflammatory cytokine production as well as providing neurotrophic support via
increased glial cell-derived neurotrophic factor (GDNF) production by astrocytes (Benner
et al., 2004, Boska et al., 2005, Laurie et al., 2007). Interestingly, cytokines from one
particular Teff subtype tend to regulate the other types (Zhu and Paul, 2010).

For

instance, Th2-produced IL-4 suppresses Th1 and Th17 development and Th1-specfic
IFN-γ inhibits Th2 and Th17 cell maturation, while IL-17 produced by Th17 effectors
inhibits Th1 and Th2 function.
Another T cell population with neuroprotective capabilities is the regulatory T cell
(Treg).

Tregs play an indispensable role in maintaining immune homeostasis and

controlling immune mediated inflammation, and are thought, at least in part, responsible
for the establishment and maintenance of immunological tolerance to self and protection
from autoimmunity (Sakaguchi et al., 2001). Moreover, after foreign pathogens and
antigens are removed by immune responses, suppression of active effectors is
necessary to minimize cytotoxic effects of inflammation on self-tissues. Natural Tregs
(nTregs) are generated in the thymus and express both CD4 and CD25 cell surface
markers in addition to the transcription factor regulatory forkhead box P3 (FoxP3), which
is required not only for development and maintenance in the periphery, but also for
function (Faraco et al., 2009). Indeed some mutations in FoxP3 lead to Treg dysfunction
and

a

systemic

autoimmune

disorder

designated

as

immune-dysregulation,

polyendocrinopathy, enteropathy X-linked syndrome (Wildin et al., 2002), which, without
hematopoietic reconstitution of the Treg component, is a fatal condition. While nTregs
are derived directly from the thymus, generation of induced or inducible Tregs (iTregs) is
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possible with CD4+ T cells and the appropriate polarizing conditions, such as co-culture
in the presence of transforming growth factor-β (TGF-β), IL-2, IL-10, and/or all-trans
retinoic acid (Mosley et al., 2012).

Tregs regulate immune responses by different

mechanisms at several different levels. Mechanisms of Treg control include secretion of
anti-inflammatory cytokines such as IL-10 and TGF-β (Hawrylowicz and O'Garra, 2005,
Joetham et al., 2007), cytolysis of Teffs (Grossman et al., 2004), metabolic disruption by
removing IL-2 (“IL-2 sponge”) (Pandiyan et al., 2007), and modulation of dendritic cell
maturation or function through CTLA4 ligation (Tadokoro et al., 2006, Tang et al., 2006).
Effector cells such as T cells, B cells, or myeloid and APCs, including microglia are
inactivated or neutralized via cell-cell interaction of receptors with Tregs, albeit the
requirement is determined through in vitro measurements, thus the necessity of proximal
contact in vivo has not been adequately addressed (Suri-Payer et al., 1998, Cederbom
et al., 2000, Thornton and Shevach, 2000). Previous reports have shown Tregs induce
significant reductions in the number of activated microglia in the SN by decreasing
mRNA expression of TNF-α and iNOS in the midbrain, indicating the reduction of
microglia-mediated inflammation and oxidative stress (Reynolds et al., 2007, Reynolds
et al., 2008a, Reynolds et al., 2008b, Reynolds et al., 2009a, Stone et al., 2009, Cao et
al., 2011, Mosley et al., 2012). Tregs also reduce nuclear factor-kappa B (NF-ҡB) gene
expression and nuclear translocation, thereby reducing production and release of
proinflammatory factors from activated microglia. Interestingly, co-culture with Tregs
prior to stimulation of microglia with N-α-Syn results in the suppression of microglial
production of ROS and proinflammatory cytokines/chemokines; however co-culture after
microglial stimulation results in the upregulation of Fas by microglia and Fas ligand by
Tregs with subsequent killing of the stimulated microglia by Fas-Fas ligand interactions
(Reynolds et al., 2009a). It is increasingly evident proinflammatory innate and adaptive
immune responses are upregulated in PD and are thought to play a major role in
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disease exacerbation and hence progression. In fact, the discovery of a mechanism of
action for effector T cell involvement, specifically Th17 cells, and the role they play in the
exacerbation of neurodegeneration in PD would allow further investigation into immune
modulatory regimens as possible treatment strategies.

Discovery of a Distinct T Cell Lineage
In the late 1960’s the B cell was initially distinguished from the T cell. After the
distinction of antibody producing B lymphocytes from their helper T lymphocytes came
the division of helper T cell population s and cytotoxic T cell populations, followed by the
discovery of distinct lineages of helper T cells (Claman et al., 1966, Mitchell and Miller,
1968, Cantor and Boyse, 1975, Mosmann and Coffman, 1989). A lineage, according to
these early studies, can be defined as naïve T helper cells that differentiate
independently into each lineage both in vitro and in vivo, along with each lineage having
a gene expression signature that is distinct and heritable (Dong, 2008). It was with
these ground rules that the common cluster of differentiation (CD) were denoted as
CD4+ T helper cell lineages.
Early descriptions of the Th1/Th2 model by Mossman, Coffman, and associates
looked to explain the responses observed in many different models of infection and autoinflammatory diseases in the context of Th1 and Th2 phenotype CD4+ T cells (Mosmann
et al., 1986, Heinzel et al., 1989, Mosmann and Coffman, 1989). Th1 cells, promoted by
IL-12 and IFN-γ signaling, induce the expression of master transcription factor T-box 21
(T-bet) and secrete a hallmark cytokine, IFN-γ (Szabo et al., 2000, Afkarian et al., 2002,
Oestreich and Weinmann, 2012). Th2 cells, on the other hand, are induced by IL-4
signaling via signal transducer and activator of transcription-6 (STAT6), which up
regulates the GATA3 transcription factor and secretes anti-inflammatory cytokines such
as IL-4, IL-5, and IL-13 (Kaplan et al., 1996, Zheng and Flavell, 1997). Later discovery
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of FoxP3 expressing CD4+ T cells (Tregs) only sought to compliment the initial findings
of the Th1/Th2 paradigm and early views of naïve CD4+ T cell differentiation into T
helper cells (Hori et al., 2003).
Nonetheless, not all CD4+ T cell activity could be confined into these initial
categories leading investigators to seek to expand upon the two-mode Th polarization
scheme established by Mossman and colleagues.

The first sign of the Th17 cell

phenotype and lineage was made in the year 2000 in relation to the role of these cells in
the host immune response to Borrelia burgdorferi, which induced the production of IL-17
by the T helper cells (Infante-Duarte et al., 2000). The first distinction of the CD4+ T
helper cell phenotype Th17 was first described by Harrington et al. and Park et al. in
2005 (Harrington et al., 2005, Langrish et al., 2005, Park et al., 2005, Muranski and
Restifo, 2013). This discovery of a true distinct lineage (Th17 cells), whose in vitro
generation was heightened when IL-4 (Th2 differentiation) and IFN-γ (Th1 differentiation)
were blocked, was found to be independent of the Th1 and Th2 related transcription
factors such as T-bet, STAT1, STAT4, and STAT6.
The CD4+ T helper cell lineages have been found to be essential to the normal
functioning of the entire immune system. They work to coordinate and facilitate B cell
responses in addition to regulating CD8+ T cells, all while recruiting and modulating
multiple components of innate immunity (Sun and Bevan, 2003, Bevan, 2004, Muranski
and Restifo, 2009, Swain et al., 2012). The Th17 cell evolved to promote the clearance
of attacking pathogens, such as parasites, and infections that were outside the range of
capabilities of the Th1 and Th2 cell phenotypes.
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Generation and Development of Th17 cells
The induction of Th17 type T cells can be attributed to an effect of IL-23 and IL-6
signaling. Initially IL-23 signaling via the IL-23 receptor (IL-23R) was found to trigger the
STAT3 pathway and subsequent Th17 cell differentiation, although in vitro culturing
using this process showed only small fractions of IL-17a producing Th17 cells generated
(Oppmann et al., 2000, Langrish et al., 2005). In vivo testing demonstrated the ability of
IL-23 to selectively induce the proliferation of IL-17 producing cells (Langrish et al.,
2005). Further testing of IL-6 and TGF-β1 signaling was efficient enough to generate a
robust Th17 population via signaling through Smad family proteins and STAT3 (Hirahara
et al., 2010). Eventually the transcription factors retinoic acid (RA) –related orphan
receptor-C (RORC) for humans and ROR-thymus (RORɣT) for mice were identified as
the master transcription factors that define the Th17 phenotype, while RA-related orphan
receptor α (RORα) was recognized as an additional transcription factor leading to the
differentiation of the Th17 lineage CD4+ T cells (Ivanov et al., 2006, Yang et al., 2008b,
Azizi et al., 2013).
It is the positive and negative regulations of different factors on these lineage
specific transcription factors which lead to the differentiation of the CD4+ Th17
phenotype helper T cell. The release of IL-2 from Th1 cells and subsequent signaling
via STAT5 has the ability to attenuate Th17 polarization and STAT5 has been shown to
have a direct negative effect on IL-17A gene expression (Laurence et al., 2007, Yang et
al., 2011).

Another Th1 cytokine, IFN-γ, clearly has the ability to attenuate Th17

differentiation as well (Lazarevic et al., 2011). In addition to the transcription factors
stated, aryl hydrocarbon factor-4 and basic leucine zipper transcription factor (BATF)
have also been identified as factors that can effect differentiation and development of the
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Th17 phenotype (Brustle et al., 2007, Kimura et al., 2008, Veldhoen et al., 2008, Hirota
et al., 2010).
Th17 cells are derived from CD161+ precursor cells (Cosmi et al., 2008). As with
all T helper cell lineages the functional differentiation of Th17 cells is orchestrated by the
innate immune system which provides co-stimulatory molecules that allows for ideal T
cell activation and proliferation. In addition to the co-stimulatory effects of the innate
immune system is a distinct cytokine production that leads to the development of the
Th17 specific lineage of T helper cells.
When investigating the realm of co-stimulatory molecules potentially provided by
the innate immune system, it becomes clear that CD28 and

inducible T cell co-

stimulator (ICOS) are important for the generation of Th17 cells (Park et al., 2005,
Nurieva et al., 2006). This finding is consistent with the development of the Th2 lineage
which also requires the same co-stimulatory molecules, but is in stark contrast to what is
required for Th1 differentiation that may require only one of the co-stimulatory molecules
(Dong, 2008). The findings of Harrington and Park demonstrate the lack of necessity for
either IL-4 or IFN-ɣ in the differentiation of the Th17 lineage, indicating yet again that
Th17 cells are their own distinct and separate lineage from that of the Th1 and Th2 cells
(Harrington et al., 2005, Park et al., 2005).
In vitro testing of CD4+ T cells has shown ligation of toll like receptor-3 (TLR3),
TLR4, and/or TLR9 leads to the secretion of cytokines that support the differentiation of
naïve CD4+ T cells into Th17 cells such as TGF-β and IL-6 (Veldhoen et al., 2006a).
Several groups have also shown the necessity for synergistic effects of TGF-β and IL-6
for Th17 cell differentiation both in vitro and in vivo (Bettelli et al., 2006, Mangan et al.,
2006, Veldhoen et al., 2006a). Moreover, in order for naïve CD4+ T cells to take on a
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Th17 phenotype they need the support of several different cytokines for their growth
including TGF-β, IL-1β, IL-6, IL-21, and IL-23 in mice and/or humans (Acosta-Rodriguez
et al., 2007a, Chen et al., 2007, Evans et al., 2007, Wilson et al., 2007, Liu and
Rohowsky-Kochan, 2008, Yang et al., 2008a, Chung et al., 2009, Korn et al., 2009,
Sutton et al., 2009, Hirahara et al., 2010, Jadidi-Niaragh and Mirshafiey, 2011, Azizi et
al., 2013). It is these cytokines that drive activation of the STAT3 pathway, inducing
expression of the RORɣT transcription factor and subsequently leading naïve CD4+ T
cells to Th17 differentiation (Holland et al., 2007, Yang et al., 2007, Ma et al., 2008,
Jadidi-Niaragh and Mirshafiey, 2011, Azizi et al., 2013). In humans specifically IL-1, IL-6
and IL-23 have been shown to promote Th17 cell differentiation, whereas the role of
TGF-β and/or whether it is required at all still remains unsolved (Korn et al., 2007,
Wilson et al., 2007, Du et al., 2009, Jadidi-Niaragh and Mirshafiey, 2011).
The pathway leading to Th17 differentiation in vivo requires conditions that
include the presence of IL-23, a product of APCs, consisting of a p19 polypeptide and a
peptide shared with IL-12, p40 (Aggarwal et al., 2003, Ghilardi et al., 2004, Langrish et
al., 2005). In addition, mice deficient in the p19 polypeptide show resistance in a variety
of adjuvant induced models of autoimmunity, mainly thought to be the result of the
absence of IL-17 producing T cells that would normally be present (Cua et al., 2003,
Murphy et al., 2003). In vitro testing has shown the inability of IL-23 to induce the
differentiation of naïve CD4+ T cells to the Th17 lineage, whereas a combination of IL-6
and TFG-β has the capability to do so.

The expression of TGF-β leading to the

differentiation of Th17 cells also allows for the prevention of Th1 (Santarlasci et al.,
2009) and Th2 lineage commitment through STAT4 suppression and GATA3 expression
(Das et al., 2009, Ghoreschi et al., 2010, Jadidi-Niaragh and Mirshafiey, 2011).
Alongside TGF-β induced suppression, IL-1β works to negatively regulate Th1
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differentiation through the induction of cyclooxygenase 2 (COX-2) leading to an increase
of secretion of prostaglandin E2 (PGE2) which suppresses IFN-γ production from Th1
differentiated T cells (Reznikov et al., 2000, Waite and Skokos, 2012).
IL-21, a cytokine shown to support the growth and differentiation of Th17 cells
has no effect on the Th17 differentiation when the cytokine is absent (Sonderegger et
al., 2008). IL-21 action is mediated by IL-6, which, through the binding of the cytokine to
its receptor, causes the activation of the STAT1/STAT3 pathway (Leonard and Spolski,
2005, Azizi et al., 2013) In addition to the above cytokine secretion leading to the
differentiation of naïve CD4+ T cells into the Th17 phenotype, IL-6 induced expression of
IL-21 from mature Th17 cells promote further Th17 differentiation in an autocrine fashion
(Korn et al., 2007, Nurieva et al., 2007, Zhou et al., 2007). In accordance with the
necessity of TGF-β to be present for CD4+ naïve T cells proliferation and differentiation
to the Th17 cell lineage in mice, TGF-β deficient mice show a significant decrease in the
number of Th17 cells present in addition to a higher number of IFN-ɣ expressing Th1
cells, yet again propagating the need for TGF-β in Th17 cell differentiation (Li et al.,
2007). In contrast, while the presence of IL-6 has been reported by multiple studies to
be necessary for naïve CD4+ T cell differentiation to the Th17 phenotype, one group has
shown that the Th17 lineage can in fact be produced in IL-6 deficient mice through the
use of IL-21 (Zhou et al., 2007).
Many different factors and cytokines released from other T helper cell
phenotypes have the ability to attenuate Th17 cell differentiation. Two Th1 hallmark
cytokines, IFN-ɣ and IL-12, have been shown to inhibit Th17 phenotype differentiation in
many ways. IFN-ɣ can prevent IL-23 driven expansion of the Th17 phenotype as well as
driving T-bet overexpression, again leading to the decline in Th17 cell differentiation
(Lighvani et al., 2001, Cua et al., 2003, Harrington et al., 2005, Mathur et al., 2006,
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Gocke et al., 2007). The transcription factor regulators of IFN-ɣ and IL-12 induction,
STAT1 and STAT4, also play a part in the negative regulation of Th17 development as
STAT1 deficient T cells show an increase in IL-17 production (Harrington et al., 2005,
Azizi et al., 2013). IL-27, another known negative regulator of Th17 cells, mediates its
regulation through the engagement of STAT1 (Azizi et al., 2013). Just as Th1 cells have
the ability to inhibit Th17 cell differentiation, Th2 cells act similarly through the use of IL4, GATA3, proto-oncogene c-MAF, and STAT6 to inhibit Th17 phenotype differentiation
(Murphy and Reiner, 2002, Harrington et al., 2005, Park et al., 2005). In addition, the
critical cytokine growth factor for Tregs, IL-2, has also been shown to have inhibitory
effects on Th17 phenotype differentiation.

Characterization of Th17 Cells
Interleukin 17 acts through signaling via its IL-17 receptors.

The first IL-17

receptor identified was IL-17Ra, and since its discovery four additional receptors have
been added to the family including IL17Rb, IL-17Rc, IL-17Rd, and IL-17Re (Miossec and
Kolls, 2012).

IL-17a can form homodimers to initiate signaling, as well as form

heterodimers with IL-17c and IL-17d to mediate downstream signaling of Th17 cell
cytokine IL-17 (Rong et al., 2009).

In addition, an IL-17Ra/IL-17Rb heterodimer is

required to mediate IL-17e signaling, although IL-17e has not been shown to be a
cytokine produced from Th17 cells (Miossec and Kolls, 2012).
The hallmark cytokine expressed by Th17 cells is IL-17, a cytokine associated
with host defense against infectious agents as well as autoimmune diseases. While the
IL-17 cytokine family is composed of 6 members, IL-17a through IL-17f, it is generally
believed that Th17 cells are only induced to express IL-17a and IL-17f (Kolls and Linden,
2004, Muranski and Restifo, 2013). The IL-17 gene and associated IL-17 protein were
first discovered by Rouvier et al. as a gene product of murine T cells and were initially
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named cytotoxic T lymphocyte-associated antigen 8 (CTLA8) (Rouvier et al., 1993). In
humans, IL-17 was first discovered in patients with rheumatoid arthritis and its effect of
normal skin fibroblasts from non-affected individuals revealed that IL-17 could induce the
production of IL-6 and IL-8 (Fossiez et al., 1996, Miossec et al., 2009). In addition to IL17, other known signature cytokine secretions from Th17 cells include IL-21, and IL-22
(Harrington et al., 2005, Langrish et al., 2005, Park et al., 2005, Bending et al., 2011).
Studies have shown the cytokines TGF-β and IL-6 use the RORɣT transcription factor to
promote IL-21R and IL-23R expression from Th17 cells (Ivanov et al., 2006). In addition
to IL-17 secretion, Th17 cells have been shown to secrete other proinflammatory
cytokines and chemokines such as TNF-α, IL-1β, IL-6, IL-4, IL-10, IL-9, IL-26, CXCL8,
and chemokine C-C motif ligand 20 (CCL20) in order to amplify ongoing proinflammatory
effects in sites of inflammation (Annunziato et al., 2007, McGeachy et al., 2007, Weaver
et al., 2007, Boniface et al., 2008, Beriou et al., 2010, Cosmi et al., 2010, Jadidi-Niaragh
and Mirshafiey, 2011). Expression of chemokines such as CXCL1, CXCL5, IL-8, CCL2,
and CCL7 through IL-17 stimulation of IL-17R has been shown to be responsible for the
recruitment of neutrophils to site of inflammation (Kolls and Linden, 2004). A prime
example of such an instance includes neutrophil recruitment in the experimental
autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis due to the local
production of IL-17 by Th17 cells in the CNS (Park et al., 2005, Veldhoen et al., 2006b).
Receptors for the cytokine IL-23 (expressed by mature Th17 cells) found
downstream of T cell activation also promotes further differentiation of naïve CD4+ T
cells into Th17 cells through a STAT3 dependent manner (Chung et al., 2009, Guo et al.,
2009). IL-17 has been shown to bind to and signal through IL-17Ra and IL-17Rf. The
IL-17 receptor family contains conserved extracellular fibronectin III-like domains and
cytoplasmic similar expression to FGF/IL-17R (SERIF) domains (Gaffen, 2009).

28
Because of this high level of conservation, Il-17Ra and IL-17Rf are 55% identical and
have the ability to form both homodimers and heterodimers with each other for IL-17
receptor activation (Kolls and Linden, 2004, Wright et al., 2007). Furthermore, IL-17Ra
is known to be widely expressed by immune cells along with mesenchymal cells such as
epithelial cells, endothelial cells, and fibroblasts (Yao et al., 2011).

Additionally, as

IL17Rc has been found on the surface of epithelial cells and fibroblasts, recent studies
have shown the possibility of IL-17Ra to form a heterodimer with IL-17Rc thereby
allowing for additional forms of IL-17 receptor activation and signaling through the IL-17
receptor family (Toy et al., 2006, Kuestner et al., 2007, Ishigame et al., 2009).
Activation of the IL-17 receptor pathway leads to downstream signaling that
activates NF-κβ and mitogen-activated protein kinase (MAPK) pathways (Shalom-Barak
et al., 1998, Schwandner et al., 2000, Ho and Gaffen, 2010). Once the ligand engages
IL-17R downstream signaling ensues that includes activation of the NF-κβ, MAPK, and
C/EBP pathways via the SERIF domain containing the adaptor protein ACT1 (Kuestner
et al., 2007, Ishigame et al., 2009). More recent studies have shown the use of the
adaptor protein ACT1 as an essential signaling component of the IL-17Ra (Chang et al.,
2006). ACT1 is able to directly associate with intracellular regions of IL-17Ra and is
found to be a required component of NF-κβ pathway activation and the pathways leading
to the induction of many pro-inflammatory genes. In fact, ACT1 deficient mice have
been shown to be resistant to many diseases such as EAE and dextran sulphate
sodium-induced colitis (Qian et al., 2007). Upon signal activation in the SERIF domain,
ACT1 further signals through interaction with TNF receptor (TNFR) –associated factor 6
(TRAF6) and protein kinase TAK1, promoting signal transduction along with cytokine
and chemokine secretion (Ho and Gaffen, 2010).

Former studies have shown IL-6

expression depends upon IL-17 activation of TRAF6 (Schwandner et al., 2000).

29
Activation of IL-22R by Th17 cell-produced IL-22 leads to activation of STAT3,
which induces the expression of anti-microbial peptides β-defensin-2 and β-defensin-3
(Wolk et al., 2004).

In addition, IL-22 and IL-17a/IL-17f work to co-regulate the

expression of β-defensin-2 and S100 calcium-binding protein A9 (S100A9), thereby
showing the combined effect of Th17 cytokine production on proinflammatory responses
(Liang et al., 2006).

Furthermore, induction of STAT3 by IL-6 causes downstream

signaling leading to the expression of IL-21 (Nurieva et al., 2006, Wei et al., 2007, Zhou
et al., 2007).
Once the generation and differentiation of the Th17 cell lineage was defined, the
role Th17 cells played in the human body was also of question. The evolution of the
Th17 phenotype CD4+ helper T cell was, in fact, most likely due to the need to promote
host clearance of a range of pathogens beyond those targeted by Th1 and Th2 cells
(Weaver et al., 2006, Bettelli et al., 2007).

These pathogens include a variety of

bacterial and fungal infections at mucosal surfaces for which the Th17 lineage is tasked
with clearing (Harrington et al., 2006, Liang et al., 2006). In fact, experiments have
shown that IL-17 and IL-17R knockout mice have increased vulnerability to infection by
microorganisms and pathogens (Milner and Holland, 2013, Gaffen et al., 2014). Similar
evidence has led investigators to the conclusion that peripheral Th17 cells are essential
to clear a pathogen during host defense reactions and to maintain a healthy immune
system (Korn et al., 2009).
While Th17 cells have the capacity to facilitate a strong inflammatory response in
the body they also, like any inflammatory response, have a system of regulation in place
as well. The effects of FoxP3+ regulatory T cells work to facilitate erroneous or overactivated Th17 cells to preserve immune homeostasis. As IL-10 is a known negative
regulator of inflammation, Chaudhry and colleagues demonstrated the use of a positive
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feedback loop in T regulatory cells, that used signaling via IL-10R on Tregs and led to
STAT3 dependent expression of further IL-10, cooperatively working to contain Th17
responses (Chaudhry et al., 2011, Sie et al., 2014).

Role of Th17 Cells in Neuroinflammation
IL-17 producing Th17 cells play a role in several areas of inflammation in the
human body including local and systemic components. The release of IL-17 mediates
the release of IL-6 and IL-8, leading to fever (systemic) as well as the accumulation of
neutrophils in blood and tissues (local) (Miossec and Kolls, 2012).

In general the

proinflammatory cytokine IL-17, secreted from Th17 cells, is a powerful proinflammatory
cytokine that works to recruit inflammatory mediators to the site of local tissue
inflammation. IL-17 has the ability to promote recruitment of monocytes and neutrophils
to sites of inflammation, manage the expansion of myeloid cells, as well as drive T cell
responses using CCL20 induction (Fossiez et al., 1996, Linden et al., 2000, Kao et al.,
2005, Kebir et al., 2007). The receptor for the CCL20, CCR6, as mentioned before is
highly up-regulated in Th17 cells and could potentially play a part in amplifying the IL-17
inflammatory effects through recruitment of more Th17 cells via a positive feedback loop
(Brucklacher-Waldert et al., 2009). In addition, IL-17 has the ability, upon release, to
enhance T cell priming as well as stimulate fibroblasts, endothelial cells, macrophages,
and epithelial cells to release a milieu of proinflammatory mediators such as IL-1, IL-6,
TNF-α, nitric oxide synthase-2 (NOS2 or iNOS), metalloproteases and chemokines
(Nakae et al., 2003, Kolls and Linden, 2004, Iwakura and Ishigame, 2006).

These

mediators can further enhance inflammation.
The expression of IL-17 has been shown through various studies to be
associated with many inflammatory diseases such as rheumatoid arthritis, systemic
lupus erythematosus, allograft rejection, multiple sclerosis, psoriasis, and inflammatory
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bowel disease (Moseley et al., 2003, Kolls and Linden, 2004) (Marwaha et al., 2012).
The elusive status of being a destructive element to the disease progression of
inflammatory diseases in humans was initially due to correlative data documenting an
increase in IL-17 producing cells in sites of tissue inflammation for those diseases (Wilke
et al., 2011), and in animal models such as EAE and collagen induced arthritis
demonstrating the lack of IL-17 producing cells ameliorated inflammatory progression
(Cua et al., 2003). This initial prognosis of the exacerbation of disease through Th17
cells effects is, in most cases, an over simplification of the role these cells play in
different diseases. In addition, in vivo testing has shown the requirement of TGF-β for
the initiation of Th17 dependent autoimmune encephalitis (Veldhoen et al., 2006b).
As for the role of Th17 cells in neuroinflammation, Th17 cells have been shown
to attach to endothelial cells of the brain better than Th1 cells due to the presence of
CD146 (melanoma cell adhesion molecule) on the surface of Th17 cells (BrucklacherWaldert et al., 2009).

Higher levels of cell surface markers that facilitate entry of

infiltrating T cells into the CNS such as CCR6 and CD6 have been shown to be highly
expressed on Th17 cells in the EAE model of multiple sclerosis, giving Th17 cells an
advantage for entry into the CNS upon activation (Cayrol et al., 2008, BrucklacherWaldert et al., 2009, Reboldi et al., 2009). The breakdown of the BBB and subsequent
infiltration of these mononuclear cells, including Th17 cells, is considered essential to the
formation of inflammatory lesions in the CNS and a necessary prerequisite to the
proinflammatory effects produced by Th17 effector cells (Kermode et al., 1990, Sie et al.,
2014). It is the production of cytokines and chemokines by the infiltrating Th17 cells that
produce downstream effects leading to the up-regulation of inflammation in the areas of
the CNS the Th17 cells were primed to infiltrate. After infiltration, Th17 cells also have
the capacity to directly affect resident cells of the CNS such as microglia, as well as
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exert some effect on a wide range of cells including endothelial cells, epithelial cells,
fibroblasts, myeloid cells, and synoviocytes. As it is clear that effector T cells are able to
enter into areas of inflammation in the brain, it raises the question as to how exactly they
are able to do so.
Cell adhesion molecules (CAMs) are a unique set of proteins that play an
essential role in immune cell extravasation from circulation to sites of inflammation.
Research addressing infiltration of circulating lymphocytes across epithelial cells (ECs)
of the BBB has proven the expression of CAMs and cell adhesion ligands change
following antigen activation and/or cytokine release. These changes typically precede
disease initiation and work to either increase or decrease the binding affinity of
circulating lymphocytes to target the endothelium (Wong et al., 1999).
The CAM profile of circulating lymphocytes does have the ability to change.
Chemokines and cytokines released during inflammatory conditions play a crucial role in
immune cell arrest through the vasculature. Not only do they alter the CAM profile on
ECs but they modulate the affinity of CAMs for their respective ligand, as well as induce
clustering of CAMs on the immune cells to further strengthen the binding capabilities of
immune cells to vasculature walls.
Activated CD4+ T cells, as opposed to naïve CD4+ T cells, circulate through the
vasculature differently (Andersson et al., 1994). Much of what we know today about
immune involvement in the CNS comes from studies of the EAE mouse model for
multiple sclerosis. Carrithers and others demonstrated that following adoptive transfer of
myelin basic protein specific cells, vascular cell adhesion molecule (VCAM) and
intracellular adhesion molecule-1 (ICAM-1) were up regulated after 48 hours (Carrithers
et al., 2000). Specific blocking of either α4-integrins or VCAM-1 inhibits the development
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of EAE in several models, proving α4-integrin interactions with VCAM-1 play a critical
role in the recruitment of inflammatory cells across the BBB (Yednock et al., 1992,
Laschinger and Engelhardt, 2000). Each of the steps in crossing the BBB, capture,
arrest, crawling, and diapedesis, are controlled by a different set of CAMs and CAMligands, tightening the regulation of cell infiltration (Andersson et al., 1994, Omari and
Dorovini-Zis, 2003).
The altered CAM expression on circulating CD4+ T cells has been well-studied.
Moreover, two studies have demonstrated wild-type α-Syn and mutant forms of α-Syn
(A30P; E46K; A53T) can alter the expression level of ICAM-1 and CD44, the binding
partner for E- and P-selectin, on human astrocytes, astrocytic cell lines, and murine
microglial cell lines (Klegeris et al., 2006, Kim et al., 2009). The up regulation of CD44
was shown to correspond with an increased migratory capacity of microglial cells both in
vivo and in vitro. The authors concluded up-regulation of CAMs by wild-type and mutant
α-Syn plays a regulatory role in cell migration into the substantia nigra, thereby causing
the acceleration of the pathogenesis of Parkinson’s disease (Klegeris et al., 2006, Kim et
al., 2009).

Protective Immunity and Plasticity
While most initial investigations sought to prove Th17 cells are associated with
exacerbation of proinflammatory autoimmunity, many studies have shown the protective
value of T cells associated with the plasticity of the Th17 cell. Th17 cells have been
shown to have a close developmental link with FoxP3+/CD4+ regulatory T cells, as during
Th17 cell development transient expression of FoxP3 is seen (Mitchell and Miller, 1968).
Th17 cells and Tregs have also been shown to transformatively interact with each other
during development.

In fact, FoxP3 and RORC2 can directly interact via a DNA-

independent mechanism during Th17 development and allow FoxP3 to be transiently
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expressed (Zhou et al., 2008).

In addition, regulatory T cells can assist in the

differentiation of purified naïve CD4+ T cells to Th17 cells and exogenous TGF-β can
facilitate this differentiation in vitro in the absence of Tregs (Veldhoen et al., 2006a).
This finding is in stark contrast to the original thought of Wing and others, who
believed Tregs and TGF-β were inhibitory and would restrict T cell proliferation and
differentiation, as TGF-β has long been known to induce the expression of FoxP3 and
the subsequent development of iTregs (Wing et al., 2006, Dong, 2008). While TGF-β
has the ability to induce differentiation of both Tregs and Th17 cells, simultaneous
regulation by IL-6 will inhibit the expression of FoxP3, thereby inhibiting Treg
differentiation and promoting the Th17 lineage (Veldhoen et al., 2006a). The loss of IL-6
during autoimmune responses results in significantly increased number of Tregs (Korn et
al., 2007). In fact, TGF-β and IL-6 promote optimal differentiation of the Th17 lineage
while inhibiting regulatory T cell differentiation, indicating that while the two cell lineages
may share a common cytokine, TGF-β, they are reciprocally regulated during
differentiation when IL-6 is present. This delicate balance between the two is a prime
example of how the environmental milieu surrounding naïve CD4+ T cell differentiation is
a determining factor of lineage checkpoints for CD4+ T cell that will delineate the Teff
phenotype produced.
For a long time differentiation of naïve CD4+ T cells into specific effector subsets
was thought to be a permanent, committed event. But, many studies have led to the
modified belief that Th17 cells are not as committed to their phenotype as their
counterpart phenotypes Th1 and Th2 (Dong and Zhu, 2012).

A high degree of

phenotypic instability paired with plasticity has shown that Th17 cells are in fact capable
of acquiring functional characteristics exhibited by Th1 phenotypic cells (Lexberg et al.,
2010).

In vivo discovery of cells capable of producing both IL-17a and IFN-ɣ, a
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prototypical Th1 type cell secretion, lends itself to the theory of Th17 cells which have
the plasticity to act in part like Th1 type cells at times (Korn et al., 2009, Muranski and
Restifo, 2013). This plasticity of the Th17 phenotype T cells is associated with higher in
vivo survival and self-renewal capacity than that conferred by Th1 differentiated cells
which show less plasticity and more phenotypic stability (Muranski and Restifo, 2013).
In fact, in vitro studies have shown Th17 cells are able to convert to this new Th17
phenotype under conditions that mimic the human autoimmune arthritis disease state,
including low TGF-β and high IL-12 levels (Nistala et al., 2010). In addition, in a study of
the spinal fluid of patients with juvenile idiopathic arthritis, where Th1 cells are the
leading T helper phenotype, high levels of Th1 cells were found to be due, in part, to the
ability of Th17 cells to fully shift to a Th1 phenotype in the presence of IL-12 (Maggi et
al., 2013, Cosmi et al., 2014). In contrast, Th1 cells are unable to make this conversion
to the new double cytokine producing phenotype. Additional ex vivo studies have shown
the ability of combined IFN-ɣ and IL-12 signaling through IFN-ɣ induced expression of IL12Rβ2, restoring IL-12 responsiveness and allowing for the stable induction of T-bet and
functional imprinting of the IFN-ɣ gene for re-expression along with the RORɣT and IL-17
gene machinery already found in the Th17 cell (Lexberg et al., 2010).
This new subtype of Th17 cell, identified as Th17.1 cells by some, can produce
both IL-17 and IFN-ɣ and has been found to mainly populate memory CD4+ T cells
(Jadidi-Niaragh and Mirshafiey, 2011). One clear distinction made between the two
subtypes is in the cell surface markers, with the cell surface of Th17 cells expressing
CCR6 and CCR4, whereas TH17.1 cells have been shown to express CCR6 and
CXCR3 (Acosta-Rodriguez et al., 2007b, Chen et al., 2007). Moreover, as examined by
Ghoreschi (Ghoreschi et al., 2011) and Zuniga (Zuniga et al., 2013), the pathogenic
subtype of Th17 cell is one that secretes both IL-17 and IFN-ɣ, among a myriad of other
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cytokines and chemokines. Additionally, years after discovery of the Th17 phenotype T
cell, pathogenic and non-pathogenic T cell subsets could be distinguished.

This

distinction relies heavily upon their cytokine secretion profile, with pathogenic Th17 cells
secreting Il-17, IL-21, IL-22, IL-2, IFN-ɣ, and GM-CSF whereas non-pathogenic Th17
cells secrete IL-17, IL-21, IL-9, and IL-10, again indicating the strong possibility that the
cells are able to co-express both Th1 and Th17 hallmark cytokines (Ghoreschi et al.,
2011, Zuniga et al., 2013).

The discovery of pathogenic and non-pathogenic

phenotypes combined with the delineation of seemingly two different subtypes of Th17
cells that can be separated from each other based upon cell surface markers, leads to
the believe that perhaps the Th17 cell lineage is increasingly more complicated than
originally thought upon its discovery. When thinking along the vein of a new subtype of
Th17 cell, one may also ponder the possibility that this elusive new subtype may be due
to the plasticity of the Th17 cell and its ability to adapt a Th1 like phenotype, potentially
giving the Th17 cell the ability to co-secrete both IL-17 and IFN-ɣ, thereby questioning
the theory of a new Th17 subtype.

Hypothesis and Rationale
PD is a progressive disease in which physical symptoms do not manifest until an
irreversible loss of greater than 50% of dopaminergic neurons in the substantia nigra
pars compacta or 70-80% of striatal dopamine termini are lost (Riederer and Wuketich,
1976, McGeer et al., 1988a, Fearnley and Lees, 1991, Dunnett and Bjorklund, 1999,
Davie, 2008). Clinically, PD is characterized by a chronic and progressive decline in
motor, cognitive, behavioral, and autonomic functions (Marti et al., 2003). Innate and
adaptive immune dysfunction underlies the pathobiology of Parkinson’s disease.
Immune activation by a nitrated and misfolded form of the native protein, α-Syn, and
subsequent neurotoxicity exacerbates nigrostriatal degeneration (Reynolds et al., 2008a,

37
Reynolds et al., 2009a, Stone et al., 2009, Kosloski et al., 2010, Reynolds et al., 2010,
Hutter-Saunders et al., 2011, Anderson K.A., 2014, Wilshusen, 2014). An overwhelming
amount of evidence shows microglia play a prominent role in PD. Activated microglial
cells have been found in and around degenerating neurons in the SN of PD patients
(McGeer et al., 1988a, Yamada et al., 1992, Vila et al., 2001, Teismann et al., 2003b,
Croisier et al., 2005). These accumulated microglia found in the SN are often reactive,
overexpress surface proteins that function to activate the adaptive immune system, and
overall can function as one sensitive biomarker for disease (McGeer et al., 1988a,
Croisier et al., 2005).

Microglial activation and neurotoxicity are associated with

degenerating dopaminergic neurons and N-α-Syn containing Lewy bodies, and
laboratory studies have shown N-α-Syn activates microglia, causing release of ROS and
neurotoxicity (Croisier et al., 2005, Zhou et al., 2005).
Not only are activated microglia found in the SN of post mortem patients with PD,
a robust microglial response occurs in the midbrains of MPTP intoxicated animals, one
of the foremost model systems for dopaminergic neurodegeneration in PD (Hurley et al.,
2003). Thus the initial acute insult to dopaminergic neurons likely leads to a secondary
and perpetuated neuroinflammatory response that exacerbates the neurodegeneration
seen in PD.

The inflammatory processes are believed to play a critical role in the

modification of self-proteins to yield neoantigens such as N-α-Syn. In addition, data
suggests further exacerbation of these inflammatory processes by effector T cells that
are specific for and recognize these modified self-proteins, but not unmodified proteins,
quantitatively and temporally enhances the neurodegenerative processes to worsen the
lesion as demonstrated in the MPTP-treated model (Benner et al., 2008). As disease is
linked to the formation of aggregated or misfolded proteins that become deposited within
Lewy bodies, we theorize that, during injury and death of dopaminergic neurons, release
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of modified protein aggregates such as N-α-Syn serve to activate resident microglia and
antigen presenting cells; as well as engage peripheral T cells which induce an
exacerbated lethal cascade of microglial-induced neurotoxicity.
The adaptive immune system provides the ability to recognize specific
pathogens and mount stronger responses with each encounter due to immunological
memory.

An adaptive immune response ensues when the innate immune system

encounters a pathogen and consequently links the adaptive immune response through
antigen presentation via APCs which serve to phagocytose or endocytose foreign
pathogens, such as N-α-Syn, process and present this foreign antigen complexed with
surface MHC molecules that are subsequently recognized by CD4+ or CD8+ T cells. It
is postulated these activated T cells are then able to travel to the site of inflammation to
exert their neurotoxic effects. Cells of the adaptive arm of the immune system are
normally precluded from entry into the CNS.

However, under conditions of a

neuroinflammatory state, activated glial cells secrete factors which disrupt the BBB,
thereby allowing entry of leukocytes into damaged areas of the brain (Hornykiewicz and
Kish, 1987, Coombes et al., 2005, Rentzos et al., 2009). CD4+ and CD8+ T cells have
been reported in close proximity to activated microglia and degenerating neurons within
the SN of PD patients (McGeer et al., 1988a, Brochard et al., 2009). Whether these T
cells are activated, antigen-specific, or migrating in response to microglial inflammation
has yet to be determined; however the presence of a major T cell subset in ratios
exceeding those typically found in the periphery suggests a more profound role in PD
than merely performing a surveillance function (Wekerle et al., 1986, Kreutzberg, 1996,
Aloisi et al., 2001, Ransohoff et al., 2003). Indeed, T cell CNS infiltration is operative in
PD, with the adoptive transfer of immunocytes into MPTP-treated mice resulting in
significant brain infiltration and localization within the inflamed SN, demonstrating the
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necessity for T cells in dopaminergic neurodegeneration (Reynolds et al., 2007). T cells
exacerbate dopaminergic neuronal loss during induction of adaptive immune responses
by N-α-Syn, suggesting a causal link between T cell infiltration, SN neurodegeneration,
and sustained microglial activation.
Overwhelming evidence indicates Parkinson’s disease patients exhibit intensified
proinflammatory adaptive immune functions with increased infiltration of activated T cells
and proinflammatory cytokine responses (Mosley et al., 2012). A recent clinical study
demonstrated PD patients present a greater degree of T cells with effector/memory
phenotypes which correlate with movement disorder scores and loss of regulatory T cell
function (Saunders et al., 2012b). Moreover, it has been shown in an animal model of
PD that T cells modulate microglial responses and N-α-Syn specific T cells exacerbate
neuroinflammation and neurodegeneration induced by MPTP-intoxication (Benner et al.,
2008).

However, the mechanisms by which N-α-Syn-specific T cells exacerbate

neuroinflammation and neurodegeneration remain enigmatic. Previous studies showed
that effector T cells, particularly Th17 Teffs and to a lesser degree Th1 Teffs, induce
greater loss of MPTP-induced dopaminergic neurodegeneration after intoxication by
MPTP (Reynolds et al., 2010).
Thus, we hypothesize that N-α-Syn specific effector T cells exacerbate
neurodegeneration

indirectly

via

hyperactivation

of

microglial-mediated

neurotoxicity and/or alternatively by direct cytotoxicity of neurons. Ample studies
have shown that activation of macrophages or microglia using infectious agents, LPS,
MPP+, or apoptotic neurons profoundly enhances neurodegeneration, however none
have assessed microglial or T cell mediated dopaminergic neurodegeneration in the
context of microglia enhanced by N-α-Syn-specific T cells (Strle et al., 2002, Potolicchio
et al., 2005, Zhang et al., 2005, Zhou et al., 2005, McLaughlin et al., 2006). Increased T
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cell-mediated immune function has been noted in many clinical measured parameters
among PD patients. Previous studies have shown the adaptive immune system has the
ability to play a significant role in PD due to the increased expression of MHC class I and
II molecules by reactive microglia and the increased ratios of IFN-γ/IL-4-producing CD4+
T cells, among other things (McGeer et al., 1988a, Boka et al., 1994, Mogi et al., 1995,
Hunot et al., 1999, Nagatsu et al., 2000, Hunot, 2003, Baba et al., 2005, Wersinger and
Sidhu, 2006, Monahan et al., 2008). In fact, in vitro polarization of T cells to Th17 Teffs
and then subsequent adoptive transfer to MPTP-intoxicated recipients elicits greater
neuroinflammation and neurodegeneration than that of MPTP recipients adoptively
transferred with Th1 or Th2 Teffs (Reynolds et al., 2010). However, since polarization of
recent T cell explants may not be functionally stable and are prone to transformation, the
exact mechanisms by which N-α-Syn-specific effector T cells mediate exacerbated
neurodegeneration remains enigmatic. These studies test our hypothesis using cloned,
N-α-Syn-specific T cell lines that have been maintained to ensure stability of the T cell
utilized to test those mechanisms.
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Figure 1. Innate and adaptive immune contributions to PD pathogenesis. Reactive
microglia are a prominent feature of PD. Microglia are sensitive to changes in their
microenvironment, which include factors released from damaged/dying neurons such as
DAMPs and self-proteins such as α-Syn that have been modified, misfolded, or
aggregated. These factors drive resting microglial to an activated M1 phenotype
characterized by secretion of proinflammatory and neurotoxic factors and upregulation of
proinflammatory mediator enzymes such as iNOS, COX-2, and NADPH oxidase.
Induction of these enzymes increases ROS/RNS production and oxidative stress, which
perpetuate

neuronal

injury

and

death.

Microglia-derived

proinflammatory

cytokine/chemokine gradients recruit other lymphocytes to migrate across the BBB to
sites of inflammation. One such T lymphocyte population is the regulatory T cell subset
(R in figure). Tregs produce anti-inflammatory cytokines, such as IL-10 and TGF-β,
which induce microglia to switch from a proinflammatory (M1) phenotype to an antiinflammatory (M2) phenotype. The M2 phenotype is characterized by downregulation of
iNOS, COX-2, and NADPH oxidase, and upregulation of arginase-1, an enzyme with
capabilities to suppress activated microglia or T cells. Changes in these enzyme
functions diminish ROS/RNS formation and maintain oxidative stress at homeostatic
levels. Moreover, in the presence of activated microglia which upregulate Fas, Tregs
upregulate Fas ligand that leads to subsequent killing of activated microglia via Fas:
FasL interactions. Additionally, Tregs induce astrocytes to increase expression of
neurotrophic factors GDNF and BDNF which afford another neuroprotective mechanism.
However, with age PD progresses, Treg functions decline, and regulatory control over
proinflammatory microglia and neurotrophic support is not maintained. Thus,
inflammation and dopaminergic neurodegeneration increase with augmented misfolding
of modified self-proteins such as N-α-Syn. These proteins and the ensuring inflammatory
milieu may drain to periphery immune compartments, where, as neoantigens, adaptive
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immune responses such as effector T cells (E in figure) are mounted against the
modified epitopes. With increased inflammation, Th1 and Th17 Teffs are recruited and
migrate across the BBB to the sites of inflammation and encounter cognate antigen
presented by activated microglia. Th1 and Th17 cells express proinflammatory cytokines
such as TNF-α, IFN-γ, IL-17, and IL-22, which drive microglia to higher levels of
inflammation, thus indirectly enhancing neurotoxicity. A mechanism by which Teffs may
directly kill neurons is suggested since both Th1 and Th17 cells produce TNF-α and
nigral neurons express TNF receptors capable of triggering apoptotic pathways. Of
importance, proinflammatory cytokines from Teffs inhibit Treg functions, which further
restrict regulatory control and exacerbate Teff- and microglia-mediated inflammatory
responses.

.
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CHAPTER ONE: MATERIALS AND METHODS
Animals
C57BL/6J male mice (6-8 weeks old) were obtained from Jackson Laboratory
(Bar Harbor, ME) for all experiments.

All animal procedures were performed in

accordance with National Institute of Health guidelines and were approved by the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center. All mice were house and maintained on a 12 hour light/12 hour dark cycle with
unconstrained access to food and water.

Purification and Nitration of α-Synuclein
For α-Syn expression a BL21 bacterial clone was transformed with the His-Tag
containing expression vector, pET-28a, and sub cloned with a mouse C-terminal tail of
the recombinant gene for α-Syn in accordance with previously established methods
(Benner et al., 2008). In short, a single bacterial colony was grown in the presence of
Kanamycin (MediaTech Inc, Manassas, VA) and isopropyl β-D-1-thiogalactopyranoside
(EMD Millipore, Burlington, MA).

The bacteria was lysed using BugBuster Protein

Extraction Reagent (Novagen, Burlington, MA), the His-Tag containing mouse Cterminal tail α-Syn was purified utilizing a Ni-NTA column (Thermo Scientific, Waltham,
MA) and eluted using Imidazole. Endotoxin was removed from the elute via a Polymixin
B-Agarose Endotoxin Removal column (Thermo Scientific), and the sample was then
nitrated using 5 mM ferric chloride and 100 µl/mg peroxynitrite (EMD Millipore), and
purified via dialysis. Protein quality and molecular weight determination was assessed
via MALDI-TOF and Western Blot.

T Cell Line Generation
C57BL/6J male mice were immunized (subcutaneous injection near the base of
the tail) with the C-terminal tail of recombinant N-α-Syn (N-4YSyn, 50 µg) emulsified in
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an equal volume of Freund’s complete adjuvant (Sigma-Aldrich, St. Louis, MO)
containing 1 mg/ml Mycobacterium tuberculosis. Immunized animals were boosted 2
weeks later with 50 µg N-4YSyn emulsified in Freund’s incomplete adjuvant (SigmaAldrich).

Seven days after boosting the mice were sacrificed and single-cell

suspensions were obtained from spleens and lymph nodes (cervical, brachial, axial, and
inguinal) of immunized mice by passing tissues through a 70 µm cell strainer (Fisher
Scientific, Hampton, NH). Red blood cells were lysed via swelling and rupture following
exposure to ACK lysis buffer (Sigma Aldrich). CD4+ cells were positively selected from
the single cell suspension using the mouse CD4+ T cell Enrichment Kit, per the
manufacturer’s instructions (R&D Systems, Minneapolis, MN).

CD4+ T cells were

cultured in complete RPMI medium (RPMI 1640 supplemented with 10% fetal bovine
serum (FBS), 2mM L-glutamine, 25 mM HEPES, 1 mM sodium pyruvate, 1X
nonessential amino acids, 55 nM 2-mercaptoethanol, 100 U/ml penicillin, and 100 µg
streptomycin) in the presence of 10 µg/ml N-4YSyn, 2.5x107 irradiated splenocytes, and
a cocktail of cytokines and antibodies necessary for Th17 polarization, which included 3
ng/ml TGF-β, 10-50 ng/ml IL-6, 5 ng/ml IL-1β, 10-40 ng/ml IL-23, 3 µg/ml anti-IL-4, 3
µg/ml anti-IFN-ɣ, and 3 µg/ml anti-IL-2.

The cells were re-passaged into the same

culture medium every 7 days for 4 weeks, after which they were continually passaged
once per week in the complete culture medium minus anti IL-4, anti-IFN-ɣ, and anti-IL-2.
This cell line (NMCTC1.0) shall hereto be known as Parent Th17 Cell Line. In order to
cultivate a Th1 cell line the CD4+ T cells were cultured in complete RPMI medium
containing 10 µg/ml N-4YSyn, 2.5x107 irradiated splenocytes, and 2.5 U/ml IL-2. To
cultivate a Th17.1 cell line the CD4+ T cells were cultured in complete RPMI medium
containing 10 µg/ml N-4YSyn, 2.5x107 irradiated splenocytes, 3 ng/ml TGF-β, 50 ng/ml
IL-6, 5 ng/ml IL-1β, 40 ng/ml IL-23, and 1.25 U/ml IL-2.
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Cloning of T Cell Line(s)
In order to create a pure population of CD4+ effector T cell phenotypic cells from
the parent Th17 cell line was cultured at 100, 10, or 1 cell per well in a 96-well plate in
complete RPMI medium including associated cytokines. Cells were incubated for up to
10 days in order to reach confluency. Multiple wells with single cell populations (T cell
clones) were then chosen to be passaged from the 96-well plate to a 24 well plate.
Once each T cell clone reached confluency (within 10 days), they were re-passaged into
multiple wells of a 24 well plate in order to complete phenotypic testing via flow
cytometric analysis. Flow cytometry was used to analyze the T cell clones for CD3,
CD4, IFN-ɣ, and IL-17 production, choosing a cloned cell line highly positive for a
selected cytokine, IL-17 for Th17, IFN-ɣ for Th1, and IFN-ɣ AND IL-17 for Th17. The
Th17 clone (NCMTCC9.0) cultured in 3 ng/ml TGF-β, 150 ng/ml IL-6, 5 ng/ml IL-1β, 40
ng/ml IL-23, 3 µg/ml anti-IL-4, 3 µg/ml anti-IFN-ɣ, 3 µg/ml anti-IL-2, and displaying high
IL-17 production post cloning shall hereto be known as the Th17 Cell Line. Th1 clone
(NCMTC1.0c) cultured in 25 U/ml IL-2 and displaying high IFN-ɣ production shall hereto
be known as the Th1 Cell Line. The CD4+ T cell clone (NCMTCCT’15) cultured in 3
ng/ml TGF-β, 150 ng/ml IL-6, 5 ng/ml IL-1β, 40 ng/ml IL-23, 1.25 U/ml IL-2, and
displaying high IL-17 and IFN-ɣ production post cloning shall hereto be known as the
Th17.1 Cell Line.

Isolation and Cultivation of Murine Primary Microglia
Microglia from C57BL/6J mice neonates (1-3 days old) were prepared utilizing
whole-brain harvest and mechanical dissociation. In brief, brains were removed from
neonates and mechanically dissociated one time via 10 ml serological pipet. Tissue was
rinsed twice with Hanks Balanced Salt Solution (Thermo Scientific) before incubation for
30 minutes with 1 ml of 2.5% trypsin (Thermo Scientific) and 1 mg/ml DNAse (Sigma-
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Aldrich) to chemically dissociate the tissue.

The tissue was again mechanically

dissociated via a 5 ml serological pipet before filtering out larger un-dissociated pieces
with a 70 µm filter and culturing the cells at 5.0x107 cells/75 cm2 culture flask in medium
containing 10% macrophage-colony stimulating factor. Adherent cells were harvested to
test for purity (via flow cytometric analysis) and experimental purposes at 7 and 14 days.

Culture of MES23.5 and BV-2 Cell Lines
In order to evaluate direct and indirect toxicity in vitro microglial (BV-2) and
dopaminergic (MES23.5) cell lines were utilized. Cells from the BV-2 cell line were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5 g/L D-glucose,
supplemented with 5% FBS, 10 mM HEPES, 100 U/ml penicillin-streptomycin, 2 mM Lglutamine, and 22 nM 2-mercaptoethanol.

Cells from the MES23.5 dopaminergic

neuroblastoma cell line were cultured in poly-D-lysine (Sigma-Aldrich) coated 75 cm2
flasks in DMEM/F-12 medium with 15 mM HEPES (Invitrogen, Carlsbad, CA) containing
N2 supplement (Invitrogen), 100 U/ml penicillin, 100 µg/ml streptomycin, and 5% FBS
(Crawford et al., 1992). Cells from both lines were grown to 80% confluence before
passage with 1% EDTA in PBS. Cells were plated at 1.0x104 – 3.0x104 for all
experiments, with MES23.5 cells cultured on poly-D-lysine coated plates.

Acute MPTP Intoxication and Adoptive Transfer
Male mice, age 8-10 weeks, were randomized into adoptive transfer recipient
treatment groups and four subcutaneous injections were administered at 2 hour intervals
of either vehicle (PBS, 10 ml/kg) or MPTP-HCl (calculated for free base dose of 10,14,
or 16 mg/kg in a 10 ml/kg volume, Sigma Aldrich, St. Louis, MO). Twelve hours post
MPTP intoxication graded numbers of T cells from the effector T cell lines were
adoptively transferred to randomly selected mice via intravenous tail vein injection in 250
µl of Hanks Balanced Salt Solution (N=3-7/group).

On days 2 and 7 post MPTP
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treatment mice terminally anesthetized with pentobarbital and were pericardically
perfused with PBS and 4% paraformaldehyde (Sigma-Aldrich) dissolved in PBS (pH
7.4). Brains of the perfused mice were harvested and transferred to 30% sucrose for 48
hours, subsequently snap frozen on dry ice, and embedded in optimal cutting
temperature compound (TissueTek, Torrance, CA) in order to cut 30 µm sections
through the midbrain and striatum for further immunohistochemical analysis. Prior to
sectioning, one hemisphere was pierced with a needle to ensure examination of the
same hemisphere during quantification.

MPTP handling and safety measures were

conducted in accordance with the National Institute of Health and the University of
Nebraska Medical Center (Przedborski et al., 2001).

Immunohistochemistry
To asses tyrosine hydroxylase (TH) expressing-dopaminergic neurons in the SN
frozen midbrain sections were stained utilizing a free-floating technique and primary
antibodies against tyrosine hydroxylase (anti-TH, 1:2000, Calbiochem, San Diego, CA),
biotinylated secondary antibodies against IgG (1:400, Vector Laboratories, Burlingame,
CA), and counterstained for Nissl substance by thionin staining (Benner et al., 2004).
The same anti-TH antibody was utilized to assess dopaminergic neuron loss in the
associated termini at a concentration of 1:1000. To visualize antibody labeled tissues,
the free-floating sections were incubated for 1 hour in streptavidin-HRP solution (ABC
Elite Kit, Vector Laboratories), and color developed for 15 minutes using a H2O2 color
generation system containing daiminobenzidine chromogen, as previously described
(DAB, Sigma-Aldrich) (Benner et al., 2004).
Stereological analysis of Th+Nissl+ dopaminergic neurons and TH-Nissl+ nondopaminergic neurons in the SN were estimated by stereological analysis with
StereoInvestigator using optical fractionator module stereology software (MBF
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Bioscience, Williston, VT) interfaced with a Nikon Eclipse 90i fluorescence microscope
equipped with a monochrome camera and three filter blocks. Using simple random
sampling image series workflow the region of interest, the SN, was outlined for one
hemisphere of each tissue section at 4x magnification. Fluorescent images of each
region were taken at 40x objective. Workflow parameters were defined to count approx.
20% of the total cell population in the SN (counting frame size 120x100 µm, 245x240 µm
grid size) and Gunderson coefficient of error (C.E. m=1) was less than or equal to 0.10.
Additionally, the estimated population size was generated by the software, for the same
hemisphere of interest, and multiplied x2 to obtain the overall population estimate for
both hemispheres of the sample.

The opposite hemisphere was utilized in the event

that the hemisphere of choice was corrupted. The TH-Nissl+ population served as a
control to show the specificity of neuronal cellular death to dopaminergic neurons in the
SN. The density of TH+ termini in the striatum was determined form scanned sections of
TH+ stained sections by digital densitometry using Image J software (NIH, Bethesda,
MD).

Background values were obtained and subtracted from striatal density to

normalize differences between groups.
To assess reactive microglial density within the SN, free-floating sections from
the midbrain were stained by incubating in 5% normal rabbit serum to block endogenous
staining before using a rat IgG primary antibody against Mac-1 (CD11b, 1:500, Bio-Rad,
Hercules, CA) overnight, and then incubating with a biotinylated secondary antibody
against rat IgG (1:200, Vector Laboratories) for 1 hour. After incubation in secondary
antibody staining was visualized using the streptavidin-HRP/DAB system outlined above.
Total density of Mac1+ cells/mm2 within the SN was estimated from the total area (mm2)
by stereological analysis utilizing StereoInvestigator software.
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Determination of Microglial Oxidative Activation
Oxidative activation of primary microglia and the BV-2 microglial cell line was
determined with use of assays to measure hydrogen peroxide (H2O2, ROS), and nitrite
(RNS) levels released into medium. BV-2 or primary microglial cells were cultured in a
96 well plate at 3.0x104 cells/well. CD3+/CD28+ transactivator bead stimulated T cell
supernatant or 1.0 - 3.0x104 T cells were added to microglial culture for 24 hours. After
24 hours T cells and/or medium was replaced with fresh microglial medium, and H2O2 or
nitrite levels were read 8 hours later. To measure nitrite levels the Griess Reagent
System (Promega, Madison, WI) was used according to manufacturer’s guidelines.
Briefly, a standard reference curve was prepared from a nitrite standard at dilutions from
0 µM to 100 µM. Fifty microliters of medium from the experimental microglial wells was
transferred to a 96 well plate with the nitrite standard and Sulfanimide solution was
incubated in the wells for 10 minutes before N-1-napthylethylenediamine dihydrochloride
(NED) is added, according to the manufacturer’s guidelines.

Absorbance was then

measured within 30 minutes using a SynergyMX plate reader (Biotek, Winooski, VT) with
a filter between 520 nm – 550 nm, and the Gen5 Microplate Data Collection and
Analysis Software (Biotek) to analyze the results.

Experimental well concentrations

were calculated by referencing absorbance values to the standard curve (R2>0.95). To
measure H2O2 levels, the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit
(Invitrogen) was utilized according to manufacturer’s guidelines. In short, a standard
H2O2 reference curve was generated with concentrations ranging from 0 µM to 10 µM.
Fifty microliters of experimental sample and standard curve was loaded into a 96-well
plate before a mixture of 10 mM Amplex Red (in DMSO) and 10 U/ml of horseradish
peroxidase in 1X reaction buffer was added to the wells. After a 30 minute incubation
H2O2 levels were read via the Synergy MX plate reader using fluorescent excitation of
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530-560 nm and emission detection at 590 nm. Experimental well concentrations were
calculated by referencing absorbance values to the standard curve (R2>0.95).

Determination of Neuronal Cell Cytotoxicity
Cytotoxicity and viability of the MES23.5 dopaminergic neuroblastoma cell line
was measured via multiple assays quantifying different enzymes, proteases, and cellular
activity. For all assays MES23.5 cells were incubated with cells or supernatant from the
stimulated T cell lines, BV-2 cells, or primary microglia in a 96-well poly-D-lysine coated
plate.

Cytotoxicity was measured via the Pierce Lactate Dehydrogenase (LDH)

Cytotoxicity Assay Kit (Thermo Scientific) according to manufacturer’s guidelines. Upon
addition of the reaction mixture to the sample wells LDH (a cytosolic enzyme present
within intact cells), released from damaged cellular membranes and present in the
culture medium, was quantified by a coupled enzymatic reaction in which LDH catalyzed
the conversion of lactate to pyruvate through NAD+ reduction to NADH, which is used to
further reduce a tetrazolium salt into a red formazan product (formazan formation is
directly proportional to LDH levels in medium) that can be measured by absorbance at
490 nm. Appropriate positive and negative controls were conducted with the use of lysis
buffer and complete medium only wells. Toxicity was also measured via the CellTox
Green Cytotoxicity Assay (Promega) according to manufacturer’s guidelines. Addition of
the CellTox Green reagent (assay buffer and dye solution at 2X concentration) allowed
for the measure of membrane integrity of the MES23.5 cells, as the reagent is
impermeable to intact and viable cells, yet can enter nonviable cells, bind to the
compromised DNA, cause enhanced fluorescence as measured at 485-500 nm
excitation/520-530 nm emission by a SynergyMX plate reader. Appropriate controls for
positive and negative toxicity readings were performed. Viability of the MES23.5 cells
was conversely measured utilizing the alamarBlue Cell Viability Assay Reagent (Thermo
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Scientific) and the CellTiter-Glo 2.0 Assay (Promega). In short, alamarBlue reagent
was added to sample wells in an amount equal to 10% the volume of the well, incubated
for 4-8 hours, and then fluorescence (530-560 nm excitation/590 nm emission) or
absorbance (570 nm and 600 nm) was measured via SynergyMX plate reader.
Incubation with assay reagent allows for the oxidized reagent (blue in color) to be
reduced within the cytoplasm of intact, viable cells, changing the color of the reagent to
red and allowing it to become fluorescent. In the CellTiter-Glo assay, addition of the
luciferase reagent to the sample wells resulted in cell lysis and generation of a
luminescent signal (mono-oxygenation of luciferin is catalyzed by the presence of ATP
from viable cells) that is proportional to the amount of ATP present in the viable cells,
and is directly proportional to the number of viable cells present in the culture.
Luminescence was read via the SynergyMX plate reader. Appropriate controls were
conducted utilizing MES23.5 cells in culture alone, as well as T cell, T cell supernatant,
and microglial supernatant in culture alone. When applicable the values of T cell/T cell
supernatant/microglial supernatant were deducted from the experimental wells
containing MES23.5 cells.

Detection of Neuronal Apoptosis
Apoptosis of MES23.5 neuronal cells due to T cell and microglial mediated
reactions was assessed via the ApoTox-Glo Triplex Assay (Promega), an assay
combining three chemistries to assess viability, cytotoxicity, and apoptosis (caspase
activation). In short, MES23.5 cells were incubated with stimulated T cells/supernatant,
and/or BV-2/primary microglial medium for 6 hours in a 96-well poly-D-lysine coated
plate before viability, toxicity, and apoptosis were measured via fluorescence (viability
and cytotoxicity) and luminescence (apoptosis).

Addition of cytoxicity and viability

reagent, containing GF-AFC and bis-AAF-R110 substrate allowed the GF-AFC substrate
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to enter intact cells to be cleaved by live cell proteases, resulting in the generation of a
fluorescent signal directly proportional to the number of living cells. Conversely, the
fluorogenic cell-impermeable bis-AFF-R110 measures the activity of proteases that are
released from injured and dead/dying cells that have lost membrane integrity.

The

second part of the assay utilizes the luminogenic caspase-3/7 substrate, which contains
the tetrapeptide sequence DEVD.

Addition of the Caspase-Glo 3/7 reagent to the

sample wells results in total cell lysis followed by caspase cleavage of the substrate
(containing the DEVD sequence) by activated caspase 3 and 7, resulting in generation
of luminescent signal directly proportional to the level of caspase 3 and 7 activity.
Additionally, the caspase inhibitor Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl] - fluoromethylketone, R&D systems) was added to the MES23.5 cells 15 minutes
before addition of T cell/BV-2 stimulus, at a concentration of 200 µM, in order to
measure apoptosis inhibition.

Cytokine Analysis via Flow Cytometric Analysis
Prior to staining with extracellular or intracellular antibodies cells were incubated
with mouse gamma globulin at 10 µg/ml to block non-specific staining. For extracellular
staining cells were incubated for 30 minutes at 4°C with 1 µg of one or more of the
following antibodies: anti-mouse CD3e-PE (eBioscience, Waltham, MA), anti-mouse
CD4-APC-H7 (BD Pharmigen, Hampton, NH), anti-mouse CD8a-Pe-Cyanine 5.5
(eBioscience), anti-mouse CD11b-PE (eBioscience), and anti-mouse CD45-APC
(eBioscience). For intracellular staining cells were stimulated for 5 hours with 20 ng/ml
phorbol-12-myristate-13-acetate (PMA), 1 µM ionomycin (Sigma Aldrich), and Brefeldin
A (eBioscience, San Diego, CA) to stop intracellular cytokine secretion. Cells were then
incubated for 1 hour at 4°C with 1 µg of one or more of these antibodies: anti-mouse
IFN-ɣ-FITC (eBioscience), anti-mouse TNF-α-eFluor 450 (eBioscience), or anti-mouse
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IL-17a-Alexa Fluor 647 (BioLegend, San Diego, CA). Cellular samples were analyzed
using an LSRII flow cytometer equipped with FACSDiva software (BD Biosciences, San
Jose, CA). In all instances the corresponding isotype was incubated with the cells as a
negative control.

Additionally, fluorescence minus one (FMO) and controls without

antibody were incubated as well. Gates were set based upon exclusion of fluorescent
events in the present of appropriate isotype, non-stained, and FMO controls for each
specified color and type of antibody. Positive cells were identified by those events within
the lymphocyte gate falling on the side designated positive by the appropriate controls.

Cytokine Analysis via Cytokine Bead Array
Extracellular secretion of cytokines was analyzed via the mouse Th1/Th2/Th17
Cytokine Kit (BD Biosciences) according to manufacturer’s protocol after stimulation. T
cells from T cell lines were stimulated in a 24 well plate at 4.0x105 cells with 10 mM
ionomycin and 200 µg/ml PMA (Sigma-Aldrich) for 5 hours. Medium was collected from
the samples and stored at -80°C until analysis. A cytokine standard was reconstituted
from a lyophilized vial which included cytokines for IL-2, Il-4, Il-6, IFN-ɣ, TNFα, IL-17a,
and IL-10 at dilutions ranging from 0 pg/ml to 5,000 pg/ml. Each standard and sample
were transferred to a filter plate and incubated with capture beads and PE Detection
Reagent for 2 hours before being washed using a vacuum manifold. Samples were
acquired on BD FACSARIA and analyzed using FCAP Array Software (BD Biosciences).
All data was normalized to cell number for each assay.

Statistical Analyses
All values are expressed as a mean ± standard error of the mean (SEM).
Differences among means were analyzed by one-way ANOVA followed by Tukey or
Bonferroni post-hoc testing for pair-wise comparison using GraphPad Prism software (La
Jolla, CA). All treatment effects were analyzed at the 95% confidence interval.
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CHAPTER TWO: GENERATION OF STABLE TH17, TH1, AND
TH17.1 CELL LINES
In order to better study the effect of Teffs on microglia and neurons in vitro and in
vivo it was imperative to generate a T cell line that was derived from immunized animals,
polarized, and passaged over multiple weeks for experiments, while still retaining a
stable phenotype and producing a quantity of cells sufficient to complete experimental
testing. There has been a plethora of information published in the literature on the
polarization of fresh CD4+ isolates into phenotypes and use within 5-10 days (Mucida et
al., 2007, Reynolds et al., 2010, Komatsu et al., 2014), however few reports have been
published on the ability to maintain a stable Th17 cell line over long periods of time.
Conducting in vitro and in vivo adoptive transfer experiments utilizing fresh CD4+ isolates
requires thousands of dollars’ worth of materials (animals, cytokines, antibodies), in
addition to large amounts of time. In fact, immunization, extraction, and polarization of T
cells into a respective phenotype alone takes 28 days, even before the cellular effects
can be tested in vivo, which takes another 30 days before the tissue is ready for
analysis. Due to these constraints, creation of T cell lines capable of survival over a long
period of time ex vivo without losing phenotypic characteristics and still retaining
neurotoxic function was imperative.
To create a T effector cell line, C57BL/6J mice were immunized with the nitrated
form of the C-terminal tail of α-synuclein (N-4YSyn) emulsified in Freund’s complete
adjuvant containing Mycobacterium to increase the immune response to N-4YSyn.
Fourteen days later, the mice were boosted with 50 µg/ml N-4YSyn in incomplete
Freund’s adjuvant, and 7 days post-boost spleens and lymph nodes were harvested
from the animals. A single cell suspension was prepared and CD4+ cells were positively
selected with the use of an R&D CD4+ T cell enrichment column. Many reports have
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detailed the cytokine and antibody milieu necessary for the polarization of effector T cells
to a Th17 phenotype (Reynolds et al., 2010, Komatsu et al., 2014). With this in mind a
cytokine cocktail of 3 ng/ml TGF-β, 10 ng/ml IL-6, 5 ng/ml IL-1β, and 10 ng/ml IL-23, and
an antibody cocktail of 3 µg/ml anti-IL-4, 3 µg/ml anti-IFN-ɣ, and 3 µg/ml anti-IL-2.
Additionally, 50 µg/ml N-4YSyn was added to the culture to maintain T cell activation and
selective pressure for antigen specificity.

Additionally, 2.5x107 splenocytes X-ray

irradiated with 3300 rads (33 Gy) acted as APCs for the N-4YSyn. After 7 days the cells
were harvested and passaged into the same cytokine and antibody milieu. This process
was repeated for 4 weeks. After 4 weeks, the process was continued, but with the
removal of all antibodies, as it was believed the cells were terminally differentiated,
therefore antibodies against other phenotypes were not necessary. Indeed, continuous
polarization in cytokines and antibodies results in a non-cloned T cell line with a
phenotype highly skewed toward a CD3+CD4+ effector cell type as opposed to a CD8+ T
cell type (Figure 2). Additionally, cytokine profiling after 5 hours of stimulation with PMA
and ionomycin resulted in a large release of IL-17a (>6000 pg/ml) a moderate release of
TNF-α (>4000 pg/ml) and a small release of IFN-ɣ (~1500 pg/ml) indicating the T cells
are polarizing to a Th17 phenotype, yet there may be a small amount of cells which are
Th-1 skewed or double producers of IL-17 and IFN-ɣ (Figure 3).
While the in vitro polarized non-cloned T cell line was shown to be Th17 skewed,
its functionality was still in question. In general, stimulation of microglia with activated T
cells induces pattern recognition receptors (PRRs) to trigger

M1-like activation in

microglia, resulting in the release of proinflammatory cytokines and increased ROS and
RNS production (Mosley et al., 2012, Heneka et al., 2014, Wilshusen, 2014). To test
the capacity of the non-cloned T cell line to induce proinflammatory response, polarized
T cells were stimulated for 24 hours with varying concentrations of N-4YSyn before
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either the T cells or T cell supernatant was cultured with BV-2 microglial cells for 24
hours. Eight hours later RNS production from the microglia was read via the Griess
assay (Promega) to measure nitrite (a stable breakdown product of nitric oxide) release.
The Th17-skewed T cells demonstrated the ability to increase nitrite concentration at all
concentrations of N-4YSyn, with the largest increase of 88 µM from the BV-2 cells
stimulated with 10 µM N-4YSyn. In fact, even without N-4YSyn stimulation, the T cells
were able to increase nitrite release to 57 µM, most likely due to the T cells still being at
least partially activated from constant culture with N-4YSyn stimulating medium, and
only had 24 hours to rest before culture with BV-2 microglial cells (Figure 4).
Furthermore, culture of BV-2 microglia with T cell supernatant for 24 hours also results in
an increase of nitrite release from T cell supernatant stimulated BV-2 cells. Although,
the largest increase in nitrite release was from BV-2 cells cultured with T cell
supernatants stimulated with lower concentrations of N-4YSyn (0-1 µM N-4YSyn),
resulting in 39-43 pg/ml. Taken together, culture of CD4+ effector T cells in a Th17
cytokine milieu results in functional Th17 skewed effector T cells that exacerbate RNS
production by cells of the BV-2 microglial cell line.
The function of the non-cloned Th17 cell line was also tested in vivo in the MPTP
mouse model. Previous studies have demonstrated that adoptive transfer of Th1 or
Th17 effector T cells results in an increased loss of dopaminergic neurons within the SN
(Reynolds et al., 2010). Therefore, mice were intoxicated with 14 or 16 mg/kg MPTP,
and were adoptively transferred with graded numbers of T cells (1, 5, or 10 million) 12
hours post intoxication.

At 10 mg/kg dose of MPTP neuronal loss barely reached

significance, and adoptive transfer of Th17 cells did not substantially increase loss (data
not shown). While 14 mg/kg of MPTP showed significant loss of neurons, adoptive
transfer of Th17 cells did not significantly increase the loss of TH+ neurons at 14 mg/kg.
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However, adoptive transfer of Th17 cells into mice intoxicated with 16 mg/kg MPTP
afforded an appreciable exacerbation of loss of nigral neurons (Figure 5a). In fact, at 16
mg/kg, 10x106 Th17 cells caused a significant exacerbation of dopaminergic cellular
death, with MPTP control group showing 49% loss, and adoptively transferred group
showing 83% loss (Figure 5b). Adoptive transfer of anything less (1.0x106 and 5.0x106)
did not significantly increase TH+ neuronal loss in the SN of MPTP treated mice.
Moreover, treatment with the non-cloned Th17 cell line allowed for less Th17 cells (10
million vs. 25 million) to induce greater exacerbation of neuronal cell loss in comparison
to previous reports (Reynolds et al., 2010). Overall, the use of continuously polarized
Th17-skewed cells which are cultured long-term allows experiments to be conducted at
a faster pace, with less cells, and a heightened loss of dopaminergic neurons for less
expense per experiment than previous studies.
In addition, regression analysis of TH+ neuronal loss as a function of T cell and
MPTP dose indicates a strong combined effect of neuronal loss by MPTP and T cell
dose. While neuronal loss was mostly dependent upon increased MPTP dose rather
than T cell numbers, the effect of T cell dose on neuronal loss becomes apparent as
each slope progressively increases at each MPTP dose, with the largest dose of MPTP
(16 mg/kg) shows a significant P and R2 value, indicating 49% of the cellular loss at 16
mg/kg is attributed to the number of T cells adoptively transferred (Figure 6). The lower
doses, 10 and 14 mg/kg, were not seen to be attributed to the dose of T cells adoptively
transferred, meaning at lower MPTP concentrations it may be imperative to adoptively
transfer larger numbers of Th17 cells in order to significantly influence the rather low
lesion effected by low MPTP dose.
After 20 weeks of continuous culture in 3 ng/ml TGF-β, 10 ng/ml IL-6, 5 ng/ml IL1β, and 10 ng/ml IL-23, 50 µg/ml N-4YSyn, and 2.5x107 irradiated splenocytes the Th17
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skewed cells were still proliferating at a rapid rate, yet the cytokine profile of the cells
had begun to change. Phenotypic analysis of the cellular surface of the Th17-skewed
cells demonstrated the cells had begun to morph to a CD4+/CD8+ phenotypic population
with 9.1% of the cells staining as double positive (Figure 7). It is possible for terminally
differentiated CD4+ T cells to adapt and acquire the α-chain of CD8, and this is
correlated with increased frequency and poor prognosis in some autoimmune diseases
(Parel and Chizzolini, 2004). Also, the possibility of the expansion of a cryptic, slowgrowing CD4+/CD8+ T cell contaminant could not be ruled out. Further analysis was
needed to ensure the long-term polarized T cells still retained the characteristics of Th17
cells. Intracellular analysis of cytokines via cytometric bead analysis of Th1/Th2/Th17
cytokines exhibited a large switch from an IL-17 producing population to an IFN-ɣ
producer. In fact, while the cells still secreted 2,300 pg/ml IL-17a, the IFN-ɣ levels
significantly increased to 4,300 pg/ml (Figure 8) Additionally, TNF-α levels dropped to
1,700 pg/ml and IL-10 (a Th2 cytokine) levels increased to 2,000 pg/ml. While the
polarized T cells appeared to be relatively stable over long periods of time, it was evident
the proposed cytokine milieu would not support the long term generation of a stable
Th17 effector T cell line. Other possibilities remain, in which the non-cloned T cell line
with several putative, but unexpressed phenotypes available, is extremely sensitive to
environmental changes. Alterations in the culture milieu, such as those from exogenous
cytokine/antibody cocktails or endogenous APCs could shift a non-expressed phenotype
to an overtly expressed phenotype in a short period of time. One solution for this would
be to derive a cloned T cell line retaining desired phenotypic properties, while
maintaining antigenic and cytokine pressures to retain its reactivity.
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Generation of a Cloned Th17 Cell Line
In order to ensure the generation of a stable T cell line which would remain
unchanged over a long period of time and retain the characteristics of a Th17 cell
without changing or gaining the attributes of other effector cell types such as Th1 and
Th2 cells, a new strategy with multiple arms was employed throughout the life of this cell
line. One strategy included the increase of the cytokines IL-6 and IL-23 in culture. IL-6
is purported to work synergistically with TGF-β to regulate the induction and
maintenance of Th17 cells as well as the expression of IL-17 (Bi and Yang, 2012).
Moreover, IL-23 decreases dedifferentiation of Th17 cells, increases proliferation, and
causes upregulation of IL-23R expression, thereby inducing an amplification loop to
contribute to the proliferation of TH17 cells. Due to these findings, the concentrations of
IL-6 and IL-23 were increased to 50 ng/ml and 40 ng/ml, respectively, after 6 months.
Additionally, the antibodies to IL-4, IFN-ɣ, and IL-2 were continued in culture past 4
weeks in order to quell any dedifferentiation and plasticity changes to other effector T
cell phenotypes that may be derived from the APCs in culture with the T cell line. Lastly,
in order to establish a uniform cellular population the polarized Th17 cells, a single cell
colony was chosen and clonally expanded. In brief, cells were plated in a 96 well plate
at 100, 10, and 1 cell per well for up to 10 days before a single cell colonies were
chosen. These colonies were then expanded in a 24 well plate, screened via flow
cytometric analysis and cytokine bead array for Th17 characteristics, and the best
phenotypically stable Th17 cells were chosen for clonal expansion into a T cell line
(Figure 9).
To create this phenotypically stable Th17 cell line naïve T cells were extracted
from the spleens and lymph nodes of C57BL/6J male mice after immunization with N4YSyn. CD4+ cells were selected by a positive selection column, and cultured for 7 days
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in 3 ng/ml TGF-β, 10 ng/ml IL-6, 5 ng/ml IL-1β, 10 ng/ml IL-23, 3 µg/ml anti-IL-4, 3 µg/ml
anti-IFN-ɣ, 3 µg/ml anti-IL-2, 50 µg/ml N-4YSyn, and 2.5x107 irradiated splenocytes.
After 7 days, T cells were re-passaged into the same cytokine and antibody milieu once
a week in perpetuum). After 4 weeks the parent Th17 cell line was cloned via the use of
single cell colonies and clonal expansion. Following cloning, the parent Th17 cells were
evaluated periodically for extracellular markers and intracellular cytokine expression via
flow cytometry, as well as secreted cytokine expression via cytokine bead array. Flow
analysis over 0-12 months showed the frequency of CD3+CD4+ cells ranged from 7094%, with 26-36% of the cells producing IL-17a, but a peak at 72% between 8-10
months, and 3-20% producing TNF-α (Figure 10a, 10b). Most importantly, IFN-ɣ levels,
as measured by intracellular cytokine analysis ranged from 0.6-2.5%.

Additionally,

cytokine secretion measured demonstrated IL-17a levels remained high (8,700 pg/ml –
16,800 pg/ml), while IFN-ɣ levels remained below 1,000 pg/ml over 12 months (Figure
10c). Interestingly, TNF-α levels started high at 9,800 pg/ml during the first two months,
and rapidly decreased to barely distinguishable levels at 6 (1,200 pg/ml) and 12 months
(200 pg/ml). While IFN-ɣ levels remained low and IL-17a levels high, the sharp loss of
CD3+CD4+ IL-17 producing cells along with a decrease in proliferation (data not shown)
led to staggeringly low cell numbers which precluded the use of the cells experimentally.
Due to this loss in proliferative capacity, the parent Th17 cell line was re-cloned
utilizing the same methods of culture at 100, 10, and 1 cell per well for up to 10 days
before single cell colonies were chosen.

These colonies were again expanded,

screened via flow cytometric analysis and cytokine bead array for Th17 characteristics,
and the clone with the best Th17 attributes (high IL-17 and TNF-α production) and low
Th1 attributes (IFN-ɣ production were chosen. This clone, known as the Th17 cell line,
was cultured in a cytokine and antibody cocktail consisting of 3 ng/ml TGF-β, 50 ng/ml
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IL-6, 5 ng/ml IL-1β, 40 ng/ml IL-23, 3 µg/ml anti-IL-4, 3 µg/ml anti-IFN-ɣ, 3 µg/ml anti-IL2, 50 µg/ml N-4YSyn, and 2.5x107 irradiated splenocytes in order to propagate the TH17
phenotype. This re-cloning of the parent Th17 cell line in combination with altering the
cytokine levels in culture gave rise to a Th17 cell line with increasingly high levels of
intracellular IL-17 production over an eight month period. IL-6 and IL-23 are essential to
Th17 polarization due to their propensity to activate IL-17 specific transcription factor
RORɣT, decrease de-differentiation and transformation to other T effector cell types,
induce expression of characteristic Th17 cytokines, and increase survival and expansion
of the cells.

Therefore increased concentration of IL-6 and IL-23 within the culture

should result in a more phenotypically stable, proliferative Th17 cell line. Interestingly,
IL-6 has been shown necessary in non-cloned human and mouse Th17 cell lines of short
derivation yet has not been considered within the context of long-term culture
(Stadhouders et al., 2017). In fact, this re-cloned Th7 cell line resulted in increasing
levels of intracellular IL-17 production (17.3-92.4%), as measured by flow cytometric
analysis over 8 months (Figure 11a, 11b). Additionally, few cells of the cloned Th17 cell
line produced little intracellular IFN-ɣ, nor was it detectable in culture supernatant.
Moderate levels of IL-17a were detected within culture supernatant directly after cloning
(2,000 pg/ml), and within 3 months of re-cloning the levels reached 18,300 pg/ml, and
remained high through 18 months (10,700 pg/ml) (Figure 11c). Moderate to high levels
of TNF-α were measure via intracellular analysis (7.2-36.7%) and cellular secretion
(2,500 – 11,000 pg/ml). Taken together, the re-cloning of the parent Th17 cell line
resulted in a phenotypically stable Th17 cell line that was used to test the neurotoxicity
of Th17 cells both in vitro and in vivo through the MPTP mouse model.
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Generation of a Cloned Th1 and Th17.1 Cell Line
The ability of effector T cells to permanently commit to a single phenotype is
highly controversial. The ability of Th17 cells to take on a Th1 phenotype has been
established in recent years (Muranski and Restifo, 2013, Bommiasamy, 2014, Harbour
et al., 2015). While it is well known that IL-12 is an inducer of the Th1 phenotype, recent
studies have shown IL-2 has the capacity to induce Th1 phenotypic cells as well (Zhou
et al., 2003, Liao et al., 2011, Liao et al., 2013). IL-12 induces IFN-ɣ through T cell
proliferation as well as the upregulation of IL-12Rβ2 (via a STAT5 dependent step),
which allows the cells to recognize IL-12 and polarize to a Th1 phenotype. In fact, naïve
CD4+ T cells do not display the IL-12Rβ2 traditionally, and in the presence of IL-12 are
unable to respond and differentiate to the Th1 phenotype without help from Jak3 and
STAT5 signaling (Owen and Farrar, 2017). Furthermore, the blockade of IL-2 can inhibit
Th1 differentiation (Shi et al., 2008), thereby revealing IL-2 signaling, via STAT5
activation, induces T-bet and IL-12Rβ2 expression, allowing the cells to respond to IL-12
and differentiate toward a Th1 fate. In order to test the plasticity of effector Th17 cells,
Th17 cells that had been initially polarized within 6 weeks were cultured in medium
containing 50 U/ml IL-2, 50 µg/ml N-4YSyn, and 2.5x107 irradiated splenocytes to push
the T cells from a Th17 commitment to a Th1. Switching the cytokine environment
allowed for the development of a T cell line comprised of cells producing primarily
intracellular IFN-ɣ (40-60% and TNF-α (50-75%), but little IL-17a, indicative of a Th1 cell
line (Figure 12a, 12b). Moreover, utilizing a cytokine bead array to evaluate cytokine
secretion, the converted Th1 cell line secreted 2,000-20,000 pg/ml IFN-ɣ and 100-400
pg/ml TNF-α, but little to no IL-17a (Figure 12c). Thus confirming the previous results
and validating the Th1 phenotype of the cell line.
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While it is evident that Th17 effector T cells may not be as committed to their
phenotype as their countertype phenotypes (Th1 and Th2), early polarized Th17 cells
display a high degree of phenotypic plasticity. However, recent literature has shown that
Th17 cells are also capable of acquiring functional characteristics exhibited by Th1
phenotypic cells while still retaining the characteristics of a Th17 type cell (Cosmi et al.,
2011, Muranski and Restifo, 2013, Reinert-Hartwall et al., 2015, Kotake et al., 2017) and
have been associated with inflammatory autoimmune conditions (Edwards et al., 2010,
Nistala et al., 2010, Stadhouders et al., 2017, Kaskow and Baecher-Allan, 2018, Zhao et
al., 2018). Th17.1 cells have been shown to up-regulate multiple drug resistance-1
(MDR-1 or P-glycoprotein), thus rendering them resistant to glucocorticoid-mediated
suppression and thus difficult to regulate (Nistala et al., 2010, Stadhouders et al., 2017).
Whereas Th17 cells can transform to Th1 cells as shown with our Th1 cell line, Th17.1
cells are thought more resistant to total conversion and retain Th17 properties. To
examine this further we used a long-term Th17 clone and cultured in the presence of
increased IL-6 (50 ng/ml) and IL-23 (40 ng/ml) without the addition of antibodies. A
Th17 clone was selected which displayed double positive expression of intracellular IL17 and IFN-ɣ, indicative of a dual expressive Th17.1 T cell line. IL-2 was added to the
culture cocktail at 25 U/ml to induce increased proliferation and increased IFN-ɣ
production. Continued culture of the Th17.1 cells in an environment favoring both a
Th17 and Th1 phenotype resulted in a stable cell line highly positive for CD3+CD4+ with
10-40% of cells producing IL-17 and 27-42% producing IFN-ɣ over a period of 8 months
(Figure 13a, 13b).

Analysis of secreted cytokine production confirms the Th17.1

phenotype with moderate levels of secreted IL-17a (250-2,500pg/ml), IFN-ɣ (400-6,000
pg/ml), and TNF-α (200-5,000pg/ml) after 5 hours of stimulation with PMA/Ionomycin.
The development of a cloned Th17, Th1, and Th17.1 cell lines allowed their utilization to
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test their in vitro and in vivo effects on microglia and cytotoxicity to dopaminergic
neurons.
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Figure 2. Phenotypic testing of polarized T cells demonstrates continuous
polarization results in a CD3+/CD4+ effector T cells.

Expression of extracellular

markers by the Th17 polarized T cells were evaluated by flow cytometric analysis. Th17
polarized T cells were blocked with gamma globulin before incubation with 0.1 µg of
CD3, CD4, and CD8 antibody. Gating was performed based upon analysis of unstained
and isotype stained controls.
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Figure 3. Phenotypic evaluation polarized T cells by cytokine production reveals
continuous polarization results in T cells skewed towards the Th17 phenotype.
The phenotype of the polarized T cells was further evaluated through the use of a
cytometric bead array to test for specific Th1, Th2, and Th17 cytokines. Cells from the
polarization were stimulated for 5 hours with PMA and ionomycin before being analyzed
for IL-17a, TNF-α, IFN-ɣ, IL-10, IL-6, IL-4, and IL-2 expression.
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Figure 4. Recurrent polarization of T cells are functional and increase microglial
reactive state.

Polarized Th17 cells were stimulated for 24 hours with varying

concentrations of N-4YSyn from 0.0 µg/ml to 10 µg/ml before the T cells (A) or T cell
supernatant (B) was transferred to BV-2 microglial cells for 24 hours. Following the 24
hour co-culture the T cells/supernatant were removed and after 8 hours nitrite
concentration was quantified from the BV-2 cells via the Griess Assay.
regression analysis was performed via GraphPad Prism software.

Linear
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Figure 5. Polarized CD4+ T cells exacerbate the loss of TH+ dopaminergic neurons
in the substantia nigra. To determine the functional ability of the TH17 polarized T cells
to exacerbate dopaminergic neurodegeneration in the substantia nigra, graded numbers
(1.0 x 106, 5.0 x 106, 10.0 x 106) of Teffs were adoptively transferred to mice treated with
10 mg/kg (not shown), 14 mg/kg (A), or 16 mg/kg MPTP (B). After 7 days, brain tissue
was harvested and surviving numbers of TH+ neurons were assessed via
immunohistochemical

staining,

visualized

with

DAB,

and

enumerated

using

StereoInvestigator software interfaced with a Nikon Eclipse microscope. Scale bar in
representative photos equivalent to 1,000 μm in length. The difference in means (±
SEM) were determined where P<0.05 in comparison with aPBS and bMPTP.
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Figure 6. Regression analysis of MPTP intoxication and subsequent adoptive
transfer. Post intoxicated with graded concentrations of MPTP (10 mg/kg, 14 mg/kg, 16
mg/kg) mice were adoptively transferred with 1.0, 5.0, or 10.0 x 106 Teffs from the Th17
polarized T cell line. Regression analysis of TH+ neuronal loss as a function of T cell
dose and MPTP dose indicated a strong combined effect of neuronal loss by MPTP and
T cell dose. Regression analysis was performed via GraphPad Prism software.
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Figure 7. Five months of weekly polarization lead to a loss of external Th17 cells
characteristics. The phenotype of polarized Th17 cells was continually tested via flow
cytometric analysis. The polarized T cells were incubated with 0.1 µg of antibody again
CD3, CD4, and CD8 for 30 minutes to evaluate extracellular markers of phenotype.
Gating was performed based upon analysis of unstained and isotype controls.
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Figure 8. Five months of weekly polarization lead to a loss of Th17 skewed
cytokine production. The phenotype of the polarized Th17 cells was continually tested
for cytokine production via cytokine bead array.

Cells from the polarization were

stimulated for 5 hours with PMA and ionomycin before being analyzed for IL-17a, TNF-α,
IFN-ɣ, IL-10, IL-6, IL-4, and IL-2 expression.
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Figure 9. Cloning of polarized T cells to create a single cell colony T cell line. To
create a T cell line the single cell colonies must be separated and chosen. To achieve
this goal cells were plated in 96 well plates at 100, 10, or 1 cell per well in complete
medium containing all necessary cytokines, antibodies, APCs, and antigen (N-4YSyn).
After 7-10 days single cell colonies were chosen from the wells and transferred to 24
well plates in the same complete medium tailored for cellular growth and proliferation.
Single cell colonies were then phenotypically tested by flow cytometric analysis and
cytokine bead array. Lastly, single cell colonies selected based upon their cytokine
profile were transferred to a T25 flask for growth expansion.
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Figure 10. Expansion of the parent Th17 cell line over a period of 12 months
demonstrates phenotypic stability over time.

Expression of extracellular and

intracellular markers by the parent Th17 cell line was assessed by flow cytometric
analysis. After recurrent polarization with Th17 polarizing cytokines, cells of the effector
T cell line were stained with antibodies against CD3, CD4, CD8, IL-17a, IFN-ɣ, and TNFα (A, B). Representative pictures of flow analysis at 2, 6, and 12 months (B). Cytokine
expression was analyzed by cytometric bead array after stimulation with phorbol-12myristate-13-acetate and ionomycin for 5 hours using a kit specific for Th1, Th2, and
Th17 cytokines. Supernatant from the cell line were analyzed for cytokines at 2, 6, and
12 months (C).
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Figure 11. Re-cloning of the parent Th17 cell line resulted in the Th17 cell line
which demonstrated further phenotypic stability over 12-20 months. After a 3 week
cloning period the cytokine expression and phenotype of the Th17 cell line was
evaluated by flow cytometric analysis using antibodies against CD3, CD4, CD8, IL-17a,
IFN-ɣ, and TNF-α (A, B). Representative pictures of flow analysis at 12, 16, and 18
months (B). Cytokine expression was measured using a Th1/2/17 cytokine bead array
after 5 hours of stimulation with 200µg/ml PMA and 10mM ionomycin. Supernatant from
the Th17 cell line were analyzed at 12, 15, and 18 months for cytokine production (C).
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Figure 12. Changing the cytokine milieu of the parent Th17 cell line results in the
phenotypically stable Th1 cell line. The cytokine milieu of the parent Th17 cell line
was switched from a Th17 environment to a Th1 environment (through the removal of all
Th17 cytokines and antibodies and the addition of 50 U/ml IL-2), and 2 months of weekly
passage resulted in the generation of the Th1 cell line, a phenotypically stable Th1 cell
line. The Th1 cell line was characterized using flow cytometry and antibodies against
CD3, CD4, CD8, IL-17a, IFN-ɣ, and TNF-α (A, B). Representative pictures of flow
analysis at 13, 18, and 20 months (B). Cytokine expression of the Th1 cell line was also
analyzed using cytokine bead array to test for TH1/2/17 cytokines, including IL-17a,
TNF-α, IFN-ɣ, IL-10, IL-6, IL-4, and IL-2 (C). Supernatant was analyzed at 14, 18, and
20 months.
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Figure 13. Cloned Th17.1 cell line established phenotypic stability of a Th17.1 cell
line, consisting of IL-17+/IFN-ɣ+ dual expressing cells. Cloning of the parent Th17
cell line resulted in the generation of the Th17.1 cell line, which was phenotypically
characterized using flow cytometry and antibodies against CD3, CD4, CD8, IL-17a, IFNɣ, and TNF-α (A, B). Representative pictures of flow analysis at 2, 6, and 8 months (B).
Cytokine expression of the Th17.1 cell line was also analyzed using cytokine bead array
to test for TH1/2/17 cytokines, including IL-17a, TNF-α, IFN-ɣ, IL-10, IL-6, IL-4, and IL-2
(C). Supernatants were analyzed at 30, 32, and 36 months.
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CHAPTER THREE: T CELL MEDIATED NEURONAL DEATH
In order to ensure the cloned Th17 cell line was functional and cytotoxic to
neuronal cells the Th 17 cell line was evaluated for the exacerbation of dopaminergic
loss in the MPTP mouse model and ability to increase microgliosis in vivo. Previous
data has shown that adoptive transfer of effector T cells which recognize N-α-Syn as
non-self

exacerbate

microglial-mediated

neuroinflammation,

dopaminergic neurodegeneration (Reynolds et al., 2009a).

inducing

amplified

Moreover, the adoptive

transfer of Th17 effector T cells demonstrated increased dopaminergic loss in
comparison to other effector subtypes, including Th1 and Th2 T cells (Reynolds et al.,
2010). Intoxication of C57Bl/6 wild-type mice with 16mg/kg MPTP followed by adoptive
transfer of a gradient of T cells from the Th17 cloned cell line demonstrated a significant
increase in toxicity of TH+ dopaminergic neurons in the SN in comparison to MPTPtreated controls (43% loss) with T cell treatments of 5 (62% loss) and 10 (59% loss)
million cells (Figure 14a). There was no appreciably significant loss of the dopaminergic
neuronal termini in the striatum (Figure 14b), indicating that 16mg/kg dose of MPTP may
cause maximal termini loss without the help of exogenous T cells. Additionally, staining
of Mac1+ cells shows the adoptive transfer of 10 million cells from the Th17 clone results
in greater than a 2-fold increase in microgliosis at 2 days post MPTP intoxication (Figure
15). This data suggests the cloned Th17 cell line is in fact functional, and able to cause
hyperactivation of microglia and increase neurotoxicity of dopaminergic neurons in the
MPTP mouse model of PD.

Stimulation of the Th17 Cell Line Increases Microglial Activation and
Alters Viability of MES23.5 Neuronal Cells
In pursuit of optimal stimulation of the N-4YSyn-specific Th17 cell line that would
garner the greatest neurotoxic phenotype, the T cell line was incubated with varying
stimuli to detect differences in neurotoxic ability, including 10 - 100 µg/ml N-4YSyn and 9
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µg anti-CD3. The Th17 cell line was stimulated for 24 hours with varying concentrations
of N-4YSyn or anti-CD3 and the supernatant from the T cell line was transferred to
culture with MES23.5 cells for 24 hours. Measurement of viability using alamar blue
indicated stimulation for 24 hours with varying antigens did not cause a significant
increase in the loss of viability for MES23.5 cells compared with unstimulated Th17 cells
rested for 24 hours (Figure 16a). In fact, no appreciable difference between any of the T
cell stimuli samples and the unstimulated T cell controls were detected, indicating the T
cell line may already be at peak neurotoxic capabilities due to constant culture with
antigen (N-4YSyn) each week with cytokines and antibodies that promote activation,
growth and maturation, in addition to the T cell line typically being harvested for
evaluation at the time of peak growth.

The ability of the Th17 cell line to induce

microglial activation was also assessed via co-culture of the stimulated T cell line
supernatant with the BV-2 microglial cell line for 24 hours. Activation of microglial BV-2
cells was measured by production of H2O2 and nitrite.

Nitrite, a stable breakdown

product of NO, is an important physiological messenger and effector molecule, as well
as a useful measure of microglial activation. Stimulation of BV-2 cells with stimulated
and un-stimulated supernatant from the Th17 cell line resulted in a 7-fold increase in
nitrite production and a 5-fold increase in H2O2 production from BV-2 cells (Figure 16b
and 16c. No significant differences in BV-2 ROS and RNS production were detected
after co-culture with stimulated Th17 cells compared to unstimulated Th17 cells,
indicating the cell line yields peak neurotoxic effects without the need for further
stimulation.
Considering that the Th17 cell line was maintained under conditions necessary
for growth, and not necessarily inflammatory condition required to induce toxicity, we
sought to elevate the level of activation. For these studies, we stimulated the Th17
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clone with CD3/CD28 transactivator beads for 24 hours and assessed the neurotoxic
ability in vitro with MES23.5 cells, a hybrid dopaminergic neuronal cell line (Crawford et
al., 1992).

The toxicity of the Th17 cell line was first tested in vitro utilizing the

membrane impermeable CellTox Green assay to measure cell death via binding of DNA
by membrane compromised cells, and the Cell-Titer Glo assay to measure viability
through the amount of ATP present in metabolically active cells.

After 24 hours of

CD3/CD28 transactivator beads stimulated Th17 cells or supernatant were co-cultured
with MES23.5 neuronal cells.

Co-culture caused a significant increase in neuron

cytotoxicity, with the Th17 cells significantly increasing 1.4-fold and the Th17 cell
supernatant 2.1-fold in comparison to untreated controls of Mes23.5 cells which received
no treatment (Figure 17a). Moreover, this increase in toxicity was accompanied by a
significant decrease in viability by the Th17 cells and supernatant (0.79-fold and 0.70fold loss, respectively).

This data was verified utilizing the alamar blue assay to

measure cell viability through the reduction of redox indicator within viable cells
maintaining a reducing environment within their cytoplasm. Conversely, the LDH assay
measured cell death via the release of lactate dehydrogenase, a cytosolic enzyme
present within intact cells, into cell culture medium. Employing the same experimental
conditions to test the cytotoxicity and viability of MES23.5 cells, anti-CD3/CD28
stimulated Th17 cells or supernatant significantly increased cytotoxicity by 6.6-fold and
8.2-fold, respectively. Whereas Th17 cells and supernatant also decrease viability of
MES23.5 neurons by 0.85-fold and 0.64-fold, as measured by LDH release from dead or
dying cells.

Interestingly, in all cases the Th17 cell supernatant had the ability to

significantly increase toxicity and decrease viability.

Taken together, this data

demonstrated the neurotoxic capacity of the Th17 cell line in vitro through direct
mechanism(s) of T cell interaction with neurons.
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Further analysis of the effects of the Th17 cell line in microglial-mediated
neurotoxicity was assessed utilizing primary microglia and the BV-2 microglial cell line.
Additionally, ROS and RNS production by the Th17 cell line supernatant was also
investigated.

As

resting

microglia

remain

sensitive

to

changes

in

their

microenvironment, particularly when DAMPS and self-modified proteins (N-α-Syn) are
released from dead and dying neurons, these factors drive microglia to their activated
M1 phenotype.

This phenotype is consistent with production of pro-inflammatory

cytokines, superoxide, and release of ROS and RNS such as H2O2 and NO (Wilshusen,
2014, Le et al., 2016). To assess the effects of the Th17 cell line on microglial activity,
cloned Th17 cells were stimulated and either activated Th17 cells or supernatant were
co-cultured with the BV-2 cell line for 24 hours, whereupon T cells or supernatant were
removed and nitrite levels were examined. The Th17 cloned cells significantly increased
nitrite production from BV-2 cells by 4-fold, whereas the supernatant induced a 5-fold
increase, indicating the Th17 line cells and supernatant can induce microglia to the M1
activated phenotype (Figure 18a).
To test the effects of Th17 cells on the neurotoxic activity of microglia, we
cultured CD3/CD28-stimulated cloned Th17 cells before co-culture of the cells or their 24
hour culture supernatant with primary microglia or BV-2 cells, removed the T cells or
supernatant, cultured the microglia or BV-2 cells for 24 hours, and co-cultured the
subsequent culture supernatant with MES23.5 cells. This strategy was similar to that
used to assess neurotoxicity mediated by direct exposure of T cells or supernatant to
MES23.5 cells, but with the inclusion of microglial cell types as an indirect intermediary.
To assess cytotoxicity and viability, we used CellTox Green and CellTiter-Glo assays,
respectively.

Measurements of cytotoxicity and reduction in viability from stimulated

supernatant alone were subtracted from reactivity’s induced by supernatants from
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stimulated cells. First, primary microglia culture supernatant derived from co-cultures
with stimulated Th17 cells or supernatant therefrom increased cytotoxicity and
decreased viability of MES23.5 dopaminergic cells (Figure 18b). We demonstrated that
microglial supernatants from co-culture with stimulated Th17 cloned cells increase
MES23.5 cytotoxicity by 1.3-fold, whereas the supernatants from stimulated Th17
induced microglial cells to produce factors that elevated dopaminergic toxicity to higher
levels of 1.7-fold. As expected, measurements of reduced MES23.5 viability validated
the cytotoxicity findings, reducing viability from supernatants derived by Th17 cloned
cells (0.88-fold) and supernatant (0.80-fold).

These findings also demonstrated that

induction of neurotoxic factors from microglia was better facilitated by the supernatants
of stimulated Th17 cells, rather than Th17 cells themselves.
One question center to our hypothesis was the neurotoxic potential mediated
directly by T cells or that mediated indirectly by T cell-activated microglia. To assess
this, we measured cytotoxicity and viability of MES23.5 dopaminergic cells after culture
with supernatants from cloned CD3/CD28 stimulated Th17 cells, or from BV-2 cells that
were induced by those Th17 supernatants.

Results demonstrated that while

dopaminergic neurotoxicity was increased for both microglial supernatant (1.2-fold) and
Th17 supernatant (1.5-fold), cytotoxicity from CD3/CD28-stimulated Th17 clones
showed greater neurotoxicity to dopaminergic neurons (Figure 18c). These results were
confirmed by MES23.5 viability determinations which showed 12% diminution by BV-2
supernatants compared to 21% by Th17 culture supernatants. Interestingly, while the
cloned Th17 cell line appears to work both directly and indirectly to cause neuronal
toxicity, Th17 cells themselves appear more toxic to MES23.5 cells than the T cell
stimulated microglial cultures. Taken together, these results validate the ability of the
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Th17 cell line to cause direct toxicity of neuronal cells as well as indirect toxicity through
the activation of microglia.

IFN-ɣ+/IL-17+ Dual Expressing Th17.1 Cells Demonstrate Increased
Pathogenicity
In vivo studies have demonstrated the occurrence of dual expressing IFN-ɣ+/IL17+ CD4+ T cells within serum and tissues of patients with pulmonary sarcoidosis and
multiple sclerosis (Kebir et al., 2009, Ramstein et al., 2016). These cells reflect a hybrid
T cell lineage that is Th17-derived and has been termed the Th17.1 lineage. In vitro
analysis also confirmed the pathogenicity of Th17.1 cells and the possible need for a
Th17 cell with a secretion profile which includes both IL-17 and IFN-ɣ in order to present
a more proinflammatory phenotype and/or produce a more pathogenic mediator
(Ghoreschi et al., 2010, Ghoreschi et al., 2011, Zuniga et al., 2013, Gartlan et al., 2017).
We previously described the derivation of two cloned, N-α-Syn-specific T cell lines, a
Th1 cell line and a Th17.1 cell line; both derived by repolarization of the same Th17
clone, but at times early and late, respectively, after establishment of Th17 clonality
(Chapter 2).
As Th17.1 cells are thought to be more pathogenic under autoimmune
conditions, we first sough to compare neurotoxic pathogenicity of our cloned Th17.1 cell
line with the cloned Th17 cell line (parent of the Th17.1 cell line). For these studies, we
measured cytotoxicity and viability as directly mediated by either CD3/CD28 stimulated T
cells or the supernatants derived therefrom. Incubation of the CD3/CD28-stimulated T
cell line cells and culture supernatants with MES23.5 dopaminergic neuronal cells
showed that both T cells and supernatants from the T cell lines caused significant
neurotoxicity’s (Figure 19).

Cells from the cloned Th17 cell line induced a 1.3-fold

increase in MES23.5 cytotoxicity, whereas cloned Th17.1 cells mediated 1.7-fold
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neurotoxicity (Figure 19a). Viability estimated of MES23.5 co-cultured with both cell
lines validated cytotoxicity results. Additionally, supernatants from both cloned T cell
lines were cytotoxic to MES23.5 cells (Figure 19b). Compared to media controls, Th17
supernatants provided 1.4-fold neurotoxicity, whereas Th17.1 supernatants yielded 1.8fold toxicity.

Collectively, these data indicate the Th17.1 cell line is more toxic to

dopaminergic neurons in vitro than its parental Th17 cell line.
We next compared the neurotoxic capacities of the parental Th17 cell line with
those of early and late progeny Th1 and Th17.1 cell lines, respectively. In addition, we
sought to determine cytotoxic mechanism(s) by which T cell lines are killing neurons.
For these studies, supernatants from CD3/CD28-stimulated T cell lines were co-cultured
with MES23.5 cells, and then assessed for cytotoxicity, viability, and apoptosis using the
ApoTox-Glo Triplex Assay.

This assay measures not only toxicity (via a cell

impermeable bis-AAF-R110 substrate to detect dead cell proteases leaked from
compromised membranes) and viability (via a cell permeable GF-AFC substrate that is
cleaved only by live cell proteases), but also assesses caspase 3 and 7 activity as
markers of apoptosis (via cleavage of the Ac-DEVD-pNA substrate and detection of the
cleaved amino luciferin by luciferase).

To verify the involvement of an apoptotic

mechanism in neurotoxicity, a pan caspase inhibitor, Z-VAD-FMK, was added to the cocultures. Z-VAD-FMK binds the catalytic site of activated caspases, blocking cleavage
to active caspase and the apoptosis program. Culture of the MES23.5 neuronal cells
with T cell supernatant resulted in a ~7-fold increase in cytotoxicity for Th17 and Th1
supernatant, whereas Th17.1 cell supernatant significantly increased toxicity by 11-fold
compared to controls (Figure 20a). Additionally, Th17 and Th1 supernatants decreased
viability by at least 30%, and Th17.1 supernatant by 50% compared to controls, thus
validating cytotoxicity measurements compared to untreated controls. Th17 and Th1 cell

97
line supernatants increased apoptosis by ~ 1.5-fold, whereas the Th17.1 supernatant
caused a 2-fold increase in apoptosis (Figure 20b). Moreover, the addition of Z-VADFMK led to complete ablation of apoptosis (Figure 20b), cytotoxicity (Figure 20a), and
rescued viability of MES23.5 cells to the effects of all three effector cell types. Taken
together, these data demonstrate that Th17.1 exhibited increased neurotoxicity
compared to the parental Th17 and sibling Th1 cell lines. Moreover, one mechanism of
direct neurotoxicity by secreted T cell factors is by induction of an apoptotic program.

Th17.1 Cells Cause the Largest Microglial Activation and Subsequent
Neuronal Cytotoxicity via Apoptotic Factors
Previous studies have shown adoptive transfer of Th17 effector T cells into the
MPTP mouse model resulted in exacerbated neuroinflammation with amplified
dopaminergic

neurodegeneration,

and

exacerbated

microglial-mediated

neuroinflammation (Reynolds et al., 2007, Reynolds et al., 2010). It was shown that
Th17 effector T cells exacerbated neurodegeneration to greater levels than effector T
cell types secreting IFN-ɣ, such as Th1. In fact, it is altogether possible that the effector
T cells are able to exert hyper-toxic effects through both direct and indirect mechanism.
A recent review has shed light on the Th17/Th1 intermediary Th17.1 phenotype causing
amplified toxicity in comparison to its counterparts (Ghoreschi et al., 2011). With this in
mind, the ability of the Th17.1 cell line to exacerbate microglial-mediated cytotoxicity of
MES23.5 cells in vitro was investigated.

First, we sought to establish the ability of

effector T cell lines to activate microglia. In short, primary microglial and BV-2 cells were
cultured with cells or supernatant from the Th17, Th1, and Th17.1 cell lines after
activation using CD3/CD28 transactivator beads.

After co-culture for 24 hours with

microglia, T cells or supernatants were removed and microglia cultured for 8 hours
before testing for nitrite and hydrogen peroxide production as activation products.
Culture of T cell line cells and supernatant with BV-2 microglial cells induced significant
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production of nitrite and hydrogen peroxide with all T cell types in comparison to
untreated controls (Figure 21a, 22a).

Nitrite concentration was most significantly

increased in the presence of Th17.1 cell line cells (26.7 µM) and supernatant (31.1 µM)
in comparison to untreated controls, the Th17 cell line, and Th1 cell line. Additionally,
culture of BV-2 microglial cells with Th17 and Th1 cells and supernatant resulted in a
significantly larger increase in nitrite production from Th17 cells (10.9 µM) and
supernatant (11.7 µM). Moreover, the Th17.1 cell line cells and supernatant significantly
increased hydrogen peroxide levels by 0.39 pg/ml and 0.34 pg/ml, respectively, in
comparison to all controls and T cell types. Again, the Th17 cell line cells and
supernatant increased H2O2 production in comparison to its Th1 counterpart, with a 0.18
pg/ml increase by the cells and a 0.11 pg/ml increase by the supernatant. While primary
microglia did not show any increase in hydrogen peroxide levels after 24 hours, both T
cells and T cell supernatants induced a significant increase in nitrite production with all T
cell types (Figure 21b, 22b). In fact, T cells and supernatant from the Th17.1 cell line
induced the largest nitrite increase, at 1.1 µM and 7.6 µM respectively. Moreover, Th17
supernatant, but not cells, demonstrated a more significant increase of nitrite (2.94 µM
respectively) in comparison to Th1 cells (1.2 µM).

These data indicate the T cell lines,

most specifically the Th17.1 cell line, are able to induce resting microglia into their
activated forms.

These data showed that CD3/CD28-stimulated T cells activate

microglia to produce ROS and RNS, and of those tested, the Th17.1 cells exhibited the
capacity to induce the greatest levels of reactive species. Moreover, taken together
these data suggested that the Th17.1 cell line may exhibit an enhanced neurotoxic
capacity.
To test that possibility, we investigated the neurotoxic potential of T cellstimulated primary microglia.

For these studies, T cells from each Th17, Th1, and
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Th17.1 cell line were stimulated for 24 hours before T cells or supernatants were
transferred to primary microglial cells for activation. After 24 hours of stimulation the
media was exchanged and the supernatants from the microglial cells were transferred to
MES23.5 neuronal cells for 6 hours, after which MES23.5 cells were tested for
cytotoxicity, viability, and apoptosis via the ApoTox-Glo Triplex assay. Stimulation of
microglia with all T cell effector types induced a significant increase in neurotoxicity, but
only Th17 and Th17.1 cells induced microglial medium that decreased viability and
increased apoptosis (Figure 23a).

In fact, while there was a significant increase in

toxicity and decrease in viability for both the Th17 and Th1 cell lines, there was not a
significant difference between the two in their ability to induce MES23.5 cellular death
(2.3-fold and 1.7-fold, respectively). More importantly, the Th17.1 cell line caused the
largest changes in cytotoxic factors (4.8-fold), largest decrease of viability factors (34%)
and largest increase of apoptotic factors caspase 3 and 7 catalytic activity (1.3-fold).
The Th17.1 cell line induced the greatest levels of microglia-mediated neurotoxicity and
apoptosis as well as diminution of viability, whereas Th1 cells induce the lowest levels of
microglial-mediated effects on MES23.5 cells.

In comparison, supernatants from all

three T cell lines stimulated microglial reactivity to levels that increased neurotoxicity and
apoptosis, and Th17 diminished viability (Figure 23b). After co-culture of the T cell
medium with microglia, the primary microglia medium was transferred to culture with the
MES23.5 cells.

After 6 hours all the T cell types significantly increased toxicity,

decreased viability (except theTh1 cell line), and increased factors of apoptosis (Fig.
23b). In fact, The Th1 cell line demonstrated the smallest increase in cytoxicity (4.0fold), while the Th17.1 cell line exhibited the most significant increase of 6.8-fold. In
terms of viability, while the Th1 cell line did not exhibit a significant decrease in
comparison to untreated controls, the Th17 cell line caused a significant loss of 25%,
whereas the Th17.1 cell line caused the most significant loss of 44%.

Lastly, the
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smallest increase in apoptotic factors was demonstrated with the Th1 cell line stimulation
(1.3-fold), and the largest with the Th17.1 cell line (1.7-fold). The ability of the Th17.1
cell line to cause the largest increase in microglial mediated toxicity of neuronal cells in
comparison to its Th17 and Th1 counterparts has become evident, and while the
mechanism appears to utilize factors of apoptosis, the ability to inhibit apoptosis and
therefore restore viability to the MES23.5 neurons will aid in the confirmation of this
mechanism. Taken together, these data suggest one mechanism of T effector cellmediated neurotoxicity is by activation of microglia to produce factors that induce the
apoptotic program in neurons.
To confirm the apoptotic mechanism of neurotoxicity T cells and supernatants
from each of the CD3/CD28-stimulated T cell lines were cultured with BV-2 microglial
cells for 24 hours, T cells and supernatants removed, media replaced, and the microglial
medium transferred to MES23.5 cells, in the presence or absence of the pan caspase
inhibitor Z-VAD-FMK, for 6 hours before assessing cytotoxicity, viability, and apoptosis.
As previously shown with primary microglial cultures, culture of the T cell-stimulated
microglial medium with neuronal cells resulted increased cytotoxicity, decreased viability,
and increased apoptosis by all T cell types (Fig 24a). The Th1 cell line demonstrated
the smallest toxicity increase (4-fold), decrease in viability (30%), and increase in
apoptotic factors (1.8-fold), whereas the Th17.1 cell line again exhibited the largest
increase of cytotoxicity (7-fold), decrease in viability (40%) and increase of apoptosis (5fold). Moreover, evaluation of the cytotoxic effects of T cell line supernatant-stimulated
BV-2 medium displayed similar results, with each T cell line inducing significant changes
in BV-2 mediated neurotoxicity, viability, apoptotic factors (Fig 24b). In fact, there was
no significant difference between the cytotoxicity that was induced by the Th17 and Th1
cell lines (6-fold and 5.9-fold respectively), whereas the Th17.1 cell line increased
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neurotoxicity by 7.8-fold. Additionally, no significant differences were detected in viability
diminution for the Th17 (30%) and Th1 (20%) cell lines, while the Th17.1 cell line
demonstrated a significant diminution of 50% in comparison to untreated control, Th17,
and Th1 cell lines. As to the extent of apoptosis, the Th1 cell line induced the smallest
increase in microglial-mediated apoptosis by 1.2-fold, whereas the Th17 cell line
increased microglial-mediated apoptosis by 1.5-fold, and the Th17.1 cell line by 3.8-fold.
Finally, inclusion of Z-VAD-FMK with co-cultures of MES23.5 and supernatants from T
cell- or T cell supernatant-stimulated BV-2 cells returned neurotoxicity, viability, and
apoptosis to control levels (Figure 24a and 24b). Taken together these results confirm
the ability of the effector T cell lines to induce microglial-mediated cellular death by
apoptosis of dopaminergic MES23.5 neuronal cells.

Moreover the Th17.1 cell line

exhibited the strongest effects on microglial activation and microglial-mediated neuronal
cell death. These data suggest that since the Th17.1 cell line and supernatants exhibit
such influential effects on microglia and BV-2 cells, and in turn on laboratory models of
neurotoxicity, the assessment of Th17.1 cells in an in vivo model of neurodegeneration
is warranted.

In Vivo Adoptive Transfer of Th17.1 Cell Line Causes Increased
Toxicity of Neurons and Prolonged Microgliosis
Increasing evidence suggests that neurotoxic inflammatory activities have a
profound effect on the pathogenesis of PD. In fact, cells of the adaptive immune system,
such as effector T cells, can modulate microglial responses and exacerbate
neuroinflammation and neurodegeneration in the MPTP-intoxicated mouse model of PD.
Indeed, while the creation of Th17, Th1, and Th17.1 cell lines which are functional within
in vitro assays is essential, it is imperative to assess the cell lines function in vivo and
their capacity to intensify inflammation and dopaminergic neurodegeneration along the
nigrostriatal axis.

Therefore, 10.0x106 cells from the Th17, Th1, and Th17.1 were
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adoptively transferred into MPTP-intoxicated mice 12 hours after intoxication with 16
mg/kg MPTP. These cells were harvested from cell culture at day 4 within their growth
cycle, and were not stimulated with CD3/CD28 transactivator beads. Seven days after
intoxication with MPTP, brains were harvested in order to assess the number of TH+
dopaminergic neurons residing the in the substantia nigra, its associated termini in the
striatum, and extended microgliosis after 7 days.

Evaluation of TH+ dopaminergic

neuron counts revealed MPTP intoxication alone reduced the number of TH+
dopaminergic neurons in the SN to 65% that of untreated controls (Figure 25a). T cells
from the Th1 cell line significantly decreased neuron numbers to 56% that of the
untreated control, Th17 cell line to 40%, and Th17.1 cell to 26%. No effects of nondopaminergic (TH-Nissl+) neurons were discernible.

While the effector T cell lines

significantly decreased the number of nigral TH+ neurons in the SN in comparison to
untreated and MPTP treated controls, only T cells from the Th17.1 cells exacerbated
dopaminergic (TH+) termini in the striatum, whereas no additive effects on
neurodegenerative by T cells from Th1 and Th17 cell lines were discernible (Figure 25b).
However, the possibility exists that the striatum reaches a threshold near maximum loss
of TH+ dopaminergic termini whereby only highly intensive levels of neurodegenerative
processes may exacerbate loss greater than that induced by MPTP alone.
While peak neuronal loss in the MPTP mouse model is assessed 7 days postintoxication, changes in microglial activation, including morphology and number, is
initiated as early as 90 minutes after intoxication (Huang et al., 2017, Subramaniam and
Federoff, 2017).
intoxication.

Factors of microglial activation are still detected at 7-9 days after

Markers of microglial activation including amoeboid morphology and

expression of MHC II, Mac-1, and Iba-1, are upregulated by 2 days post-intoxication.
Moreover, MHC II levels in the ventral midbrain are upregulated at 2 days post MPTP
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intoxication and is found to be localized to resident microglia, indicating microglial cell
activation via MHC II T cell mediated affects may be required for the full expression of
M1 type microglial pathology (Martin et al., 2016). In fact, adoptive transfer of CD4+
effector T cells after MPTP intoxication increases microglial activation at day 2 and
extends reactive microgliosis to beyond 5 days post MPTP intoxication (Reynolds et al.,
2008a, Reynolds et al., 2009a). Thus, in light of the results showing that Th1, Th17, and
Th17.1 cell lines exacerbate TH+ dopaminergic loss, and that the TH17.1 cell line has
enhanced capability compared to Th17 and Th1 cell lines, we sought to investigate the
possibility of extended microgliosis as a pathway for increased dopaminergic neuronal
cell loss. Therefore, 10.0x106 cells from the Th17, Th1, and Th17.1 cell lines were
adoptively transferred to MPTP intoxicated mice, and evaluated for extended
microgliosis at 7 days post intoxication. T cells were harvested from cell culture at day 4
within their growth cycle and were not stimulated with CD3/CD28 transactivator beads.
Reactive microglia with amoeboid morphology and upregulated Iba-1 expression were
enumerated within the SN. After 7 days, activated microglia are still upregulated 10-fold
in MPTP treated controls compared to PBS treated controls (Figure 26).

Adoptive

transfer of Th17 and Th1 cells produced a significant 18-fold and 16-fold increase in
comparison to untreated controls. Most importantly, the adoptive transfer of Th17.1 cells
yielded the largest increase in microglial activation of 34-fold at 7 days post MPTP
intoxication. Taken together, these results demonstrate the ability of effector T cells
from the Th17, Th1, and Th17.1 cell lines enhance dopaminergic cell loss within the SN
of MPTP-treated mice.

Moreover, the Th17.1 cell line exhibits greater levels of

pathogenicity compared to the parental Th17 cell line and the earlier sibling Th1 cell line
in terms of exacerbation of neuronal cell loss and exacerbation of microgliosis.
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Figure 14. MPTP intoxication and subsequent adoptive transfer of the Th17 cell
line exacerbates the loss of TH+ neurons. To determine the ability of the T cell line to
amplify DA neurodegeneration in the substantia nigra, wild-type mice were adoptively
transferred graded numbers (1-10 x 106) of Teffs 12 hours post treatment with16 mg/kg
MPTP and assessed the surviving numbers of TH-IR neurons in the SN (A) and the
associated striatum (B) 7 days after intoxication. Scale bar in representative photos
equivalent to 1,000 μm in length. The difference in means (± SEM) were determined
where P<0.05 compare in length. The difference in means (± SEM) were determined
where P<0.05 compared with controls for aPBS and bMPTP (A, B)
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Figure 15. MPTP intoxication and subsequent adoptive transfer of the Th17 cell
line increases the number of Mac1+ reactive microglia in the SN. To determine the
ability of the Th17 cell line to increase microgliosis in the SN after treatment with MPTP,
C57BL/6 mice were adoptively transferred graded numbers (1-10 x 106) of Teffs 12
hours post treatment with16 mg/kg MPTP. Two days post MPTP intoxication and
adoptive transfer microgliosis was assessed via DAB staining to determine the number
of Mac1+ cells/mM2 in the SN. Scale bar in representative photos equivalent to 1,000
μm in length.

The difference in means (± SEM) were determined where P<0.05

compared with controls for aPBS and bMPTP.
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Figure 16. Stimulation of the Th17 cell line with different antigens fails to alter
viability of MES23.5 neuronal cells. To determine the ability of different T cell stimuli
to cause a loss in neuronal viability the Th17 cell line was incubated for 24 hours with
varying concentrations of N-4YSyn or anti-CD3 and supernatant was transferred to
MES23.5 cells for 24 hours before measuring viability via Alamar Blue (A). The ability of
the stimulated T cells line to induce microglial activation was assessed utilizing Th17
supernatant stimulated in culture with BV-2 microglial cells for 24 hours.

Microglial

activation was measured by nitrite and H2O2 production (B, C). The difference in means
(± SEM) were determined where P<0.05 in comparison with aControl (A, B, C).
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Figure 17. Co-culture of cells or supernatant from the Th17 cell line with neuronal
cells increases cytotoxicity and decreases viability of MES23.5 cells. The Th17 cell
line was stimulated for 24 hours with CD3/CD28 mouse T activator beads and cultured
with MES23.5 cells for 6 hours before cytotoxicity was read via the CellTox Green or
LDH assay and viability via the CellTiter-Glo or Alamar Blue assay. Cytotoxicity and
viability was examined utilizing co-culture of MES23.5 neuronal cells directly with Th17
cells or supernatant, resulting in a larger increase in cytotoxicity from the supernatant of
Th17 (A). The findings of part A were confirmed utilizing the same methods with the
LDH and Alamar Blue assays for cytotoxicity and viability (B). Relative fluorescent,
luminescent and absorbance units were expressed as fold change. The difference in
fold change (± SEM) was determined where P<0.05 in comparison with aControl and
b

Th17 cells (A, B).
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Figure 18. Co-culture of BV-2 or microglial cells with stimulated Th17 cell line
increases BV-2 nitrite production, and increases neurotoxic potential of BV-2
supernatant. The Th17 cell line was stimulated for 24 hours with CD3/CD28 mouse T
activator beads and then the cells or supernatant were cultured with primary microglia or
BV-2 cells for an additional 24 hours. Subsequent microglial activation was measured by
the release of a primary nitric oxide breakdown product, nitrite, from BV-2 cells (A).
Stimulus of primary microglial cells with Th17 cells or supernatant and subsequent coculture of the microglial supernatant with MES23.5 cells induces a loss in viability and an
increase in cytotoxicity as measured by Promega CellTiter-Glo and CellTox Green
assays (B).

Culture of MES23.5 cells with Th17 supernatant or Th17 supernatant-

stimulated BV-2 cells results in increased in toxicity and decreased viability, with Th17
cells resulting in the largest increase in toxicity (C).

Relative fluorescent and

luminescent units were expressed as fold change. The difference in mean and fold
change (± SEM) was determined where P<0.05 in comparison with aControl, bTh17 cells
(A), bTh17 cells/microglia (B), and bTh17 supernatant/BV-2 (C).

113

114
Figure 19. Co-culture of Th17 or Th17.1 cells and supernatant with neurons
increases cytotoxicity and decreases viability of MES23.5 cells. The Th17 and
Th17.1 cell lines were stimulated for 24 hours before culture of the T cells or T cell
supernatants with MES23.5 neuronal cells. Cytotoxicity and viability of the MES23.5
cells was measured utilizing the CellTox Green and the CellTiter-Glo assays. Culture
with T cells resulted in a larger increase in cytotoxicity and an accompanying decrease
in viability with the Th17.1 cells in comparison to the Th17 cells (A). Culture of the
MES23.5 cells with T cell supernatant demonstrated higher levels cytotoxicity with both
T cell types (B). Relative fluorescent and luminescent units were expressed as fold
change.

The difference in fold change (± SEM) was determined where P<0.05 in

comparison with aControl, bTh17 cells (A), and bTh17 supernatant (B).
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Figure 20. The Th17.1 cell line exhibits increased MES23.5 neurotoxicity in
comparison to Th17 and Th1 cell lines. The T cell lines Th17, Th1, and Th17.1 were
stimulated for 24 hours with CD3/CD28 transactivator beads before the T cell
supernatant was transferred directly to MES23.5 cells in culture. In half the samples a
pan caspase inhibitor, Z-VED-FMK was added to the MES23.5 cells 15 minutes prior to
the addition of T cell supernatant. Six hours post co-culture cytotoxicity, viability, and
caspase activation were measured via the ApoTox-Glo Triplex Assay. Cytotoxicity and
viability of MES23.5 cells were assessed with Th17, Th1, or Th17.1 supernatants (A).
Concurrent analysis of apoptosis of MES23.5 cells induced by supernatant from
stimulated Th17, Th1, or Th17.1 cells (B). Relative fluorescent and luminescent units
were expressed as fold change. The difference in fold change (± SEM) was determined
where P<0.05 in comparison with aControl, bTh17 supernatant, cTh1 supernatant, and
d

Th17.1 supernatant (A, B).
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Figure 21. Microglia increased nitrite and hydrogen peroxide production in the
presence of Th17, Th1, or Th17.1 cells. The T cell lines were stimulated for 24 hours
with CD3/CD28 transactivator beads before the cells were incubated with primary
microglia or BV-2 cells. Twenty four hours later the T cells were removed, and after 8
hours the nitrite and hydrogen peroxide levels emanating from the microglial cells were
read via the Griess and Amplex Red assays. Co-culture of the BV-2 microglial cells with
stimulated T cells induced increased nitrite and H2O2 production (B).

Nitrate

concentrations from primary microglia co-cultured with stimulated T cells from T cell lines
(B).

Primary microglia did not show any increase in H2O2 (data not shown).

The

difference in means (± SEM) were determined where P<0.05 in comparison with
a

Control, bTh17 cells, and cTh1 cells (A, B).
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Figure

22.

Microglia

produce

increased

nitrite

and

hydrogen

peroxide

concentration in the presence of supernatants from the T cell lines. The T cell lines
Th17, Th1, and Th17.1 cell lines were stimulated for 24 hours before the T cell
supernatants were transferred to primary microglia or BV-2 cells. After 24 hours the
media was changed before nitrite and hydrogen peroxide levels were measured 8 hours
later. Stimulation of BV-2 cell line with supernatants from stimulated T cells resulted in
increased nitrite and H2O2 production (A).

Stimulation of primary microglia with

supernatants from stimulated T cell lines resulted in increased of nitrite (B). The T cell
line supernatant did not cause in increase in H2O2 (data not shown). Differences in
means (± SEM) were determined where P<0.05 in comparison with aControl, bTh17
supernatant, and cTh1 supernatant (A, B).
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Figure 23. Co-culture of primary microglia with the Th17, Th1, or Th17 cell lines
decreases viability, and increases cytotoxicity and apoptosis of MES23.5 neuronal
cells. The Th17, Th1, or Th17.1 cell lines were stimulated before culture of the cells or
supernatant with primary microglia. Subsequently the supernatants from the microglia
cells were transferred to the MES23.5 cells for 6 hours before cytotoxicity, viability, and
apoptosis were measured via the ApoTox-Glo Triplex Assay. Primary microglia were cocultured with either CD3/CD28 stimulated T cells (A) or the supernatant from CD3/CD28
stimulated T cells (B). Relative fluorescent and luminescent units were expressed as
fold change. The difference in fold change (± SEM) was determined where P<0.05 in
comparison with aControl, bTh17 cells, and cTh1 cells (A) or aControl, bTh17 supernatant,
and cTh1 supernatant (B).
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Figure 24. Co-culture of BV-2 cells with T cells or supernatant from stimulated T
cell lines increases cytotoxicity and apoptosis of MES23.5 cells, which is ablated
with the addition of caspase inhibitor. The Th17, Th1, and Th17.1 cell lines were
stimulated with CD3/CD28 transactivator beads for 24 hours before cultured cells or
supernatant were transferred to BV-2 cells for 24 hours.

Supernatants from the

microglial cells were co-cultured with MES23.5 neuronal cells before apoptosis,
cytotoxicity, and viability was measured after 6 hours. In half the samples the addition of
a pan caspase inhibitor, Z-VED-FMK, was added to the MES23.5 neuronal cells 15
minutes prior to the addition of the supernatant from the microglia.

Cells from the

Th17.1 cell line stimulation exhibited the highest increase in neurotoxicity and apoptosis
of MES23.5 cells after 6 hours (A). Concurrently supernatants from stimulated BV-2
microglial cells co-cultured with neuronal cells also demonstrated the T cell lines cause
increased MES23.5 cellular death and apoptosis, with the Th17.1 cell line showing the
largest increase (B). Relative fluorescent and luminescent units were expressed as fold
change.

The difference in fold change (± SEM) was determined where P<0.05 in

comparison with aControl, bTh17 cells, cTh1 cells, and dTh17.1 cells (A) or aControl,
b

Th17 supernatant, cTh1 supernatant and dTh17.1 supernatant (B).
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Figure 25. Adoptive transfer of cells from the T cell lines exacerbates
dopaminergic neurodegeneration in the MPTP mouse model of PD.

After

intoxication of wild-type mice with 16mg/kg MPTP, 10.0 x 106 cells from the Th17, Th1,
or Th17.1 cell lines were adoptively transferred to MPTP-treated mice via tail vein
injection. Seven days post intoxication the brains were harvested for analysis of tyrosine
hydroxylase positive (TH+Nissl+) dopaminergic neurons in the substantia nigra, and their
associated termini in the striatum. Analysis of TH+ neurons in the SN showed T cells
from all T cell lines significantly exacerbated loss of dopaminergic neurons in
comparison to MPTP controls, while the Th17.1 cell line caused the largest loss of
dopaminergic neurons (A). Adoptive transfer of T cell lines resulted in a significant loss
of striatal termini in comparison to the PBS-treated control, but not the MPTP control (B).
Scale bar in representative photos equivalent to 1,000 μm in length. The difference in
means (± SEM) were determined where P<0.05 compared with controls for aPBS,
b

MPTP, cTh17, and dTh1 (A, B).

127

128
Figure 26. Adoptive transfer of the Th17.1 cell line prolonged microgliosis in the
MPTP mouse model of PD. After intoxication of wild-type mice with 16mg/kg MPTP, 10
x 106 cells from the Th17, Th1, or Th17.1 cell lines were adoptively transferred to the
mice via tail vein injection. Seven days post intoxication the brains were harvested for
analysis of Iba1+ reactive microglia in the SN. All three cell lines induce significant,
prolonged activation of microglia after 7 days in comparison to PBS-treated controls.
Only the Th17.1 cell line increased microgliosis in comparison to MPTP-treated controls.
Scale bar in representative photos equivalent to 1,000 μm in length. The difference in
means (± SEM) were determined where P<0.05 compared with controls for aControl,
b

MPTP, cTh17, and dTh1 (A, B).
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CHAPTER FOUR: DISCUSSION
Parkinson’s disease is a prominent neurodegenerative disease in the Western
world, and by the time physical symptoms become apparent over 50% of the
dopaminergic neurons within the SN are already lost (McGeer et al., 1988a, Davie,
2008). Currently little is known about the underlying cause of PD development, and
treatment for the disease is palliative. Understanding more about the progressive nature
of PD will allow for better therapies and switch the focus of treatment from alleviating
physical symptoms to a treatment that aims to address the underlying cause of PD.
Innate and adaptive immune dysfunction underlies the pathobiology of Parkinson’s
disease. Immune activation by a nitrated and misfolded form of a native protein, N-αSyn,

and

subsequent

neurotoxicity

exacerbates

nigrostriatal

degeneration.

Overwhelming evidence demonstrates microglia play a prominent role in PD (McGeer et
al., 1988a, Vila et al., 2001, Teismann et al., 2003a, Croisier et al., 2005). It is this
innate immune response, specifically microglial activation, which leads to overexpressed
surface proteins (such as MHC II) and is involved in the recruitment and activation of the
adaptive immune system (Croisier et al., 2005, Martin et al., 2016).

Moreover,

biochemical and histological evidence of oxidative stress in PD abounds and includes
increased levels of carbonyl and nitrotyrosine protein modifications, lipid peroxidation,
DNA damage, and reduction of glutathione and ferritin (Hald and Lotharius, 2005). In
fact, NADPH oxidase, a primary producer of reactive oxygen species, is not only upregulated in PD, but is correlated with activated microglia (Babior, 1999, Wu et al.,
2003).

Microglial activation and neurotoxicity are linked with Lewy bodies and

degenerating N-α-Syn-filled dopaminergic neurons, and the innate and adaptive immune
response; all of which may have some effect on disease severity and/or progression. As
disease is linked to the formation of aggregated or misfolded proteins that become
deposited within Lewy bodies, the overarching hypothesis of this laboratory is that,
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during injury and death of dopaminergic neurons, release of modified protein aggregates
such as N-α-Syn serve to activate resident microglia and antigen presenting cells in
peripheral immune tissues, engage peripheral T cells, and induce effector T cells which
in turn exacerbate a lethal cascade of microglial-induced neurotoxicity.

In fact, the

molecular approach of these in vitro and in vivo works assessed how Teffs modulate
neurotoxic phenotype of microglia and neurodegeneration.

Due to previous work

demonstrating the ability of short-lived Teff subtypes (particularly Th17 and Th1) to
exacerbate dopaminergic loss in the MPTP mouse model, it was hypothesized that N-αSyn specific effector T cells exacerbated neurodegeneration through direct cytotoxicity to
neurons, or through the hyperactivation of microglial-mediated toxicity (Reynolds et al.,
2010). These works suggest that those putative mechanism(s) are not mutual exclusive,
but that both indirect and direct pathways may be contributing to exacerbated neuronal
cell loss in vitro and in vivo. Indeed, this recruitment of the adaptive arm of the immune
system possibly causes or augments the propagation and potentiation of the secondary
neuroinflammatory response.

Th17, Th1, Th17.1 and Their Fate in Culture
To properly evaluate direct and indirect effects of Teffs on microglia and
consequent neuronal cell loss the N-α-Syn-specific Teff cells are polarized to yield a
selected phenotype of choice. Under normal circumstances, immunization, expansion,
and polarization of effector T cells to a specific phenotype requires at least 28 days
before the cells are ready to use in an experiment. Moreover, the cells do not expand
well; therefore it requires a large number of initial immunized animals to garner enough
cells to complete in vitro and in vivo experiments.

Additionally, one round of

immunization and polarization garners enough cells to be used once, the cell replication
cycle does not allow for multiple passage attempts with the polarized effector T cells.
Due to the sheer amount of time and money required to run multiple in vitro and in vivo
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experiments, we sought to develop a stable T cell line that maintains specific properties
of the phenotypes over an extended period of time while also propagating cell survival
and expansion from week to week would alleviate time and cost constraints, and thus
allow multiple in vitro and in vivo experiments to be performed in close proximity to each
other with a stable cell line.

To create these cell lines mice were immunized and

boosted with antigen (N-4YSyn) and upon extraction and CD4+ enrichment the cells
were cultured in a rich cytokine milieu designed to polarize to a specific phenotype.
These cells were cultured repetitively for 4 weeks into the same culture medium, which
included APCs and N-4YSyn to keep the cells activated and replicating, before they
were cloned utilizing a system to allow for the selection of single cell colonies. The
cloning of the polarized T cells allowed for selection of a single cell colony which was
selectively proliferative, and which demonstrated the most perpetuative characteristics of
the phenotype of choice. For instance, the Th1 phenotype required a colony which
stably produced IFN-ɣ, but not IL-17; the Th17 necessitated the opposite characteristics,
while the Th17.1 line produced both cytokines. Once cloned, these cell lines were then
perpetually cultured within their necessary cytokine and/or antibody environments to
allow for the stable production of their respective cytokines of interest.
The known plasticity of the Th1/Th17 paradigm was the main obstacle in the
continuance of a stable Th17 line over an extended period of time. In general, the
development of each of the phenotypes relies heavily upon the cytokine milieu, with that
milieu deterring the polarization and expansion of phenotypes not of interest.

For

instance, the synergistic efforts of TGF-β1 and IL-6 drive Th17 differentiation while
inhibiting T-bet and STAT4 expression and Th1 differentiation (Das et al., 2009, JadidiNiaragh and Mirshafiey, 2011). Conversely, IFN-ɣ and IL-12 drive Th1 differentiation
while at the same time preventing Th17 differentiation (Harrington et al., 2005). While
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many reviews have postulated the plasticity of Th17 cells to Th1, very little information
has been published on the transformation of Th1 cells to Th17 cells (Liu et al., 2015,
Geginat et al., 2016). While in that instance Lie et al. transdifferentiated Th17 cells from
Th1 with the use of TGF-β and IL-6, the percentage of Th1 cells transforming to IL-17
producing Th17 cells was very low. Multiple in vitro tests utilizing somewhat similar, but
different parameters proved unsuccessful with my T cell lines. As the Th1  Th17
transformation is a somewhat rare event in vitro, conventional thought is that it is even
more rare in vivo, or that the necessary or optimal conditions have not yet been
identified. In addition to the plasticity of Th1/Th17 cells, the ability for these cells to
transform into an IL-17/IFN-ɣ dual expressing, highly pathogenic effector T cell subtype
(Th17.1) was of interest.

The discovery of a Th17.1 cell which did not fit the

characteristics of a Th17 or Th1 cell, but expressed both prototypical cytokines (IL-17
and IFN-ɣ) led to further investigations revealing this phenotype conferred higher in vivo
survival and self-renewal capacity (Korn et al., 2009, Muranski and Restifo, 2013).
Additionally, some literature belies the necessity for IL-17/IFN-ɣ dual expression to
distinguish between pathogenic and non-pathogenic Th17 and Th1 cells (Ghoreschi et
al., 2011, Zuniga et al., 2013). While it appears the newly coined Th17.1 cell may be its
own unique phenotypic lineage, the possibility cannot be ruled out for a cell lineage with
a “sliding scale” that oscillates between the two sides of Th17 to Th1 plasticity, and in
the transition from one phenotype to another the cell may exhibit what we now call the
Th17.1 phenotype. Moreover, the ability of these Th17.1 cells to stay a dual IL-17/IFN-ɣ
expressing cell in vivo and halt plasticity type transformations to Th1 and Th17
counterparts is a fascinating question, and perhaps the sequestering of CD4+ effector T
cells into the stereotypical Th1 and Th17 subsets is not sufficient enough to belie the
depth of complexity. However, because few Th17.1 cell lines exist, those possibilities
remain untested.
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Through the use of single cell colony cloning and phenotypic testing I was able to
produce long-lived Th17, Th1, and Th17.1 cell lines. Phenotypic testing included flow
analysis for surface markers CD3, CD4, and CD8, as well as intracellular markers for IL17, IFN-ɣ, and TNF-α. Intracellular cytokines were also assessed via cytokine bead
array to confirm cytokines were not only being produced, but also secreted to exert their
effects. The use of a cytokine and antibody milieu including IL-1β, IL-6, IL-β1, IL23, antiIL-4, anti-IL-2 and anti IFN-ɣ allowed for the stable passage of a Th17 cell line over a
span of 12 months due. This stability was due, in part, to high quantities of IL-6 and IL23 in culture. Inclusion of IL-6 and IL-23 at increased concentrations most likely worked
to activate the RORɣT transcription factor, decrease dedifferentiation, and increase
proliferation from week to week. Also the continued addition of antibodies past the first 4
weeks ex vivo undoubtedly assisted in curbing dedifferentiation into the Th1 phenotype
through the scavenging of any extracellular IL-4, IL-12 and IFN-ɣ that may have been
produced from the APCs in culture. To dedifferentiate the Th17 cell line into a Th1 cell
line the IL-2 cytokine was utilized. While IL-12 is the known classical activator of the Th1
phenotype, IL-2 can be considered a non-classical activator. In fact, IL-2 can induce
IFN-ɣ-producing Th1 cells through STAT5, a necessary component to potentiate the Th1
fate, as STAT5 is necessary to induce IL-12Rβ2 expression, thereby allowing the cell to
respond to extracellular IL-12 (provided by APCs which used in the culture alongside N4YSyn to keep the cell lines activated and replicating) and commit the cell to a Th1 fate
(Liao et al., 2011, Owen and Farrar, 2017). In order to propagate a Th17.1 cell line an IL17+/IFN-ɣ+ clone was selected and cultured in a cytokine milieu promoting Th17 growth
(IL-1β, IL-6 TBG-β1, IL-23) as well as a cytokine milieu promoting Th1 growth (IL-2).
While this growth environment required a large amount of tweaking to find the right
balance between a Th17 and Th1 skewed cytokine profile, it was the depletion of the IL-
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2 concentration to 50% from generally required for long-term Th1 culture to counter the
pressure to dedifferentiate into a purely Th1 cell line.
From this point forward it would be logical to address a more in depth phenotypic
analysis of the T cell lines. Evaluation of the cell lines for transcriptional factors such as
RORɣT (Th17) and Tbet (Tbx21, Th1), as well as gene expression regulators such as
STAT3 and STAT5, should be assessed to correlate the phenotype of the T cell lines to
a transcriptional signature.

Moreover, additional analysis for other cell surface

expression outside of CD markers could lend better insight into the phenotypic stability
of the T cell lines over time.

Evaluation of CCR6+/CCR4+ vs. CCR6+/CXCR3+

expression could help further delineate between the Th17 and Th17.1 phenotypes.
Additionally, analysis of the ability of IL-12 to induce the Th1 phenotype in the Th1 and
Th17 cell lines and increase phenotypic stability would be beneficial.
Taken together, the creation and use of long-term cell lines decreased the
number of animals or cells needed per experiment, decreased the cost of each
experiment, and decreased the amount of time between each experiment. Moreover,
the use of T cell lines provides a stable and thus reliant variable to the experimental
design. The in vitro and in vivo use of long term cultures of T cell lines could prove vital
to research examining the mechanistic effects of T cells or evaluating the use of
therapies aimed at dampening adaptive immune responses.

Th17 and Th17.1 cells work directly and in directly to exacerbate
neurodegeneration
The main body of work in this dissertation sought to address the cellular and
molecular mechanisms by which N-α-Syn specific effector T cell subsets modulate
neurodegeneration in models of PD.

Increasing evidence suggests neurotoxic

inflammatory activities affect pathogenesis and progression of PD and increased T cell-
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mediated immune function has been noted in many clinically measured parameters
among PD patients. Our laboratory, along with others, have shown that immunodeficient
mice are resistant to MPTP-induced dopaminergic neurodegeneration and that
subsequent reconstitution with wild type lymphocytes or CD4+ T cells, but not CD8+ T
cells, restores dopaminergic susceptibility, thus indicating the necessity for T helper cells
for dopaminergic susceptibility to MPTP (Benner et al., 2008, Brochard et al., 2009).
Moreover, immunization with N-α-Syn induces Teffs which are specific for N-α-Syn, but
not unmodified α-Syn, and upon adoptive transfer to MPTP-treated recipients those N-αSyn

Teffs

exacerbate

MPTP-induced

neuroinflammation

and

subsequent

neurodegeneration (Benner et al., 2008). In fact, previous studies have shown after
MPTP intoxication, adoptive transfer of Teffs exacerbates microglial-mediated
neuroinflammation and amplifies dopaminergic neurodegeneration with accelerated and
prolonged neuropathology (Reynolds et al., 2010). In vitro polarization of T cells to Th17
Teffs, and then subsequent adoptive transfer to MPTP-intoxicated recipients elicits
greater neuroinflammation and neurodegeneration than that afforded by adoptive
transfer of Th1 or Th2 Teffs to MPTP-treated recipients. Based upon this previous data
it was posited that Th17 Teffs provide an increased neurodegenerative potential than
Th1 or Th2 effector T cells. The mechanisms behind N-α-Syn-specific effector T cells
mediate exacerbated neurodegeneration remained enigmatic, and it was hypothesized
that Th17 effector T cells function indirectly to amplify the microglial neurotoxic
phenotype or alternatively Th17 Teffs act via direct neurotoxicity.
In this vein, the effector T cell lines were tested for in vitro, direct toxicity to a
neuronal cell line, MES23.5 cells. The ability of Th17 cells to directly impact the toxicity
of neuronal cells depends upon the T cells or T cell factors trafficking to the SN to be
able to exert their effects. This is more than likely accomplished by the upregulation of
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CAMs such as ICAM and VCAM. In fact, studies have shown mutant forms of α-Syn
(such as nitration), altered ICAM expression and increased migratory capacity (Klegeris
et al., 2006, Kim et al., 2009).

CAM alterations may be accomplished through the

drainage of N-α-Syn into the peripheral lymphatics, where it can traverse its way to the
peripheral immune compartments and activate effector T cells through antigen
presentation. These activated Teffs are postulated to travel back to the SN to exert their
inflammatory effects, and may use upregulated CAMs to make their way through the
BBB.
The allowance for T cell trafficking to the SN could account for the increased
dopaminergic cellular death seen in the MPTP mouse model, as in vitro examination
confirms that Th17 cells and supernatants are able to increase toxicity and decrease
neuronal cell viability. Moreover, the supernatant from activated Th17 cells appears
more neurotoxic to MES23.5 cells than the actual cells themselves. This could be due,
in part, to the effects of TNF-α/TNF-αR mediated apoptosis, in that TNF-α may be able
to promote independent caspase 3 activation (Alvarez et al., 2011) and that TNF-α is
produced by Th17, Th1, and Th17.1 T cell lines. Th17 cell-mediated neuronal cell death
may also be mediated through Th17 cell upregulation of Fas ligand production, in
conjunction with Fas presentation on dopaminergic neuronal cells. These represent
attractive mechanistic areas to address for future studies.
While Th17 cells show direct toxicity to neuronal cells, they also demonstrate the
ability to induce microglial-mediated neurotoxicity. The modification of the self-protein αSyn and subsequent packaging into Lewy bodies and release causes the activation of
the innate inflammatory system in the brain, which consists mainly of microglia.
Dormant microglia exist in the brain normally, and exhibit small ramified somata with
processes that extend and undergo cycles of de novo formation and withdrawal,
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participating in immune surveillance by sampling the extracellular space, thereby
allowing microglia to efficiently control the microenvironment of the brain.

With the

microglia being sensitive to small changes the release of DAMPS from damaged/dying
neurons and/or modified α-Syn has the ability to activate microglia to an activated M1
phenotype.

This phenotype is characterized by secretion of proinflammatory and

neurotoxic factors, and upregulation of proinflammatory mediator enzymes such as
iNOS, COX-2, and NADPH oxidase (Perry, 2012). Upon activation by the modified
protein the microglia undergo several changes which include proliferation, increased
ROS and RNS production, which can lead to cellular death and degeneration of neurons
through overwhelming their antioxidant system to cause oxidative stress. The activation
of the adaptive arm of the immune system and trafficking of effector T cells to the SN to
interact with M1 microglia could result in the hyperactivation of the microglia, leading to
an even more neurotoxic phenotype, thereby increasing dopaminergic cell death. In
fact, in vitro co-culture of BV-2 microglial cells with Th17 cell line Teffs or supernatants
yielded an increased nitrite production from the microglia. Additionally, T cell or T cell
supernatant stimulated BV-2 microglia had the ability to decrease MES23.5 neuronal cell
viability and increase cytotoxicity when assessed by multiple cytoxicity/viability assays.
Should effector T cells be able to traffic into the CNS after activation in the peripheral
immune compartments, T cell/microglial interactions that result in hyperactivation of
microglia would be a predicted outcome. Indeed, the work herein provided evidence that
both T cells and T cell supernatants are capable of activating microglia to produce high
levels of reactive oxygen and nitrogen species as well as increased neurotoxicity. Also,
microglia are widely renowned as the primary APC within the CNS due to their ability to
express MHC II, and therefore also function to provide continual activating stimulus to
ingressed effector T cells. Moreover, studies have demonstrated interactions of T cells
with VCAM-1 on microglia can induce microglial production of cytokines such as TNF-α
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(Strachan-Whaley et al., 2014).

Clearly, the in vitro studies provided an apoptotic

mechanism by which MES23.5 undergo neurodegeneration.

Inhibition of apoptotic

pathways via the Z-VAD-FMK pan-caspase inhibitor completely ablated the apoptotic
programs and neurotoxicity caused directly by T cells and indirectly through microglia,
rescued neuronal viability, and thus increased neuroprotection. While this inhibitor is not
specific to caspase 3 and 7, inhibition of their activity in the triplex assay, and the
neurotoxic effects of T cell and T cell-stimulated microglia could lead one to predict there
is a mechanistic pathway, yet this will require a more in depth look. In fact, I would
hazard to say the T cells and T cell-stimulated microglia are working directly and
indirectly through TNF-α and/or Fas/FasL interactions to bring about the apoptotic death
of neurons in vitro. If this is the case, it is likely to translate in vivo as the MPTP mouse
model and human patients have shown increased numbers of apoptotic neurons and
apoptotic markers post mortem (Venderova and Park, 2012).
While the abilities of the effector T cell lines to cause direct and indirect toxicity of
MES23.5 cells were established in vitro, it is important to confirm this in vivo. To test the
direct and indirect pathways of neurodegeneration in vivo it will be imperative to
separate the two and evaluate the ability of the T cell lines to induce neuronal cellular
death.

One technique to test this would include the selective depletion of resident

microglia. Microglia are formed outside of the CNS during development, and travel into
the CNS before the BBB is formed, wherein they expand and proliferate to form a gridlike distribution throughout the CNS, allowing for rapid innate immune response when
needed (Hughes and Bergles, 2014).

Moreover, microglia are known to require

activation of the colony-stimulating factor receptor 1 (CSFR1) for proliferation and
survival during development, and this receptor continues to be expressed throughout the
lifespan of adult microglia, possibly as a requirement to sustain the microglial population.
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It is possible to target this receptor through the use of a Plexxikon inhibitor that will lead
to a rapid decrease in IBA1+ microglia, which will persist throughout the administration of
the inhibitor (Elmore et al., 2014). The administration of the CSFR1 inhibitor causes the
widespread death of microglia while leaving the brain relatively undisturbed, as there are
no changes in the BBB or global increase in neuroinflammation with this treatment. The
depletion of resident microglia prior to MPTP administration and subsequent adoptive
transfer of cells from the T cell lines will allow for the study of the mechanisms behind
direct toxicity without interference of indirect toxicity mediated through microglia. While
microglia depletion can be mediated in other models such as CD11b-herpes simplex
virus thymidine kinase, CD11b-human diphtheria toxin receptor, or PU.1 knockouts, the
CSFR1 inhibited mouse model appears to be of the greatest value to this experimental
design due to the complete ablation of resident microglia without causing
neuroinflammation or BBB damage (Eyo and Wu, 2013).

While CSFR1 is mainly

produced in mononuclear phagocytes it may be transiently expressed in neurons, and
further investigation into this possibility would need to be examined before further testing
of the inhibitor with MPTP and adoptive transfer of the T cell lines.
To further this work, a more in depth approach to teasing apart the mechanistic
process of apoptosis would be necessary. This could be accomplished through the
inhibition of other factors involved in apoptosis activation, such as DISC formation,
blockage of TNF-α and Fas binding to appropriate receptors, inhibition of Fas/FADD
binding, among other things. Moreover, additional assays are necessary to validate the
apoptotic mechanism, such as annexin V translocation and protein analysis for
procaspase 3 and cleaved caspase 3. Moreover, gene expression analysis via RNA
arrays would provide another tool for the verification of apoptotic mechanism(s) of
cellular death. In fact, a cellular death pathway array would allow the confirmation of
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apoptotic mechanism(s) of action through analyzing the expression levels of different
pro-apoptotic genes. Conversely, a cell death array would also allow testing for other
cell death pathways such as autophagy and necrosis, in the scenario whereby apoptosis
does not prove to be the leading mechanism of neuronal cell death.

Th17.1 cells are more pathogenic than Th17 and Th1 cells in vitro and
in vivo
It is widely accepted that Th1, Th2, and Th17 are the 3 most common effector T
cell types.

Since the major discovery of the Th17 phenotype lineage in 2005 from

studies involving the EAE model for multiple sclerosis most of the knowledge of the Th17
cell originates from studies in experimental animal models, with much less information
on Th17 cells in humans is known. More recently the plasticity’s of the Th17 and Th1
lineages have been identified due to the close developmental link between the effector T
cell phenotypes, including Tregs. While I have shown in vitro plasticity of Th17 cells
transition to a Th1 phenotype, and this phenomenon is widely regarded in literature, the
ability of Th1 cells to transition to Th17 is much less common. The precise origin of
Th17.1 cells is still unknown, as is their biology and function. It is possible Th17.1 cells
represent a transitional phenotype between Th17 and Th1 cells. How long Teffs can
maintain this transitional phenotype in vivo may depend on many microenvironment
cues yet defined. Whether this phenotype is a transitional state between Th17 and Th1,
or its own stable phenotypic lineage will require more investigation and long term testing.
Growing evidence supports the notion that not all Th17 cells are created equally, and
some are more pathogenic than others (Ramstein et al., 2016). Although the literature is
decidedly indecisive upon what factors constitute the more pathogenic cell type. Some
indicate IL-23 and/or IL-1β are necessary for pathogenicity; some counter that IFN-ɣ
dual expression is necessary or sufficient for heightened function or pathogenicity. For
this study, IL-23 and IL-1β were used to induce Th17 and Th17.1 differentiation, and the
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Th17.1 cells were dual expressers of IFN-ɣ and IL-17.

In vitro analysis of the

pathogenicity of the Th17, Th1, and th17 cell lines indicated the Th17.1 cells are indeed
the most pathogenic when in direct contact with neuronal cells as well as when
stimulating microglial cells. In fact, the Th17.1 cell line caused the largest increase in
apoptotic factors, and induced the most extensive neuronal cell death directly via T cell/T
cell supernatant interaction, and indirectly via microglial-mediated cellular death.
Moreover, the Th17.1 cell line also demonstrated the same affects in vivo, as adoptive
transfer of Th17.1 cells caused the largest loss of TH+ dopaminergic neurons, and a
greater increase in microgliosis in comparison to its parental Th17 cell line and the
earlier-derived Th1 sibling cell line. Taken together, these results confirm the identity of
a more pathogenic type of T cell in the neurodegenerative pathway for PD which can be
induced through differentiation using IL-23 and IL-1β.
Further investigation into the pathogenic nature of Th17/Th17.1 cells along with
the origin of Th17.1 cells is essential. The identification of the source of Th17.1 cells,
whether through a transitional Th17/Th1 plasticity phase, or as an actual standalone
phenotype, could provide indispensable to the T cell community. Further analysis of the
role of Th17.1 cells in the MPTP mouse model could shed light on this issue.
Investigating gene expression after MPTP intoxication and adoptive transfer of
Th17/Th1/Th17.1 cells would enable examination of the key genes involved in the
inflammatory response of each T cell type, allowing for the investigation into the
differences between the 3 types, perhaps bringing to light major differences that lead to
greater/lesser pathogenicity.
In all, this research has helped shed light upon the ability of effector T cell types
to exacerbate neurodegeneration in vitro and in vivo, possibly through a mechanism of
apoptosis which involves TNF-α. Additionally, this work has detailed the generation and
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long-term culture of effector T cell lines in vitro through the use of different cytokine and
antibody milieus, which could potentially have an effect on effector T cell type
pathogenicity. Further investigations into the mechanistic details behind exacerbation of
neurodegeneration caused by CD4+ effector T cells in PD models has the potential to
advance therapeutic strategies that target neurotoxic mechanisms to attenuate
neuroinflammation and ameliorate neuronal loss in PD.

Implications in Parkinson’s Disease
As the links between T cell immunity and nigrostriatal degeneration become
more apparent, the mechanisms behind T cell immunity regarding how and where T
cells exert their effects become more important. Inflammation is a normal defense of the
body against invading pathogens and injury, working under normal conditions to clear
the pathogen and return the body to normal homeostatic conditions. Once this immune
reaction becomes dysregulated and chronic significant cellular damage can ensue. It is
well known that microglial cells play a central role in neuroinflammation and subsequent
neurodegeneration of dopaminergic neurons in the SN. Neurons within the brain are
highly vulnerable to the detrimental effects of reactive oxygen and nitrogen species,
possibly due to their high metabolic rate and adenosine triphosphate consumption, rich
composition of fatty acids prone to peroxidation, low antioxidant levels, and reduced
regenerative capability. Therefore, the chronic activation of resident microglia can have
extreme deleterious effects on neurons. Microglial cells, as one of the key defensive
cells within the CNS, produce ROS and RNS easily and profusely when activated, and
serve as key pathogenic elements in many neurodegenerative disorders outside of PD
such as Alzheimer’s and amyotrophic lateral sclerosis. Free radicals, once generated by
activated microglia, have many effects within the SN. For instance, nitric oxide and
superoxide anions can conjoin to form peroxynitrite, which can selectively nitrate
tyrosine residues of α-Synuclein.

Moreover, upregulation of proinflammatory factors
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from microglia such as iNOS, COX-2, and NADPH oxidase can lead to increased
oxidative stress of dopaminergic neurons by overwhelming the endogenous antioxidant
system, ultimately leading to cellular death.
The adaptive immune response is significantly more complex than the innate
response and relies, in part, on antigen specificity for activation. For a T cell response to
be mounted antigen must first be processed, incorporated into MHC molecules, and
presented by APCs such as microglia and dendritic cells. Once antigen and MHC are
recognized by the T cell receptor the adaptive immune system responds by increasing
proliferation of T cells designed to attack and destroy the foreign antigen, or be turned
off through regulation by Tregs.

However, in neurodegenerative disorders, the

persistent presence within the brain of T cell subsets in ratios greater than those
classically found in the periphery suggests a more profound role in disease than initially
anticipated. As the in vitro and in vivo experiments detailed herein have shown, it is
altogether possible the exacerbation of dopaminergic cellular death is due to the
increased presence of T cell subsets such as Th17 and Th17.1 that are normally
precluded from entry into the CNS under homeostatic conditions.

However, under

inflammatory conditions they can migrate into the brain and, most likely due to their
extreme pathogenic nature, exacerbate neuronal loss. In addition to studies having
found T cell markers within the brains of PD patients, Th17 cells and their classical
cytokine secretion, IL-17, are also found at increasing high levels within peripheral blood
(Yang, 2016, He et al., 2017, Yang et al., 2017). In glaring contrast, one recent study
found PBMC’s from PD patients did not produce IL-17, but instead were heavy
producers of IFN-ɣ (Sulzer et al., 2017). This phenomenon, however, could be due to
the culture of PMBC’s in high concentrations of IL-2 for 14 days after extraction. As
previously shown in the above data, culture in IL-2 will cause the transformation of early
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lineage Th17 cells to the Th1 effector cell subtype, thereby skewing the outcome of
cytokine production from the collected PD patient peripheral blood PBMCs.

This study

demonstrates the ability of isolated effector T cells to respond to antigenic α-Syn
peptides and elicit an immune response, indicating these cells have been previously
exposed to the antigenic forms of α-Syn. Therefore, these T cells which are normally
precluded from CNS entry are exposed to antigenic α-Syn and clonally expand, causing
the buildup of an immune response, leading to the breaking of immunological tolerance
and the attack of dopaminergic neurons within the SN. As was demonstrated through
the in vitro and in vivo experiments herein, exacerbation of neurodegeneration seen in
later stages of disease could be due to the effects of the adaptive immune system’s
effector T cells, specifically Th17 and Th17.1 cells, via direct and indirect pathways of
cell-mediated toxicity to dopaminergic neurons along the nigrostriatal axis.

While

markers for Th17 cells have more recently begun to be identified and studied within PD
patients, no data can be found on the existence of Th17 cells within the CSF and blood
of PD patients, which warrants further investigation. Further examination into the effects
of Th17 cells, and possibly Th17.1 cells, in the exacerbation of dopaminergic
neurodegeneration will open up the door to investigate therapeutic strategies to regulate
or modulate effector T cell responses.
Many diverse mechanisms, factors, and pathways involved within dopaminergic
neurodegeneration in PD are becoming increasingly evident. Thus, several strategies
for therapeutic modalities can be developed to ameliorate, prevent, or possibly reverse
dopaminergic cell death in PD. Potential therapies could include upregulation of antiinflammatory regulators such as IL-10 and TGF-β (classic Treg cytokines) which could
work to regulate the chronic pro-inflammatory state of innate microglia and turn off
adaptive T cell responses, thereby inhibiting neuronal death and slowing disease
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progression. Should dopaminergic death be primarily mediated by microglial functions,
targeting ROS/RNS production and redox stress may prove more beneficial. Decreasing
redox stress could potentially reverse the overwhelmed endogenous antioxidant system
of the neurons and permit the removal of free radicals, thereby allowing neurons to
continue relaying the dopamine chemical signal through the nigrostriatal pathway.
Moreover, inhibition of TNF-α mediated apoptosis could improve disease severity,
through the use of TNF-α specific inhibitors such as adalimumab or etanercept, if they
can be genetically modulated to cross the BBB while still retaining their properties of
inhibition.
Modulating T cell immune responses provide another avenue for therapeutic
intervention within PD. The pathogenesis of PD includes neurotoxic innate immune
responses, as well as adaptive immune responses that possibly up-regulate innate
inflammatory responses to affect the nigral microenvironment and lead to increased
dopaminergic neuronal loss. Naïve T cells are normally excluded from entry into the
CNS, but chronic neuroinflammation leads to aggressive recruitment of adaptive immune
system components, and transformation from more pro-inflammatory components to
anti-inflammatory may mediate a beneficial effect on neuronal survival.

This

transformation could be mediated through modulating IL-1β levels. IL-1 levels have
been linked to disease severity, and the administration of an IL-1 receptor antagonist
significantly reduced TNF-α and IL-1β levels, as well as attenuated dopaminergic cell
loss within an animal model of PD (Koprich et al., 2008). Moreover, removal of IL-1β
from in vitro culture induces the transformative shift of IL-17-producing Th17 cells to IL10-producing Th17 cells. Therefore, therapeutics which target IL-1 through scavenging
IL-1β or blocking the IL-1 receptor, such as anakinra, could work to transform the
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pathogenic Th17 or Th17.1 cells to the more anti-inflammatory IL-10 producing Th17
cell, thereby ameliorating dopaminergic cell loss within the SN.
While transformation of pathogenic Th17 responses to anti-inflammatory Th17
responses might be beneficial within the context of autoimmune diseases and
neurodegenerative disorders, this could potentially lead to a host of other health issues.
While utilizing the plasticity of the Th17 cell to transform its effects from pro- to antiinflammatory would potentially ameliorate exacerbated neuronal cell loss within the SN it
may also weaken the immune system, thereby allowing greater susceptibility to
opportunistic infections or neoplasia. Opportunistic infections such as cryptococcal
meningitis, toxoplasmosis, and candidiasis are pathogens that normally would not cause
disease within a healthy person with a sufficient immune system, but transforming the
Th17 immune response could potentially compromise normal immune system responses
and present an opportunity for these infections take advantage.

One therapeutic

technique which could be employed is the use of immune specificity to restore T cell
tolerance to self-proteins such as α-Syn.

As current treatment for autoimmune

responses which break immune tolerance depend upon non-specific immune
suppression, the ability to target the underlying cause of the disease (recognition of the
self-protein α-Syn) in order to reestablish tolerance could prove to be a beneficial
therapeutic. In fact, studies have shown T cell tolerance can be restored within type 1
diabetes through the induction of an altered TCR signal (Masteller et al., 2003). Small,
soluble peptides were linked with the antigenic peptide to modulate the immune
response through the TCR, thereby leading to a decrease in pro-inflammatory responses
with concomitant increase of anti-inflammatory mediators and Treg subsets. A similar
schematic could be utilized to target α-Syn, reduce proinflammatory responses, and
induce anti-inflammatory responses; however many hurdles would need to be overcome
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to accomplish this strategy.

One challenge would be the design of an appropriate

peptide which could link with α-Syn to modulate the TCR response. Another includes
the administration of said peptide in doses high enough to elicit a tolerant response,
assuming the peptide is able to cross the BBB without further modifications.

The

development of a strategy which could reverse pathogenic autoimmune responses to
self-proteins in an antigen specific manner without impairing normal antigenic immune
responses could provide an extremely useful therapeutic tool in the treatment of PD.

Immune Transformation
The in vitro assays described herein to determine a mechanistic pathway paired
with the utilization of adoptive transfer/MPTP intoxication had both its strength and
limitations.

The in vitro assays, with the use of the microglial BV-2 cell line and

dopaminergic neuronal MES 23.5 cell line, allowed for an in depth look at the exact
pathways of T cell-induced dopaminergic cellular death. To define a mechanism of
action it is imperative to be able to control all aspects of the cellular microenvironment.
This was achieved through simplifying the cellular culture to allow for individual
characteristics of direct and indirect toxicity to be tested. Specifically, we were able to
separate the effects of the T cell lines and the T cell line-stimulated BV-2 microglial cells
on the cytotoxicity to MES 23.5 neuronal cells to establish routes of direct and indirect
toxicity through possible apoptotic mechanism(s). One possible contention of this model
is that it may not be physiologically relevant to strip the cultures of all cell types except
the two under investigation. However, reductionist biology suggests this is the best
method to initiate scrutiny of the mechanistic pathways that effector T cells may take,
leading to exacerbated neuronal cell death in the MPTP mouse model.
The MPTP mouse model also has its strengths and limitations.

A classic

opposition to the MPTP model includes the lack of Lewy body formation, a pathological
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landmark of PD, within the SN of MPTP-treated animals. While Lewy bodies are not
present after acute or chronic MPTP intoxication a correlation between MPTP injection
and α-Syn expression/immunoreactivity has been identified (Purisai et al., 2005),
supporting a the notion of a relationship between neuronal injury and enhanced α-Syn
expression within the MPTP model.
categories,

the

pathogenic,

The MPTP model seemingly falls into two

acute

phase

mouse

model

and

the

symptomatic/pathophysiological primate model. The pathogenic mouse model is of value
in determining mechanistic characteristics behind T cell and microglial induced neuronal
cellular death, and can be further utilized in the development of immunotherapies aimed
at decreasing innate and adaptive induced neuronal cell death. Moreover, the use of the
pathogenic model to identify a possible therapy combined with further analysis via the
symptomatic MPTP model could prove to be a vital tool in the identification of
therapeutics to alleviate dopaminergic cell death.

The ability of the pathogenic acute

MPTP mouse model to define a therapeutic route of neuronal survival was demonstrated
with the administration of GM-CSF prior to MPTP intoxication (Kosloski et al., 2013).
Moreover, the use of this drug within the MPTP mouse model led to a recent Phase 1
clinical trial demonstrating the safety of this drug and the effectiveness at symptomatic
improvement as evaluated by UPDRS Part III (Gendelman et al., 2017). Taken together,
these studies demonstrate the effectiveness of the acute MPTP mouse model in defining
therapeutic strategies that can lead to potential Phase I trials and beyond.
Many different strategies can be employed to modulate the adaptive immune
response, including immune transformation of the effector T cell subtypes. The pro- and
anti-inflammatory cytokine levels within PD patients brains, CSF, and serum have been
measured in various studies and are found to be dysregulated, confirming the systemic
involvement of the immune system (Romero-Ramos et al., 2014). In fact, excess
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production of proinflammatory cytokines such as TNF-α and IL-1β could lead to the
sustained activation state of the innate and adaptive immune systems, which in turn
contribute to high rates of dopaminergic cell death.

Therefore, the possibility of

transforming the immune response to “turn off” the excess of proinflammatory cytokines
being released and “turn on” anti-inflammatory mediators could prove a useful
therapeutic tool in the treatment of PD. In fact, the Phase I trial detailing peripheral Treg
transformation with the use of sargramostim (human recombinant GM-CSF) may provide
such a modality (Gendelman et al., 2017). Elevated of IL-17 and Th17 effector T cells
have been found in the peripheral blood of PD patients. Th17 cells are known to have
great plasticity, being able to convert into a Th1-like Th17 hybrid cell phenotype, as well
as being able to transform into Treg-like Th17 cell secreting the anti-inflammatory
cytokine IL-10. In fact, increased IL-27 levels, in synergy with IL-6 and TGF-β can
orchestrate the switch of proinflammatory IL-17-producing Th17 cells to the more antiinflammatory IL-10-producing (Treg-like) Th17 cells (Chang et al., 2017). Moreover,
previous treatment of MPTP-treated mice with GM-CSF demonstrated a more than 15fold increase in IL-27 gene expression (Kosloski et al., 2013). Taken together, this could
certainly prove to be a prominent pathway of immune transformation from
proinflammatory Th17 cells to anti-inflammatory phenotypes induced by sargramostim
treatment, which leads to decreased disease severity as evident by decreased UPDRS
part III scores.

Further evaluation of a possible Th17 to Treg transformation is

warranted, perhaps through investigations that correlate Th17 and IL-17 diminution with
increased Treg number or function after sargramostim treatment. Nonetheless, the use
of GM-CSF in immune transformation has so far proven a fruitful avenue for treatment
and therapeutic gain. Further investigation of the paradigms for Th17/Treg plasticity
have the potential to improve therapeutic strategies that target neurotoxic mechanisms
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to diminish neuroinflammation, ameliorate neuronal loss, and reduce disease
progression in PD.
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